Cell culture medium
By optimizing the amino acid ratio and the use of ferrous cholate in cell culture medium, the problems of uncertain raw material composition and batch culture medium design in the prior art have been solved, efficient cell growth and protein production have been achieved, and biopharmaceuticals have been improved. Quality and stability.
Patent Information
- Application Number
- CN202210115607.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2016-03-31
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2036-03-31
AI Technical Summary
The existing cell culture media has an uncertain raw material composition in industrial biopharmaceuticals, leading to contaminant risks and process reproducibility issues, and it is difficult to design the best batch culture media to match cell growth and production needs.
Basal cell culture medium and feed medium with novel amino acid ratios and ferrous cholate as iron carriers are provided to optimize the growth and protein production performance of mammalian cells and ensure the stability of product titers and cell growth.
By optimizing the amino acid ratio and the use of ferrous cholate, the product titer and cell growth performance are significantly improved, the risk of contaminants is reduced, and the process reproducibility and efficiency are improved.
Smart Images

Figure _1 
Figure _2 
Figure _3
Abstract
Description
[0001] This application is a divisional application of the invention patent application with application date of March 31, 2016, application number 201680020374.7, and invention name “Cell Culture Medium”. Technical Field
[0002] The present invention relates to the field of cell culture and recombinant protein production in mammalian cells. It particularly relates to novel basal cell culture media and novel feed media for optimal production (e.g. titer) and performance (e.g. cell growth) of products (e.g. (poly)peptides, antibodies, antibody fragments and antibody-derived molecules) in mammalian cell culture using recombinant mammalian host cells. Background Art
[0003] The development of mammalian cell culture processes for large-scale industrial manufacturing of therapeutic proteins (e.g., monoclonal antibodies) began about 25 years ago. Effective bioprocesses for the production of biopharmaceuticals primarily require (i) highly productive, stable and regulatory accepted (usually mammalian) cell lines, (ii) optimal cell culture media to support cell growth and production in different (usually mammalian) host cells and in different culture systems and process modes (e.g., at different scales and as, for example, batch, fed-batch and perfusion processes), and (iii) an optimal technical bioprocess characterized by, for example, optimal supply of oxygen through appropriate configuration of agitators and gas supply, automated control of all relevant process parameters to ensure consistent product quality, or a process design that can be scaled up from small-scale process development (mL to L scale) to large-scale manufacturing (>2.000 L) without compromising performance and product quality.
[0004] In this context, cell culture media have a key role and have to meet the complex nutritional requirements of mammalian cells cultured in suspension in technological systems compared to their natural sources.For example, the most widely used cell line for biopharmaceutical production was originally derived from Chinese hamster ovary (CHO cells).
[0005] In the past, serum was used as a culture medium additive to provide nutrients or carrier proteins that are not usually present in cell culture media, such as cholesterol and transferrin or cell-substrate attachment factors (such as fibronectin), other hormones and growth factors, and to protect certain essential nutrients and bind toxic components in the cell culture medium. However, in the cell culture medium for the production of therapeutic agents, serum can potentially introduce animal viruses, and due to uncertain raw material sources, it can introduce other undesirable pollutants (such as antibiotics or proteases) into the cell culture process. These compounds are successfully replaced, and serum-free cell culture media have become industrial practices for process development and biopharmaceutical recombinant production. For example, CHO (Chinese hamster ovary) cells are continuously propagated in a serum-free medium containing human insulin as the only culture medium protein component (Keen and Rapson, Cytotechnology, Oct 17 (3): 153-63, 1995).
[0006] Another group of culture medium components commonly used in biopharmaceutical production is hydrolyzates derived from animal sources or derived from plants. Due to the relevant safety risks, hydrolyzates from animal sources are removed from the process whenever possible. Hydrolyzates usually contain a mixture of amino acids, small peptides, inorganic ions, trace elements, carbohydrates and vitamins, and are widely used to enrich culture medium with various (essential) nutrients to increase overall growth and productivity. In addition to safety aspects, another disadvantage is the fact that hydrolyzates are not chemically determined, so the exact composition between batches can change (batch-to-batch variability), and for this reason, process reproducibility is negatively affected. Because hydrolyzates contain many compounds and have complex (unknown every detail) composition, they cannot be easily replaced without affecting cell culture performance (such as product yield). Screening and subsequently replacing this uncertain raw material with chemically determined components while maintaining consistent product quality and high product titer is a persistent and unresolved challenge for bioprocess development. Not only does it need to determine the exact chemical composition, it is also necessary to determine the exact concentration of each component. Due to safety aspects, hydrolyzates from plant sources (such as soy hydrolyzates) are mainly used today. However, the problem of uncertain composition remains.
[0007] Current biopharmaceutical process development is aimed at chemically defined culture media (serum-free, animal component-free, chemically defined). This results in further reduced risk of contaminants (e.g., reduced organic materials derived from unknown nutrient sources, endotoxins, unknown metals, and trace elements), and also facilitates increased control over all aspects of upstream and downstream processing of consistent raw materials without any risks associated with safety and batch-to-batch variability. Only recently, "chemically defined" (note that there is still no industry standard that clearly defines this term) culture media have become commercially available for mammalian cell culture, but their use in industrial manufacturing is currently still limited.
[0008] The exact composition of such "chemically defined" hydrolysates or culture medium supplements is known (but usually only to the culture medium supplier) so that no undefined raw materials are used. These chemically defined media are still complex and contain up to about 40-50 "key components". But they consist of different building blocks. In order to design such complex "chemically defined" media, it is necessary to mimic plant or animal derived hydrolysates as closely as possible, which requires extensive fractionation of these hydrolysates followed by high-end analysis. The main challenge in this field is given by the huge diversity of compounds present in cell culture media.
[0009] The optimal design of high-performance cell culture media is further complicated by the fact that many processes are performed in so-called fed-batch mode, i.e. the cell culture is inoculated in a basal starting medium and then (usually after about 0 to 3 days), when the medium substrate is depleted due to cell growth, a concentrated feed medium is supplied to maintain growth and production. Providing all the medium compounds from the beginning (batch mode) leads to suboptimal process performance because the cells are then overfed at the beginning (e.g. leading to high formation of the undesirable byproduct lactate, which in turn has an adverse effect on cell growth and viability). The main challenge in this context is to design an optimal batch medium (basal cell culture medium) and an optimal fed-batch medium (feed medium) that exactly matches the optimal growth and production in the cell culture process throughout the culture run time. The design of optimal batch and fed-batch culture media (basal cell culture medium and feed medium) is a difficult task because the viable cell concentration, the viability of the cell culture and the nutrient requirements of the cell culture process change significantly over the time course of the culture process (on an hourly to daily basis). This is even more difficult since one feed medium is usually designed to provide an optimal solution for every hour and every day of a fermentation process which lasts for about 2-3 weeks in total.
[0010] The state of the art in industrial mammalian cell culture medium design using a "rational" approach has been summarized by Fletcher (Fletcher T., BioProcess International 3(1), 30–36, 2005), and this approach can still be considered as the state of the art concept for rational culture medium design in industrial practice. It should be noted that the complexity of rational culture medium design is given not only by the fact that many components are involved, but also by the specific concentrations and complex interactions of the culture medium compounds that need to be considered.
[0011] According to Fletcher, there are three basic approaches in culture medium design. These are i) (single) component titration (e.g. experiments defining dose responses on titers), ii) culture medium blending (simply blending existing (complex) culture media and identifying the best blend), iii) spent culture medium analysis (description of nutrient depletion by chemical analysis of spent culture media relative to fresh culture media; note that specific metabolic requirements on a cell basis are not considered in this approach), iv) automated screening (robotic fluid handling, where the focus is on throughput in, e.g., multiwell plates). According to Fletcher, none of these approaches is optimal in every way, and each has its own particular weaknesses. For example, i) component titration forces a large number of samples to be analyzed, which is not feasible in industrial practice for many reasons (e.g., capacity, cost, resources), ii) media blending leads to improved throughput, but this approach is weakly instructive and very limited in scope, iii) spent media analysis can provide important information on how the media chemistry changes over time, but it does not provide a complete picture of cell culture requirements based on the fact that typical spent media analysis only focuses on a rather limited number of components (note, for example, that a complete amino acid analysis of all 20 amino acids is not usually performed, and only the two most important amino acids glutamine and glutamate are routinely measured), iv) automated screening increases throughput by minimizing the culture system, but in turn has a detrimental effect on (correctly) modeling large-scale processes, as such miniaturized systems cannot correctly predict large-scale cell culture performance. Therefore, Fletcher concluded that truly rational media design can be described as a multidimensional approach. Instead of relying on a single technique, rational media design uses several complementary approaches, namely DoE (design of experiments) and full factorial design, which captures the complex interactions of multiple components and uses various statistical tools. Although this concept integrates previous media design concepts and employs advanced DoE methods for optimal experimental design, it clearly lacks cell-specific requirements, i.e., the cellular perspective of nutrient supply and cell metabolism. Therefore, there is still a need for improved cell culture media.
[0012] Cell Culture Medium:
[0013] In mammalian cell culture, the cell culture medium may contain up to about 100 compounds and more. For example, carbohydrates (e.g., for energy generation by catabolic reactions or as building blocks by anaplerotic reactions), amino acids (e.g., for building blocks for cellular proteins and products in the case of therapeutic protein production), lipids and / or fatty acids (e.g., for cell membrane synthesis), DNA and RNA (e.g., for growth and cell mitosis and meiosis), vitamins (e.g., as cofactors for enzymatic reactions), trace elements, different salts, growth factors, carriers and transporters, etc. These components or groups of compounds are needed to meet the complex nutritional requirements of mammalian cells in a technical culture environment. There are classical cell culture media, such as DMEM (Dulbecco's Modified Eagle's Medium), in which all components and all concentrations are disclosed. The development of such cell culture media dates back to the late 1950s and is fully described in the academic literature. Another example is Ham's F12 (Ham's Nutrient Mixture F12), developed in the 1970s, or a mixture / modification of this classic cell culture, such as DMEM:F12 (Dulbecco's Modified Eagle's Medium / Ham's Nutrient Mixture F12), developed in the 1970s and 1980s. Another widely used cell culture medium with known composition and concentration is RPMI. RPMI was developed by Moore et al. at Roswell Park Memorial Institute in the 1970s (hence the acronym RPMI). Different variants are used in animal cell culture, such as RPMI-1640. Although many of these classic culture media were developed decades ago, these preparations still form the basis of many cell culture studies that occur today, and represent the state of the art in animal cell culture with culture media with completely known composition and completely known concentrations of each compound. All of these culture media are commercially available and can be obtained from suppliers (e.g., from Sigma-Aldrich). Due to the growing biopharmaceutical business, commercial media suppliers have developed their own cell culture media for mammalian cell culture over the past few years.
[0014] However, compared with classical cell culture medium, the exact formulation of this commercial cell culture medium is proprietary to the manufacturer. For this reason, this commercial culture medium cannot be used as a reference and starting point for rational culture medium design, because the exact formulation is unknown (even for major compounds such as amino acids). For example, the commercially available culture medium ActiCHO (by PAA) composed of basal medium (ActiCHO P) and feed medium (ActiCHO feed A+B) is chemically determined according to the definition of the supplier (only single chemicals, without animal-derived substances, growth factors, peptides and peptones). But the exact formulation is proprietary. Two kinds of feeds are composed of concentrated amino acids, vitamins, salts, trace elements and carbon sources (feed A) and selected amino acids (feed B) in concentrated form. Another example is Ex-Cell CD CHO (SAFC Biosciences). The culture medium is animal-free, chemically determined according to SAFC, serum-free, and the formulation is also proprietary. The third example culture medium widely used in the mammalian cell culture using CHO is CD CHO (Life technologies). The culture medium is protein-free, serum-free, and chemically determined according to Life technologies. It does not contain proteins / peptides of animal, plant or synthetic origin or undefined cleavage products / hydrolysates. Again the formulation is proprietary. This CD CHO basal medium can be combined with feed media named as high efficiency feeds A, B and C. Also for the feeds, the formulation is proprietary. The feeds are of no animal origin and the components are included in higher concentrations. The feeds are chemically defined. Proteins, lipids, growth factors, hydrolysates and components of unknown composition are not used. It contains a carbon source, concentrated amino acids, vitamins and trace elements. Another commercially available feed can be obtained from Thermo Fisher, named Cell Boost 1-6. Again, the formulation is proprietary. It is chemically defined, protein-free and animal-derived components according to ThermoFisher. Cell Boost 1 and 2 contain amino acids, vitamins and glucose. Cell Boost 3 contains amino acids, vitamins, glucose and trace elements. Cell Boost 4 contains amino acids, vitamins, glucose, trace elements and growth factors. Cell Boost 5 and 6 contain amino acids, vitamins, glucose, trace elements, growth factors, lipids and cholesterol.
[0015] Amino Acids
[0016] Amino acids play an important role in protein synthesis (both for cell proteins and for product production in the case of recombinant proteins or protein-derived substances). For example, proteins are synthesized by single amino acid molecules by cellular mechanisms to form larger proteins or protein complexes. In mammalian cell culture, essential amino acids need to be provided together with cell culture media because mammalian cells cannot synthesize essential amino acids from other precursors and building blocks. Amino acids are also important in biochemistry because these molecules have two functional groups (amino and acidic groups) that allow them to interact with other biomolecules. For these reasons, cell culture media containing amino acids are usually also supplemented with various (determined and uncertain) small peptides, hydrolyzates, proteins and protein mixtures from different sources (animal-derived, plant-derived or chemically determined).
[0017] In the context of the present invention, it was found that specific amino acid compositions and novel amino acid ratios in both (basal) cell culture medium and feed medium significantly increased final product titers. This new amino acid composition and amino acid ratios are significantly different from the state of the art of commercially available cell culture media (e.g. RPMI, DMEM:F12 1:1) and provide higher product titers.
[0018] Iron and siderophores
[0019] Iron is an essential component in mammalian cell culture medium (i) as a trace element and (ii) as a ferritin substitute (e.g., iron as an iron chelator). Transferrin is generally derived from plasma. The compound is generally supplied as a lyophilized powder of partially iron-saturated human transferrin. Transferrin is a glycoprotein with homologous N-terminal and C-terminal iron binding domains, and is related to several other iron-binding proteins (including lactoferrin, melanin transferrin and ovotransferrin). Transferrin for animal cell culture is commercially available (e.g., by Sigma-Aldrich, CAS No. 11096-37-0). There are several other iron compounds used as transferrin substitutes. These exist as various salts in II / III form, as hydrated / dehydrated forms. Examples are iron phosphate (III), iron pyrophosphate (III), iron nitrate (III), iron sulfate (II), iron chloride (III), iron lactate (II), iron citrate (III), ammonium ferric citrate (III), dextran iron or sodium ethylenediaminetetraacetic acid iron salt.
[0020] We have identified iron choline citrate (iron choline citrate / iron choline citrate, CAS number 1336-80-7, molecular weight Mw = 991,5 g / mol + / - 49.57 g / mol, an iron complex with an iron content of about 10.2-12.4% due to 5% crystal water content, a molecular ratio of iron molecules: choline: citrate of 2:3:3, molecular formula C 33 H 57 Fe2N3O 24 ). However, other suitable iron choline citrate complexes are known, such as iron:choline:citrate in a 1:1:1 ratio, with a molecular weight of Mw=348.11 g / mole. The use of iron choline citrate promotes significantly higher product titers compared to state-of-the-art iron sources such as iron phosphate, iron pyrophosphate or iron citrate used in commercially available cell culture media. This effect also depends on the iron choline citrate concentration in the culture medium. Summary of the invention
[0021] The present invention provides a basal cell culture medium and a feed medium with novel amino acid ratios and / or iron choline citrate as an iron carrier, which improves the performance of mammalian cell culture processes, such as CHO culture and protein production processes, in particular product titers (e.g. monoclonal antibody (mAb) titers). Also provided are methods of using the basal cell culture medium and / or the feed medium for culturing mammalian cells and producing a target protein. The present invention also provides a culture medium platform comprising (i) a basal cell culture medium and (ii) a feed medium. Preferably, both the (basal) cell culture medium and the feed medium are chemically defined.
[0022] In one aspect, the present invention relates to a basal cell culture medium for culturing mammalian cells, comprising the following amino acids at the following molar ratios (mM / mM) relative to isoleucine: about 1.2-2.2 of L-leucine / L-isoleucine, about 0.5-0.9 of L-phenylalanine / L-isoleucine, about 1.5-2.7 of L-tyrosine / L-isoleucine, about 1.0-1.9 of L-threonine / 1-isoleucine, and about 1.0-1.9 of L-valine / L-isoleucine, wherein the basal cell culture medium has a total amino acid content of about 25 to 150 mM. In one embodiment, the basal cell culture medium further comprises L-lysine at a molar ratio (mM / mM) relative to isoleucine of about 1.6-2.9. The basal cell culture medium may further comprise at least one of the following amino acids in the following molar ratios (mM / mM) relative to isoleucine: about 0.3-0.5 of L-tryptophan / L-isoleucine, about 1.6-3.0 of L-proline / L-isoleucine; or about 0.4-0.7 of L-methionine / L-isoleucine. Preferably, the basal cell culture medium comprises L-tryptophan, L-proline and L-methionine, each in said molar ratio as defined above. The basal cell culture medium of the present invention is a serum-free medium, preferably a chemically defined medium or a chemically defined and protein-free medium. In one embodiment, the basal cell culture medium further comprises iron choline citrate at a concentration of about 0.1 to 5.0 mM, about 0.2 to 2.0 mM, about 0.2 to 1.0 mM, or about 0.4 to 1.0 mM. In certain embodiments, the basal cell culture medium has a total amino acid content of about 30 to about 130, preferably about 35 to about 120, more preferably about 40 to about 100 mM.
[0023] The present invention also relates to a basal cell culture medium for culturing mammalian cells, comprising iron choline citrate at a concentration of about 0.1 to 5.0 mM, about 0.2 to 2.0 mM, about 0.2 to 1.0 mM, or about 0.4 to 1.0 mM.
[0024] In another aspect, the present invention relates to a feed medium for culturing mammalian cells, comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine: about 2.3-4.2 L-leucine / L-isoleucine, about 0.6-1.1 L-phenylalanine / L-isoleucine, about 1.3-2.4 L-threonine / 1-isoleucine, and about 1.1-2.0 L-valine / L-isoleucine, wherein the feed medium has a total amino acid content of about 100 to 1000 mM. In one embodiment of the invention, the feed medium further comprises the following amino acids in the following molar ratios (mM / mM) relative to isoleucine: about 0.6-1.1 L-tyrosine / L-isoleucine, and / or about 1.1-2.1 L-lysine / L-isoleucine. The feed medium according to the present invention may further comprise at least one of the following amino acids in the following molar ratios (mM / mM) relative to isoleucine: about 0.3-0.6 of L-tryptophan / L-isoleucine, about 0.9-1.8 of L-proline / L-isoleucine; or about 0.4-0.8 of L-methionine / L-isoleucine. Preferably, the feed medium comprises L-tryptophan, L-proline and L-methionine in said molar ratios, each as defined above. The feed medium is typically a concentrated feed medium. Preferably, the feed medium of the present invention is a serum-free medium, more preferably a chemically defined medium or a chemically defined and protein-free medium. In one embodiment, the feed medium further comprises iron choline citrate at a concentration of about 0.4 to 5 mM, about 0.4 to 1.0 mM or about 0.5 to 1.0 mM, preferably about 0.5 to 0.6 mM. In one embodiment, the feed medium is characterized by a low salt content, preferably a low salt content of about 100 mM or less, and more preferably about 50 mM or less. In certain embodiments, the feed medium of the present invention has a total amino acid content of about 200 to about 900, preferably about 300 to about 800, more preferably about 400 to about 700 mM.
[0025] The present invention also relates to a feed medium for culturing mammalian cells, comprising iron choline citrate at a concentration of about 0.4 to 5 mM, about 0.4 to 1.0 mM or about 0.5 to 1.0 mM, preferably about 0.5 to 0.6 mM.
[0026] In a related aspect, the present invention relates to a culture medium platform for culturing mammalian cells, comprising a basal cell culture medium of the invention as described herein and a feed medium of the invention.
[0027] The basal cell culture medium and feed medium of the present invention are particularly suitable for culturing rodent or human cells, wherein the rodent cells are preferably Chinese hamster ovary (CHO) cells, such as CHO-K1 cells, CHO-DG44 cells, CHO-DUKX B11 cells or CHO glutamine synthetase (GS)-deficient cells, most preferably, the cells are CHO-DG44 or CHOGS-deficient cells.
[0028] In another aspect, the present invention relates to a method of producing a basal cell culture medium, comprising: a) providing a basal cell culture medium, and b) adding amino acids to a final molar ratio according to the present invention or adjusting the amino acid ratio to a final molar ratio according to the present invention. The method may further comprise the step of adding or adjusting iron choline citrate as an iron source, wherein the concentration of iron choline citrate is about 0.1 to 5.0 mM, about 0.2 to 2.0 mM, about 0.2 to 1.0 mM, or about 0.4 to 1.0 mM.
[0029] In another aspect, the present invention relates to a method for generating a feed medium, comprising: providing a feed medium and adding amino acids in a final molar ratio according to the present invention or adjusting the amino acid ratio to a final molar ratio according to the present invention. The method may further comprise the step of adding iron choline citrate as an iron source or adjusting the iron choline citrate as an iron source, wherein the concentration of the iron choline citrate is about 0.4 to 5 mM, about 0.4 to 1.0 mM, or about 0.5 to 1 mM, preferably about 0.5 to 0.6 mM.
[0030] The present invention further relates to a method for culturing mammalian cells, comprising the steps of: a) providing mammalian cells, b) culturing the cells in a basal cell culture medium according to the present invention, and c) optionally adding a feed medium according to the present invention to the basal cell culture medium; wherein the cells are cultured under conditions that allow cell proliferation.
[0031] The present invention further relates to a method for producing a target protein, comprising the steps of: a) providing mammalian cells comprising a target gene encoding a target protein, b) culturing the cells in a basal cell culture medium of the present invention, and c) optionally adding a feed medium of the present invention to the basal cell culture medium, and d) optionally separating and / or isolating and / or purifying the target protein from the cell culture; wherein the cells are cultured under conditions that allow expression of the target protein. The target protein may be a secreted protein, preferably, the target protein is an antibody or an Fc-fusion protein.
[0032] The mammalian cells used in any of the methods of the invention may be rodent or human cells, preferably, the rodent cells are Chinese hamster ovary (CHO) cells, such as CHO-K1 cells, CHO-DG44 cells, DuxB11 cells or CHO GS-deficient cells, most preferably, the cells are CHO-DG44 or CHO GS-deficient cells. The feed medium used in any of the methods of the invention is added to the cells cultured in the basal cell culture medium, wherein (a) the feed medium is added to the basal cell culture medium at about 10-50 ml / L / day based on the starting volume of the culture, (b) the feed medium is added starting at day 0, 1, 2 or 3, and / or (c) the feed medium is added continuously, or as a bolus several times a day, twice a day, once a day, every other day or every two days.
[0033] In a further aspect, the present invention relates to a kit of parts comprising the basal cell culture medium of the present invention and / or the feed medium of the present invention and optionally mammalian cells.
[0034] The present invention further relates to the use of the basal cell culture medium of the present invention for producing a protein, which comprises culturing mammalian cells producing a target protein in the culture medium for a period of time under conditions suitable for cell growth and protein production, harvesting the target protein, and recovering the protein from the culture medium or cell lysate. The use may further comprise supplying the cells with a feed medium of the present invention during the culture period.
[0035] The present invention further relates to the use of the feed medium of the present invention for producing a protein, which comprises culturing mammalian cells producing a target protein in the basal cell culture medium of the present invention for a period of time under conditions suitable for cell growth and protein production, supplying the cells with the feed medium, harvesting the target protein and recovering the protein from the culture medium.
[0036] Also mentioned is the use of iron choline citrate as an iron carrier in a mammalian cell culture medium, wherein the iron choline citrate is present in the mammalian cell culture medium at a concentration of about 0.2 to 2.0 mM. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 : RPMI-based basal medium with and without optimized amino acid adjustment in batch experiments at different total amino acid concentrations.
[0038] (AD): CHO2 (CHO-DG44) Rituximab cells were cultured in duplicate (N=2) in RPMI-based medium 4.1 and medium 5.0 without and with optimized amino acid ratios, with a total amino acid concentration of 44 mM, Culture in Medium 5.0 with optimized amino acid ratios (44 mM), Culture in Medium 4.1 without optimized amino acid ratios (44 mM). Shown are (A) viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44) Rituximab cells, (B) viability [%] CHO2(CHO-DG44) Rituximab cells and (C) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, (D) lactate concentration [g / L] CHO2(CHO-DG44) Rituximab.
[0039] (EH): CHO2 (CHO-DG44) Rituximab cells were cultured in duplicate (N=2) in RPMI-based medium 4.2 and medium 5.1 without and with optimized amino acid ratios, with a total amino acid concentration of 66 mM, Culture in medium 5.1 with optimized amino acid ratios (66 mM), ■ Culture in medium 4.2 without optimized amino acid ratios (66 mM). Shown are (E) viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44) Rituximab cells, (F) viability [%] CHO2(CHO-DG44) Rituximab cells and (G) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, (H) lactate concentration [g / L] CHO2(CHO-DG44) Rituximab.
[0040] (I): CHO2 (CHO-DG44) Rituximab cells were cultured in duplicate (N=2) in RPMI-based medium 4.3 and medium 5.2 without and with optimized amino acid ratios, with a total amino acid concentration of 22 or 36 mM, ■ Cultures in medium 5.2 with optimized amino acid ratios (22 mM), Cultures in medium 4.3, without the optimized amino acid ratio (22 mM), Culture in Medium 4.0 without optimized amino acid ratios (36 mM). Shown are (I) Product concentration [mg / L] CHO2 (CHO-DG44) Rituximab.
[0041] (J): CHO2 (CHO-DG44) Rituximab cells were cultured in duplicate (N=2) in RPMI-based medium 4.2 and medium 5.2 without and with optimized amino acid ratios, with total amino acid concentrations of 22 and 66 mM, ■ Culture in medium 5.2 with optimized amino acid ratios (22 mM), ● Culture in medium 4.2 without optimized amino acid ratios (66 mM). Shown is (J) Product concentration [mg / L] CHO2 (CHO-DG44) Rituximab.
[0042] Figure 2 : RPMI-based basal medium with single amino acid changes of -20% or -40% based on optimized amino acid ratios in batch experiments.
[0043] (AD): CHO2 (CHO-DG44) Rituximab cells were cultured in RPMI-based Medium 5.3 (with all amino acids at optimal ratios, control) and Medium 5.3.1 (only a single amino acid modification - 20%), Culture in medium 5.3.1 (L-leucine-20%), Culture in medium 5.3.1 (L-valine - 20%), □ Culture in medium 5.3.1 (L-phenylalanine - 20%), ■ Culture in medium 5.3 (with all amino acids, control), ● Culture in medium 5.3.1 (L-arginine - 20%), ◆ Culture in medium 5.3.1 (L-asparagine - 20%), Culture in medium 5.3.1 (L-aspartic acid-20%), Culture in medium 5.3.1 (L-histidine-20%), Culture in medium 5.3.1 (L-lysine-20%), Culture in medium 5.3.1 (L-methionine - 20%), ○ culture in medium 5.3.1 (L-proline - 20%), ◇ culture in medium 5.3.1 (L-serine - 20%), △ culture in medium 5.3.1 (L-threonine - 20%), ▽ culture in medium 5.3.1 (L-tryptophan - 20%), (leftward triangle, hollow) culture in medium 5.3.1 (L-tyrosine - 20%). Shown are (A) viable cell concentrations [1x10 5cells / mL] CHO2(CHO-DG44) Rituximab cells, (B) viability [%] CHO2(CHO-DG44) Rituximab cells, (C) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, (D) lactate concentration [mg / L] CHO2(CHO-DG44) Rituximab, controls were performed in triplicate (N=3), and tests were run in duplicate (N=2).
[0044] (EG): CHO2 (CHO-DG44) Rituximab cells were cultured in RPMI-based Medium 5.3 (with all amino acids at optimal ratios, control) and Medium 5.3.1 (only a single amino acid, such as L-leucine, L-valine or L-phenylalanine, modified -20%), ■ Cultures in Medium 5.3 (with all amino acids, control), □ Cultures in Medium 5.3.1 (L-phenylalanine -20%), Culture in medium 5.3.1 (L-leucine-20%), Cultures in Medium 5.3.1 (L-Valine-20%), (EG) Product concentrations [mg / L] CHO2 (CHO-DG44) Rituximab, Controls were performed in triplicate (N=3), and tests were run in duplicate (N=2).
[0045] (HK): CHO2 (CHO-DG44) Rituximab cells were cultured in RPMI-based Medium 5.3 (with all amino acids at optimal ratios, control) and Medium 5.3.1 (only a single amino acid, such as L-arginine, L-asparagine, L-aspartic acid, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine or L-valine, reduced by -40%), ■ Culture in Medium 5.3 (with all amino acids, control), ● Culture in Medium 5.3.1 (L-arginine -40%), ◆ Culture in Medium 5.3.1 (L-asparagine -40%), Culture in medium 5.3.1 (L-aspartic acid-40%), Culture in medium 5.3.1 (L-histidine-40%), Culture in medium 5.3.1 (L-isoleucine-40%), Culture in medium 5.3.1 (L-leucine-40%), Culture in medium 5.3.1 (L-lysine - 40%), □ Culture in medium 5.3.1 (L-methionine - 40%), ○ Culture in medium 5.3.1 (L-phenylalanine - 40%), ◇ Culture in medium 5.3.1 (L-proline - 40%), △ Culture in medium 5.3.1 (L-serine - 40%), ▽ Culture in medium 5.3.1 (L-threonine - 40%), (leftward triangle, hollow) Culture in medium 5.3.1 (L-tryptophan - 40%), (rightward triangle, hollow) Culture in medium 5.3.1 (L-tyrosine - 40%), Cultures in medium 5.3.1 (L-valine-40%), shown are (H) viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44) Rituximab cells, (I) viability [%] CHO2(CHO-DG44) Rituximab cells, (J) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, (K) lactate concentration [mg / L] CHO2(CHO-DG44) Rituximab, controls were performed in triplicate (N=3), and tests were run in duplicate (N=2).
[0046] (LO): CHO2 (CHO-DG44) Rituximab cells were cultured in RPMI-based Medium 5.3 (with all amino acids at optimal ratios, control) and Medium 5.3.1 (only a single amino acid, such as L-phenylalanine, L-valine, L-leucine, L-threonine or L-isoleucine, reduced by -40%), ■ Cultures in Medium 5.3 (with all amino acids, control), ○ Cultures in Medium 5.3.1 (L-phenylalanine -40%), Culture in medium 5.3.1 (L-valine-40%), Culture in medium 5.3.1 (L-leucine reduced -40%), ▽ Culture in medium 5.3.1 (L-threonine -40%), Cultures in medium 5.3.1 (L-isoleucine-40%). Shown are viable cell concentrations (L) [1x10 5 cells / mL] CHO2(CHO-DG44) Rituximab cells, (M) viability [%] CHO2(CHO-DG44) Rituximab cells, (N) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, (O) lactate concentration [mg / L] CHO2(CHO-DG44) Rituximab, controls were performed in triplicate (N=3) and tests were run in duplicate (N=2).
[0047] Figure 3 : -40% change of a single amino acid based on optimized amino acid ratios in basal medium in batch experiments. (AC): Cells were cultured in batch mode in medium 6.4.10–6.4.15 (only a single amino acid, such as L-lysine, L-methionine, L-proline, L-tryptophan or L-tyrosine, or two amino acids L-tyrosine and L-lysine, reduced by -40%) or in control medium 6.4.0.1 (with optimized amino acid ratios), ■ Cultures in medium 6.4.0.1 (with all amino acids, control), Culture in medium 6.4.10 (L-tyrosine and L-lysine - 40%), Culture in medium 6.4.11 (L-tyrosine - 40%), □ Culture in medium 6.4.12 (L-lysine - 40%), ● Culture in medium 6.4.13 (L-methionine - 40%), ◇ Culture in medium 6.4.14 (L-tryptophan - 40%), Cultures in medium 6.4.15 (L-proline-40%). Shown are (A) viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44)rituximab cells, (B) viability [%] CHO2(CHO-DG44)rituximab cells, and (C) product concentration [mg / L] CHO2(CHO-DG44)rituximab, all experiments were performed in duplicate (N=2).
[0048] Figure 4 : Optimized culture medium and effect of feed medium in fed-batch experiments at standard or reduced feed rates.
[0049] (AC): Effect of optimized basal medium and feed medium in a fed-batch experiment at standard feed rate. Cells were cultured in basal medium 6.2 (with optimized amino acid ratios), medium 6.3 (without optimized amino acid ratios), feed medium 6.2 (with optimized amino acid ratios) and feed medium 6.3 (without optimized amino acid ratios). CHO2 (CHO-DG44) Rituximab cells were cultured in various combinations of basal medium and feed medium, ■ Cultures in basal medium 6.2 (with optimized amino acid ratios) and feed medium 6.2 (with optimized amino acid ratios), ● Cultures in basal medium 6.2 (with optimized amino acid ratios) and feed medium 6.3 (without optimized amino acid ratios), ◆ Cultures in basal medium 6.3 (without optimized amino acid ratios) and feed medium 6.2 (with optimized amino acid ratios), Shown are (A) viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44)rituximab cells, (B) viability [%] CHO2(CHO-DG44)rituximab cells, and (C) product concentration [mg / L] CHO2(CHO-DG44)rituximab, all experiments were performed in duplicate (N=2).
[0050] (DF): Effect of optimized basal medium and feed medium at reduced feed rate. Cells were cultured in medium 6.2 (with optimized amino acid ratios), medium 6.3 (without optimized amino acid ratios), feed medium 6.2 (with optimized amino acid ratios) and feed medium 6.3 (without optimized amino acid ratios). CHO2 (CHO-DG44) Rituximab cells were cultured in various combinations of basal medium and feed medium. The feed rate for all cultures was reduced to elicit a robust response of the cultures, ■ Cultures in basal medium 6.2 (with optimized amino acid ratios) and feed medium 6.2 (with optimized amino acid ratios and reduced feed rate), ● Cultures in basal medium 6.2 (with optimized amino acid ratios) and feed medium 6.3 (without optimized amino acid ratios), ◆ Cultures in basal medium 6.3 (without optimized amino acid ratios) and feed medium 6.2 (with optimized amino acid ratios), Cultures in basal medium (without optimized amino acid ratios) and feed medium 6.3 (without optimized amino acid ratios). Shown are (D) viable cell concentrations [1x10 5cells / mL] CHO2(CHO-DG44)rituximab cells, (E) viability [%] CHO2(CHO-DG44)rituximab cells, and (F) product concentration [mg / L] CHO2(CHO-DG44)rituximab, all experiments were performed in duplicate (N=2).
[0051] (GJ): Effect of optimized media and feed media in 2-L scale. Cells were cultured in medium 6.2 (with optimized amino acid ratios), medium 6.3 (without optimized amino acid ratios), feed medium 6.2 (with optimized amino acid ratios), and feed medium 6.3 (without optimized amino acid ratios) in a fully controlled 2-L system. CHO2 (CHO-DG44) Rituximab cells were cultured in various combinations of optimized basal and feed media, ■ Cultures in basal medium 6.2 (with optimized amino acid ratios) and feed medium 6.2 (with optimized amino acid ratios), ● Cultures in basal medium 6.2 (with optimized amino acid ratios) and feed medium 6.3 (without optimized amino acid ratios), ◆ Cultures in basal medium 6.3 (without optimized amino acid ratios) and feed medium 6.2 (with optimized amino acid ratios), Shown are (G) viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44) Rituximab cells, (H) viability [%] CHO2(CHO-DG44) Rituximab cells, (I) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, (J) lactate concentration [g / L] CHO2(CHO-DG44) Rituximab, All experiments were performed in duplicate (N=2).
[0052] (KM): Effect of optimized RPMI medium and RPMI feed medium. Cells were cultured in RPMI basal medium 3.1 (without optimized amino acid ratios), RPMI medium 3.9 (with optimized amino acid ratios), RPMI feed medium-2 (without optimized amino acid ratios), and RPMI feed medium-3 (with optimized amino acid ratios). CHO2 (CHO-DG44) Rituximab cells were cultured in various combinations of optimized basal medium and feed medium, ■ Cultures in RPMI medium 3.9 (with optimized amino acid ratios) and RPMI feed medium-3 (with optimized amino acid ratios), ● Cultures in RPMI medium 3.9 (with optimized amino acid ratios) and RPMI feed medium-2 (without optimized amino acid ratios), ◆ Cultures in RPMI medium 3.1 (without optimized amino acid ratios) and RPMI feed medium-3 (with optimized amino acid ratios), Shown are (K) viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44) Rituximab cells, (L) viability [%] CHO2(CHO-DG44) Rituximab cells, (M) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, All experiments were performed in duplicate (N=2).
[0053] (NP): Effect of optimized RPMI medium and RPMI feed medium compared to basal and feed medium without optimal amino acid (AA) ratios or spent medium optimized AA ratios. Cells were cultured in RPMI medium 3.1 (without optimized amino acid ratios), RPMI medium 3.9 (with optimized amino acid ratios), RPMI feed medium-2 (without optimized amino acid ratios) and RPMI feed medium-3 (with optimized amino acid ratios), RPMI medium 3.5 (with spent medium supplemented AA), RPMI feed medium 3.5 (with spent medium supplemented AA). CHO2 (CHO-DG44) Rituximab cells were cultured in various combinations of RPMI basal medium and RPMI feed medium, ■ cultures in RPMI medium 3.9 (with optimized amino acid ratios) and RPMI feed medium-3 (with optimized amino acid ratios), ● cultures in RPMI medium 3.9 (with optimized amino acid ratios) and RPMI feed medium-2 (without optimized amino acid ratios), ◆ cultures in RPMI medium 3.1 (without optimized amino acid ratios) and RPMI feed medium-2 (without optimized amino acid ratios), Cultures in RPMI medium 3.1 (without optimized amino acid ratios) and RPMI feed medium-3 (with optimized amino acid ratios), ○ Cultures in RPMI medium 3.5 (with spent medium supplemented AA) and RPMI feed medium-2 (without optimized amino acid ratios), □ Cultures in RPMI medium 3.5 (with spent medium supplemented AA) and RPMI feed medium-3.5 (with spent medium supplemented AA), shown are (N) viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44) Rituximab cells, (O) viability [%] CHO2(CHO-DG44) Rituximab cells, and (P) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, all experiments were performed in duplicate (N=2).
[0054] Figure 5 : + / - 20% or + / - 40% variation of 5 or 7 amino acids in fed-batch experiments.
[0055] (AC): Changes of + / -40% for 5 amino acids based on novel amino acid ratios in optimized media and feeds. Amino acids L-phenylalanine, L-valine, L-leucine, L-threonine, L-isoleucine were changed by + / -40% in a positive or negative alternating pattern (uppercase or non-uppercase AA letters) compared to the control (with optimized amino acid ratios). CHO2 (CHO-DG44) Rituximab cells were cultured in fed-batch in medium 6.4.0.1 (with optimized amino acid ratios, control), basal medium 6.4.3 (5 amino acids PHE, val, LEU, thr, ILE varied by + / -40%, positive), basal medium 6.4.4 (5 amino acids phe, VAL, leu, THR, ile varied by + / -40%, negative), feed medium 6.4 (with optimized amino acid ratios, control), feed medium 6.4.3 (5 amino acids PHE, val, LEU, thr, ILE varied by + / -40%, positive), feed medium 6.4.4 (5 amino acids phe, VAL, leu, THR, ile varied by + / -40%, negative), ■ cultures in basal medium 6.4.0.1 and feed medium 6.4 (with optimized amino acid ratios, control), Cultures in basal medium 6.4.3 and feed medium 6.4.3 (five amino acids PHE, val, LEU, thr, ILE varied by + / -40%, positive), Cultures in basal medium 6.4.4 and feed medium 6.4.4 (five amino acids phe, val, leu, THR, ile varied by + / -40%, negative), shown are (A) viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44)rituximab cells, (B) viability [%] CHO2(CHO-DG44)rituximab cells, and (C) product concentration [mg / L] CHO2(CHO-DG44)rituximab, all experiments were performed in duplicate (N=2).
[0056] (DF): Changes of 7 amino acids based on novel amino acid ratios in optimized media and feeds. Compared to the control (with optimized amino acid ratios), the amino acids L-phenylalanine, L-valine, L-leucine, L-threonine, L-isoleucine, L-tyrosine, L-lysine were changed by + / -40% in a positive or negative alternating pattern (uppercase or non-uppercase AA letters). CHO2 (CHO-DG44) Rituximab cells were cultured in fed-batch medium 6.4.0.1 (with optimized amino acid ratios, control), basal medium 6.4.7 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS varied by + / -40%, positive), basal medium 6.4.8 (7 amino acids phe, VAL, leu, THR, ile, TYR, lys varied by + / -40%, negative), feed medium 6.4 (with optimized amino acid ratios, control), feed medium 6.4.7 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS varied by + / -40%, positive), feed medium 6.4.8 (7 amino acids phe, VAL, leu, THR, ile, tyr, lys varied by + / -40%, negative), ■ in basal medium 6.4.0.1 and feed medium 6.4 (with optimized amino acid ratios, control), (D) Viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44) Rituximab cells, (E) viability [%] CHO2(CHO-DG44) Rituximab cells, (F) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, All experiments were performed in duplicate (N=2).
[0057] (GH): Changes of 7 amino acids based on new amino acid ratios in optimized media and feeds. Amino acids L-phenylalanine, L-valine, L-leucine, L-threonine, L-isoleucine, L-tyrosine, L-lysine were varied by + / -20% and + / -40% at reduced feed rates in positive or negative alternating mode (upper or non-upper AA letters) compared to the control (with optimized amino acid ratios). CHO2 (CHO-DG44) Rituximab cells were grown in fed-batch at reduced feed rates in medium 6.4.0.1 and feed medium 6.4 (with optimized amino acid ratios, for control standard feed rate as well as reduced feed rate), basal medium 6.4.5 (7 amino acids acidic PHE, val, LEU, thr, ILE, tyr, LYS varied by + / -20%, positive), basal medium 6.4.7 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS varied by + / -40%, positive), basal medium 6.4.8 (7 amino acids phe, VAL, leu, THR, ile, TYR, lys varied by + / -40%, negative), feed medium 6.4 (with optimized amino acid ratios, control) , feed medium 6.4.5 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS varied by + / - 20%, positive), feed medium 6.4.7 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS varied by + / - 40%, positive) and feed medium 6.4.8 (7 amino acids phe, VAL, leu, THR, ile, tyr, lys varied by + / - 40%, negative), ■ cultures in basal medium 6.4.0.1 and feed medium 6.4 (with optimized amino acid ratios, control) with standard feed rate, ● cultures in basal medium 6.4.0.1 and feed medium 6.4 (with optimized amino acid ratios, control) and reduced feed rate, Cultures in basal medium 6.4.5 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS varied by + / -20%, positive) and feed medium 6.4.5 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS varied by + / -20%, positive), Cultures in basal medium 6.4.7 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS varied by + / -40%, positive) and feed medium 6.4.7 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS varied by + / -40%, positive), Cultures in basal medium 6.4.8 (7 amino acids phe, VAL, leu, THR, ile, TYR, lys varied by + / -40%, negative) and feed medium 6.4.8 (7 amino acids phe, VAL, leu, THR, ile, tyr, lys varied by + / -40%, negative) are shown (G) Viable cell concentration [1x10 5 cells / mL] CHO2(CHO-DG44) Rituximab cells, (H) viability [%] CHO2(CHO-DG44) Rituximab cells, and (I) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, all experiments were performed in duplicate (N=2).
[0058] Figure 6 Fed-batch culture of CHO-DG44 derived cell lines producing different therapeutic molecules in optimized basal medium 6.2 and feed medium 6.2 (with optimized amino acid ratios in basal medium and feed medium, without hydroxy-L-proline), Fc-fusion protein produced in CHO-DG44 cells, ■ Rituximab (IgG1κ) antibody produced in CHO-DG44 cells (CHO2 (CHO-DG44) Rituximab), mAb5 / IgG1κ antibody produced in CHO-DG44 cells, mAb6 / IgG1κ produced in CHO-DG44 cells. Shown are (A) viable cell concentrations [1x10 5 cells / mL], (B) viability [%] CHO-DG44, (C) product concentration [mg / L] for mAb5 / IgG1 and mAb6 / IgG1, and (D) product concentration [mg / L] Fc-fusion protein and rituximab, all experiments were performed in duplicate (N=2).
[0059] Figure 7 : Comparison of iron choline citrate with other iron carriers in approximately equimolar amounts.
[0060] (A, B) CHO2 (CHO-DG44) Rituximab cells were cultured in fed-batch mode in basal medium 6.2a (with indicated iron carriers in basal medium) and feed medium 6.2a without iron choline citrate, ■ culture in basal medium 0.2 g / L iron choline citrate, ● culture in basal medium with 1.0 g / L iron choline citrate; ◆ culture in basal medium with 2.0 g / L iron choline citrate; Culture in basal medium with 0.5 g / L ferric pyrophosphate; + Culture in basal medium with 0.8 g / L ferric pyrophosphate, (filled star) Culture in basal medium with 1.3 g / L ferric pyrophosphate, Cultures in basal medium with 0.3 g / L iron phosphate, (solid pentagons) cultures in basal medium with 0.5 g / L iron phosphate, Cultures in basal medium with 0.7 g / L iron phosphate. Shown are (A) viable cell concentrations [1x10 5 cells / mL] CHO2(CHO-DG44) Rituximab cells, (B) product concentration [mg / L] CHO2(CHO-DG44) Rituximab, All experiments were performed in duplicate (N=2).
[0061] (C) Product concentration [mg / L] of CHO2 (CHO-DG44) Rituximab cells cultured in basal medium 6.2a with different concentrations of iron choline citrate and feed medium 6.2a containing 0.56 g / l iron choline citrate in fed-batch mode (N=2), ■ Culture in basal medium without iron choline citrate, ◆ Culture in basal medium with 0.2 g / l iron choline citrate; Culture in basal medium with 0.4 g / L iron choline citrate; + culture in basal medium with 2.0 g / L iron choline citrate.
[0062] (D) Product concentration [mg / L] of CHO2 (CHO-DG44) Rituximab cells cultured in basal medium 6.2a with iron choline citrate or iron citrate in approximately equimolar amounts and feed medium 6.2a in fed-batch mode (N=2), ■ Culture in basal medium without iron choline citrate and feed medium with 0.56 g / l iron choline citrate, (filled stars) Culture in basal medium with 0.2 g / l iron choline citrate and feed medium with 0.56 g / l iron choline citrate; Cultures in basal medium with 0.1 g / L ferric citrate and feed medium with 0.25 g / l ferric citrate.
[0063] Figure 8: Comparison of iron choline citrate and iron citrate in approximately equimolar amounts in RPMI-based medium. Product concentrations of CHO2 (CHO-DG44) Rituximab cells cultured in basal medium 3.1 with iron choline citrate or iron citrate in approximately equimolar amounts and feed medium 2 containing 0.56 g / l iron citrate in fed-batch mode (N=2), ■ Cultures in basal medium without iron choline citrate, ● Cultures in basal medium with 0.2 g / l iron choline citrate; + Cultures in basal medium with 0.1 g / L iron citrate. Shown are product concentrations [mg / L] CHO2 (CHO-DG44) Rituximab, comparing (A) 0.2 g / l iron choline citrate (●) with 0.1 g / l iron citrate (+), (B) 0.4 g / l iron choline citrate With 0.2g / l ferric citrate (pentagonal), (C) 2g / l ferrous choline citrate with 1g / l ferric citrate (●), and (D) 0.2g / l (●) and 2g / l Ferrous choline chloride.
[0064] Fig. 9 : Comparison of iron choline citrate and ferric citrate in approximately equimolar amounts in medium 6.2a or RPMI-based medium in a 2 L bioreactor in fed-batch mode. CHO2 (CHO-DG44) Rituximab cells were cultured in fed-batch mode (N=2) in (AC) basal medium 6.2a with iron choline citrate or iron citrate and feed medium 6.2a containing 0.56 g / l iron choline citrate (D), or basal medium 3.1 with iron choline citrate or iron citrate and feed medium-2 containing 0.25 g / l iron citrate, + in basal medium 6.2a with 0.2 g / l iron choline citrate. (filled stars) culture in basal medium 6.2a with 2 g / L iron choline citrate and feed medium 6.2a with 0.56 g / L iron choline citrate; (filled pentagons) culture in basal medium 6.2a with 1 g / L iron citrate and feed medium 6.2a with 0.56 g / L iron choline citrate. ■ Culture in RPMI-based basal medium 3.1 with 0.2 g / l iron choline citrate and feed medium 2 with 0.25 g / l ferric citrate, ● Culture in RPMI-based basal medium 3.1 with 2 g / l iron choline citrate and feed medium 2 with 0.25 g / l ferric citrate; ◆ Culture in RPMI-based basal medium 3.1 with 1 g / L ferric citrate and feed medium 2 with 0.25 g / l ferric citrate.
[0065] Fig.10Figure : Two fed-batch cultures of a CHO-K1 GS-derived cell line producing rituximab were grown in parallel in basal medium 6.2GS and feed medium 6.2GS, both with optimized AA ratios. Shown are (A) viable cell concentrations [1x10 6 cells / mL], (B) survival rate of rituximab-producing CHO-K1 GS cells [%] and (C) final product concentration [mg / L] after 14 days of culture process. DETAILED DESCRIPTION
[0066] definition
[0067] The general embodiment of "comprising" or "comprised" includes the more specific embodiment "consisting of." Furthermore, the singular and plural forms are not used in a limiting manner. The terms used in the course of the present invention have the following meanings.
[0068] As used herein, the term "cell culture medium" is a culture medium for culturing mammalian cells, which contains the minimum essential nutrients and components such as vitamins, trace elements, salts, bulk salts, amino acids, lipids, carbohydrates in a preferably buffered medium (preferably pH about 7.0, pH = 7.3-6.6, pH = 7.0). Non-limiting examples of such cell culture media include commercially available culture media such as RPMI, DMEM: F12, DMEM, Hams / F12, etc., and proprietary culture media from various sources (e.g., culture medium 6.2). The cell culture medium can be a basic cell culture medium. The cell culture medium can also be a basic cell culture medium to which a feed medium and / or additives are added. If the cells are cultured in a fermenter or bioreactor, the cell culture medium can also be referred to as a fermentation broth.
[0069] As used herein, the term "basal medium" or "basal cell culture medium" is a cell culture medium for culturing mammalian cells as defined below. It refers to a culture medium in which cells are cultured from the start of a cell culture run, and is not used as an additive to another culture medium, although various components can be added to the culture medium. The basal medium serves as a basis to which optional further additives or feed medium can be added during cultivation (i.e., cell culture operation). The basal cell culture medium is provided from the beginning of a cell culture process. In general, the basal cell culture medium provides nutrients such as carbon sources, amino acids, vitamins, main salts (e.g., sodium chloride or potassium chloride), various trace elements (e.g., manganese sulfate), pH buffers, lipids, and glucose. The main main salts are usually provided only in the basal medium, and must not exceed a final osmotic pressure of about 280-350mOsmo / kg in the cell culture, so that the cell culture can grow and proliferate under reasonable osmotic stress.
[0070] As used herein, the term "feed" or "feed medium" refers to a nutrient concentrate / concentrated nutrient composition used as feed in a culture of mammalian cells. It is provided as a "concentrated feed medium" to avoid dilution of the cell culture, and the feed medium is usually provided at 10-50 ml / L / day, preferably at 15-45 ml / L / day, more preferably at 20-40 ml / L / day, and even more preferably at 30 ml / L / day, based on the starting volume of the culture in the container (CSV, meaning the starting volume at day 0). The feed rate is understood to be the average feed rate over the entire feed period. The feed medium usually has most but not all of the components of the basal cell culture medium at a higher concentration. Generally, the feed medium replaces nutrients consumed during the cell culture, such as amino acids and carbohydrates, while salts and buffers are less important and are usually provided together with the basal medium. The feed medium is usually added to the (basic) cell culture medium / fermentation broth in a fed batch mode. However, feed can be added in different modes such as continuous or push addition or via perfusion related techniques (chemostat or hybrid perfusion system). Preferably, feed medium is added every day, but it can also be added more frequently, such as twice a day or less frequently, such as every other day. The addition of nutrients is usually performed during the culture period (i.e., after day 0). In contrast to the basal medium, the feed consists of a highly concentrated nutrient solution (e.g. >6x) that provides all components similar to the basal medium, except for "high osmotic active compounds", such as major host salts (e.g. NaCl, KCl, NaHCO3, MgSO4, Ca(NO3)2). Typically, >6x or more concentrated basal medium with no or reduced bulk salts maintains good solubility of the compound and sufficiently low osmolarity (e.g., 270-1500 mOsmo / kg, preferably 310-800 mOsmo / kg; Medium 6.2 feed osmolarity is about 1500 mOsmo / kg due to high glucose, salts and optimal AA) to maintain osmolarity in cell culture at about 270-550 mOsmo / kg, preferably about 280-450 mOsmo / kg, more preferably about 280-350 mOsmo / kg.
[0071] The cell culture medium, basal medium and / or feed medium can both be serum-free, chemically defined or chemically defined and protein-free. As used herein, "serum-free medium" refers to a cell culture medium for in vitro cell culture that does not contain serum from an animal source. This is preferred because serum may contain contaminants such as viruses from the animal, and because serum is inexact and varies from batch to batch. The basal medium and feed medium according to the present invention are serum-free.
[0072] As used herein, "chemically defined medium" refers to a cell culture medium suitable for in vitro cell culture, in which all components are known. More specifically, it does not contain any supplements such as animal serum or plant, yeast or animal hydrolysates. It may contain hydrolysates, as long as all components have been analyzed and their exact composition is known and can be prepared reproducibly. The basal medium and feed medium according to the present invention are preferably chemically defined.
[0073] As used herein, "protein-free medium" refers to a cell culture medium for in vitro cell culture that does not contain proteins (except proteins produced by the cells to be cultured), wherein proteins refer to polypeptides of any length, but exclude single amino acids, dipeptides or tripeptides. Specifically, growth factors such as insulin and insulin-like growth factor (IGF) are not present in the culture medium. Preferably, the basal medium and feed medium according to the present invention are chemically defined and protein-free.
[0074] As used herein, a "medium platform" or "media platform" consists of a basal cell culture medium provided from the start of the cell culture process and a feed medium that is added to the basal cell culture medium during the culture period. Optionally, further additives such as glucose may be added during the cell culture period. The feed medium may be supplied in any type of fed-batch process mode (e.g., continuously, with a modified feed rate, or as a bolus feed addition).
[0075] As used herein, the term "commercially available culture medium / culture medium system" refers to a commercially available cell culture medium with a completely known composition. Due to the need for exact nutrient composition, these culture media serve as references for the culture medium of the present invention. Commercially available culture media are, for example, DMEM:F12 (1:1), DMEM, HamsF12, and RPMI. The feed medium of the commercial culture medium used herein is prepared as a 12-fold concentrate of a basal culture medium without bulk salts. The term "commercially available culture medium system" relates to a system comprising commercially available basal cell culture media such as DMEM:F12 (1:1), DMEM, HamsF12, and RPMI and a feed medium, wherein the feed medium is a corresponding concentrated basal culture medium (e.g., 12-fold concentrated) without bulk salts or with reduced bulk salts.
[0076] As used herein, "1x" means the standard concentration typically used in a particular basal medium, "2x" means twice the standard concentration, and so on. The feed medium is, for example, preferably a 6x to 20x solution, i.e., 6 to 20 times the standard concentration in the basal medium for amino acid optimization, without regard to bulk salts such as sodium chloride or potassium chloride. However, the skilled person will appreciate that cell culture requirements are different during, for example, the exponential growth phase and the protein production phase. Therefore, preferably, the basal medium and the feed medium are adapted to these changing requirements. Therefore, the amino acid ratios in the feed medium are typically different from the amino acid ratios in the basal medium.
[0077] The term "cell cultivation" or "cell culture" includes cell cultivation and fermentation processes in all scales (e.g. from microtiter plates to large-scale industrial bioreactors, i.e. from sub-mL scale to >10.000 L scale), in all different process modes (e.g. batch, fed-batch, perfusion, continuous culture), in all process control modes (e.g. uncontrolled, fully automated and controlled systems with control of e.g. pH, temperature, oxygen content), in all kinds of fermentation systems (e.g. single-use systems, stainless steel systems, glass systems). In a preferred embodiment of the invention, the cell culture is a mammalian cell culture and is a batch or fed-batch culture.
[0078] As used herein, the term "fed batch" relates to cell culture, wherein cells are continuously or periodically supplied with a feed medium containing nutrients. Feed can be started after cell culture at day 0, or more generally one, two or three days after starting culture. Feed can follow a predetermined schedule, such as every day, every two days, every three days, etc. Alternatively, cell growth, nutrients or toxic byproducts of the culture can be monitored, and the feed can be adjusted accordingly. Common monitoring methods for animal cell culture are described in the experimental section below. In general, the following parameters are usually measured every day, and viable cell concentration, product concentration and several metabolites such as glucose or lactic acid (reducing pH and derived from acidic waste metabolites of cell glucose conversion), pH, osmotic pressure (measurement of salt content) and ammonium (negatively affecting growth rate and reducing growth inhibitors of viable biomass) are covered. Compared with batch culture (culture without feed), higher product titers can be obtained in fed batch mode. Typically, fed batch culture is stopped at a certain point, and cells and / or target proteins in the harvested and optionally purified culture medium are obtained.
[0079] The terms "viability" and "survival rate" are used synonymously and refer to the % living cells in a cell culture as determined by methods known in the art, such as trypan blue exclusion using a Cedex device based on automated microscopic cell counting (Innovatis AG, Bielefeld). However, there are many other methods for determining survival rate, such as fluorescence (e.g. based on propidium iodide), calorimetric or enzymatic methods that reflect the energy metabolism of living cells, such as methods using LDH lactate dehydrogenase or certain tetrazolium salts such as Alamar Blue, MTT (3-(4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) or TTC (tetrazolium chloride).
[0080] As used herein, the term "amino acid" refers to the twenty natural amino acids encoded by the universal genetic code, usually the L-type (i.e., L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamic acid, L-glutamine, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine and L-valine). Amino acids (e.g., glutamine and / or tyrosine) can be provided as dipeptides with increased stability and / or solubility, preferably containing L-alanine (L-ala-x) or L-glycine extensions (L-gly-x), such as glycyl-glutamine and alanyl-glutamine. In addition, cysteine can also be provided as L-cystine. As used herein, the term "amino acid" includes all different salts thereof, such as (but not limited to) L-arginine monohydrochloride, L-asparagine monohydrate, L-cysteine hydrochloride monohydrate, L-cystine dihydrochloride, L-histidine monohydrochloride dihydrate, L-lysine monohydrochloride and hydroxy-L-proline, L-tyrosine disodium dehydrate. The exact form of the amino acid is not important for the present invention unless characteristics such as solubility, osmotic pressure, stability, purity are impaired. Usually and preferably, L-arginine is used as L-arginine x HCl, L-asparagine is used as L-asparagine x H2O, L-cysteine is used as L-cysteine x HCl x H2O, L-cystine is used as L-cystine x 2HCl, L-histidine is used as L-histidine x HCl x H2O, and L-tyrosine is used as L-tyrosine x 2Na x 2H2O, wherein each preferred amino acid form can be selected independently of each other or together or in any combination thereof. Also included are dipeptides comprising one or both of the relevant amino acids. For example, L-glutamine is typically added to the cell culture medium in the form of a dipeptide (e.g., L-alanyl-L-glutamine) for improved stability and reduced ammonium accumulation during storage or long-term culture. This is also effective for dipeptides containing L-glycine or other dipeptides containing L-alanine, which are considered for calculating amino acid ratios.
[0081] As used herein, the term "all amino acids in the culture medium" or "total amino acid content" refers to the sum of "amino acids" as defined above in mM. In dipeptides, each amino acid is counted separately, so 1 mM alanyl-glutamine is counted as 1 mM L-alanine and 1 mM L-glutamine (molar ratio 1: 1). Similarly in L-cystine, each cysteine is counted separately, so 1 mM L-cystine is counted as 2 mM L-cysteine (molar ratio 1: 2). Compared with the basic cell culture medium, the total amino acid content is usually about 5 to 20 times higher in the concentrated feed medium, preferably about 7 to 15 times, and more preferably about 10 times. The total amino acid content of the basal medium according to the present invention can be about 25 to 150 mM, preferably about 30 to 130 mM, more preferably about 35 to 120 mM, and even more preferably about 40 to 100 mM. The total amino acid content of the feed medium may be about 100 to 1000 mM, preferably about 200 to 900 mM, more preferably about 300 to 800 mM, and even more preferably about 400 to 700 mM. Other amino acids not directly encoded by the universal genetic code, such as L-ornithine, hydroxy-L-proline or metabolites thereof such as taurine, may further be present in the basal cell culture medium or the feed medium, but these are not counted for the total amino acid content.
[0082] As used herein, the term "amino acid ratio" refers to the ratio of the molar concentration of each amino acid associated with the molar concentration of a reference amino acid. The molar ratio is calculated for each amino acid associated with the reference amino acid (with units [mM / mM]). For the amino acid ratio calculation according to the present invention, L-isoleucine is used as the reference amino acid (although other amino acids can theoretically be used as reference amino acids, such as phenylalanine or methionine). This can be further referred to as the molar ratio relative to isoleucine (mM / mM). Typically, the reference amino acid can be easily measured with a statistically low standard variation and is provided in a similar concentration range in a commonly used culture medium.
[0083] The term "spent medium amino acid ratio adjustment" means that the amino acids are adjusted based on spent medium analysis only, without taking into account cellular and metabolic needs and specific intracellular or extracellular rates. Thus, amino acid analysis is performed on samples taken from cell culture supernatant on different days, and amino acids below a certain threshold are supplemented in basal and feed medium.
[0084] As used herein, the term "ferrous choline citrate" refers to the chemical compound choline iron citrate classified under CAS number 1336-80-7, which forms a choline iron complex. Common synonyms used are, for example, iron citrate bile salt, choline iron citrate, choline citrate, choline iron (III), choline iron citrate, tricholine citrate, choline iron citrate, 2-hydroxyethyl-trimethylammonium, 2-hydroxypropane-1,2,3-tricarboxylate, boxylato (4-) ferrate (1-) ethylamine, 2-hydroxy-n, n, n-trimethyl-hydroxy (2-hydroxy-1,2,3-propanetricarboxylic acid). The compound can be added to both the basal and feed medium as an iron carrier. Preferably, ferrous choline citrate (ferric choline citrate, CAS No. 1336-80-7, molecular weight Mw=991,5 g / mol + / - 49.57 g / mol due to 5% crystal water content, iron complex with an iron content of about 10.2-12.4%, a molecular ratio of iron: choline: citrate of 2:3:3, molecular formula C 33 H 57 Fe2N3O 24 , which is available, for example, from Dr. Paul Lohmann GmbH KG). However, other suitable iron choline citrate structures can be used in equimolar amounts based on the iron concentration, for example in a 1:1:1 ratio of iron:choline:citrate, with a molecular weight of Mw=348.11 g / mole, or in a (2):3:3 ratio of (iron):choline:citrate, with a molecular weight of Mw=501.61 g / mole, with a molecular weight of C 21 H 47 N3O 10 (Iron-free and formula). The use of iron choline citrate promoted significantly higher product titers in equimolar amounts compared to state of the art iron sources used in commercially available cell culture media (e.g., ferric phosphate, ferric pyrophosphate, or ferric citrate).
[0085] The terms "polypeptide" or "protein" or "product" or "product protein" or "amino acid residue sequence" are used interchangeably. These terms "refer to amino acid polymers of any length. These terms also include proteins that are post-translationally modified by reactions including, but not limited to, glycosylation, glycation, acetylation, phosphorylation, oxidation, amidation, or protein processing. Modifications and changes can be made in the structure of a polypeptide, such as fusion with other proteins, amino acid sequence substitutions, deletions, or insertions, while the molecule maintains its biological functional activity. For example, certain amino acid sequence substitutions can be made in a polypeptide or its underlying nucleic acid coding sequence, and a protein with similar or improved properties can be obtained. Amino acid modifications can be prepared, for example, by performing site-specific mutagenesis or polymerase chain reaction-mediated mutagenesis on its underlying nucleic acid sequence. The terms "polypeptide", "protein", "product" and "product protein" therefore also include, for example, a fusion protein consisting of an immunoglobulin component (e.g., an Fc component) and a growth factor (e.g., an interleukin), an antibody or any antibody-derived molecule form or an antibody fragment.
[0086] The term "target protein" or "target product" or "target polypeptide" includes proteins, polypeptides, fragments thereof, peptides, fusion proteins, all of which can be expressed in a selected host cell. Typically, the target protein is a recombinant protein, i.e., a protein encoded by a recombinant DNA resulting from molecular cloning. These target proteins can be antibodies, enzymes, cytokines, lymphokines, adhesion molecules, receptors and derivatives or fragments thereof, and any other polypeptides, which can act as agonists or antagonists and / or have therapeutic or diagnostic uses or can be used as research reagents. Preferably, the target protein is a secreted protein or protein fragment, more preferably an antibody or antibody fragment or Fc-fusion protein. "Target product" can also be antisense RNA, tRNA, rRNA, other RNAs as part of a ribonucleoprotein or other regulatory RNA.
[0087] As used herein, the terms "gene of interest", "desired sequence", "polynucleotide of interest" or "desired gene" have the same meaning and refer to a polynucleotide sequence of any length encoding a product of interest. The gene may further include regulatory sequences before (5' non-coding or non-translated sequence) and after (3' non-coding or non-translated sequence) the coding sequence. The selected sequence may be a full-length or truncated gene, a fusion or a tagged gene, and may be a cDNA, genomic DNA or a DNA fragment. It is generally understood that genomic DNA encoding a polypeptide or RNA includes non-coding regions (i.e., introns) that are spliced with the mature messenger RNA (mRNA) and are therefore not present in the cDNA encoding the same polypeptide or RNA. It may be a native sequence, i.e., a naturally occurring form, or may be mutated, or contain sequences derived from different sources or otherwise modified as desired. These modifications include codon optimization to optimize codon usage in the selected host cell or tagging. Furthermore, they may include the removal or addition of cis-acting sites, such as (cryptic) splice donors, acceptor sites and branch points, polyadenylation signals, TATA-boxes, chi sites, ribosome entry sites, repetitive sequences, secondary structures (e.g. stem-loops), binding sites for transcription factors or other regulatory factors, restriction endonuclease sites, etc., to give only some but non-limiting examples. The selected sequence may encode a secreted, cytoplasmic, nuclear, membrane-bound or cell surface polypeptide.
[0088] Cell culture media and amino acid ratios
[0089] The 20 standard amino acids (L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamic acid, L-glutamine, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine and L-valine) encoded by the universal genetic code play an important role in protein synthesis because they provide building blocks for cellular proteins and target proteins (e.g., monoclonal antibodies). Thus, amino acids interact multiple times in cellular metabolism. They are taken up from the cell culture medium in specific amounts, they are interconverted within cellular metabolism, are introduced into host cell proteins or product proteins, are excreted by the cell as a byproduct, and connect cellular metabolism catabolism and anabolism at various points, for example, between amino acid metabolism and the citric acid cycle. In both the basal and feed media, the optimal composition, concentration and ratio of amino acids need to be provided for optimal nutrient supply over the entire life cycle of cell culture (seeding, lag phase, exponential growth phase, conversion phase, stationary phase, death phase characterized by a significant decrease in cell viability). However, the ratio of amino acids appears to be more important than the actual exact concentration of each individual amino acid.
[0090] Therefore, in one aspect of the present invention, there is provided a basal cell culture medium for culturing mammalian cells, comprising the following amino acids at the following molar ratios (mM / mM) relative to isoleucine: about 1.2-2.2 of L-leucine / L-isoleucine, about 0.5-0.9 of L-phenylalanine / L-isoleucine, about 1.5-2.7 of L-tyrosine / L-isoleucine, about 1.0-1.9 of L-threonine / 1-isoleucine, and about 1.0-1.9 of L-valine / L-isoleucine, wherein the basal cell culture medium has a total amino acid content of about 25 to 150 mM amino acids. In one embodiment, the molar ratios (mM / mM) relative to isoleucine are: about 1.2-2.1, preferably about 1.3-1.8, more preferably about 1.5-1.8, and even more preferably about 1.7 L-leucine / L-isoleucine; about 0.5-0.9, preferably about 0.6-0.9, more preferably about 0.6-0.8, and even more preferably about 0.7 L-phenylalanine / L-isoleucine; about 1.6-2.6, preferably about 1. .7-2.5, more preferably about 1.9-2.3, and even more preferably about 2.1 of L-tyrosine / L-isoleucine; about 1.1-1.8, preferably about 1.2-1.8, more preferably about 1.3-1.6, and even more preferably about 1.5 of L-threonine / 1-isoleucine; and about 1.1-1.9, preferably about 1.2-1-8, more preferably about 1.3-1.6, and even more preferably about 1.5 of L-valine / L-isoleucine. In certain embodiments, the culture medium of the present invention further comprises L-lysine at a molar ratio relative to isoleucine of about 1.6-2.9, preferably about 1.7-2.8, more preferably about 1.8-2.7, more preferably about 2.0 to 2.5, and even more preferably about 2.2. In certain embodiments, the basal medium of the present invention further comprises L-tryptophan at a molar ratio of about 0.3-0.5, preferably about 0.3-0.5, more preferably about 0.3-0.4, more preferably about 0.3-0.4, and even more preferably about 0.4 relative to isoleucine; or L-proline at a molar ratio of about 1.6-3.0, preferably about 1.7-2.8, more preferably about 1.8-2.7, more preferably about 2.0-2.5, and even more preferably about 2.3 relative to isoleucine, or L-methionine at a molar ratio of about 0.4-0.7, preferably about 0.4-0.6, more preferably about 0.4-0.6, more preferably about 0.5-0.6, and even more preferably about 0.5 relative to isoleucine. In certain embodiments, the molar ratios of L-tryptophan, L-proline and L-methionine relative to L-isoleucine are defined above. The total amino acid content in the basal cell culture medium may be about 25-150 mM, preferably about 30-130 mM, more preferably about 35-120 mM, and even more preferably about 40-100 mM.
[0091] Preferably, the amino acid ratio of L-leucine, L-phenylalanine, L-threonine, L-valine and L-tyrosine and optionally further L-lysine, L-tryptophan, L-proline and / or L-methionine relative to isoleucine is within 30%, 25%, 20% or 10% of the ratios provided in Table 2a for the basal medium 6.2.
[0092] More specific exemplary amino acid ratios of the basal cell culture medium of the present invention (Basal Medium 6.2) are provided in Table A below, in direct comparison to the amino acid ratios in selected commercial basal cell culture media.
[0093] Table A: Amino acid ratios of each amino acid to the reference isoleucine (Ile) for basal cell culture medium.
[0094]
[0095] In another aspect of the present invention, a feed medium for culturing mammalian cells is provided, comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine: about 2.3–4.2 of L-leucine / L-isoleucine, about 0.6-1.1 of L-phenylalanine / L-isoleucine, about 1.3-2.4 of L-threonine / 1-isoleucine, and about 1.1-2.0 of L-valine / L-isoleucine, wherein the feed medium has a total amino acid content of about 100 to 1000 mM amino acids. In one embodiment, the molar ratios (mM / mM) relative to isoleucine are: about 2.4-4.0, preferably about 2.6-3.9, more preferably about 2.9-3.5, and even more preferably about 3.2 for L-leucine / L-isoleucine; about 0.6-1.1, preferably about 0.7-1.0, more preferably about 0.8-0.9, and even more preferably about 0.9 for L-phenylalanine / L-isoleucine; about 1.4-2.3, more preferably about 1.5-2.2, more preferably about 1.7-2.0, and even more preferably about 1.8 for L-threonine / 1-isoleucine; and about 1.2-2.0, preferably about 1.3-1.9, more preferably about 1.4-1.7, and more preferably about 1.6 for L-valine / L-isoleucine.
[0096] In one embodiment, the feed medium further comprises L-tyrosine in a molar ratio of about 0.6-1-1 relative to isoleucine and / or L-lysine in a molar ratio of about 1.1-2.1 relative to isoleucine. Preferably, tyrosine is present in the feed medium at a ratio of about 0.6-1.0, preferably about 0.7-1.0, more preferably about 0.7-0.9, and even more preferably about 0.8. Preferably, lysine is present in the feed medium at a ratio of about 1.2-2.0, preferably about 1.3-1.9, more preferably about 1.4-1.8, and even more preferably about 1.6. Preferably, the molar ratio of L-tyrosine and L-lysine is as defined above. In certain embodiments, the feed medium of the present invention further comprises L-tryptophan at a molar ratio relative to isoleucine of about 0.3-0.6, preferably about 0.3-0.6, more preferably about 0.4-0.5, more preferably about 0.4-0.5, and even more preferably about 0.5; or L-proline at a molar ratio relative to isoleucine of about 0.9-1.8, preferably about 1.0-1.7, more preferably about 1.1-1.6, more preferably about 1.2-1.5, and even more preferably about 1.4, or L-methionine at a molar ratio relative to isoleucine of about 0.4-0.8, preferably about 0.4-0.7, more preferably about 0.5-0.7, more preferably about 0.5-0.6, and even more preferably about 0.6. In certain embodiments, the molar ratios of L-tryptophan, L-proline and L-methionine relative to L-isoleucine are defined above. The total amino acid content in the basal cell culture medium may be about 100-1000 mM, preferably about 200 to about 900, more preferably about 300 to about 800, and even more preferably about 400 to about 700 mM.
[0097] Preferably, the amino acid ratio of L-leucine, L-phenylalanine, L-threonine and L-valine, and optionally further L-tyrosine, L-lysine, L-tryptophan, L-proline and / or L-methionine relative to L-isoleucine is within 30%, 25%, 20% or 10% of the ratios provided in Table 6 for feed medium 6.2.
[0098] More specific exemplary amino acid ratios of the feed medium of the present invention (Feed Medium 6.2) are provided in Table B below, in direct comparison with the amino acid ratios in selected commercial feed media.
[0099] Table B: Amino acid ratios of each compound to the reference isoleucine (Ile) for feed medium.
[0100]
[0101]
[0102] Feed medium is added to the basal cell culture medium or culture medium as concentrated feed medium. For example, feed medium can be based on the culture starting volume (CSV), with about 10-50ml / L / day, preferably with about 15 to 45ml / L / day, more preferably with about 20-40ml / L / day, and even more preferably with about 30ml / L / day. The rate (volume / day) at which feed medium is added to the cell culture with ml / L / day (the culture starting volume in the volume / container added with ml liters / day) is understood to be the average rate of the entire feed period, and the added volume can be changed between each addition during the feed period. Feeding can also be stopped about 1 to 3 days before cultivation and / or harvesting terminates. It is preferred to add a small volume to avoid dilution of other nutrients in the dilution cell culture, and to maintain the culture volume constant as much as possible. Feed medium can be added continuously, several times a day, every day or every other day. Preferably, the feed medium is added every day or every other day from the 0th day, the 1st day or the 2nd day.
[0103] The basal cell culture medium and / or feed medium of the present invention are serum-free, and preferably chemically defined or chemically defined and protein-free. In addition, the basal cell culture medium and feed medium of the present invention are suitable for culturing mammalian cells, i.e., they are basal mammalian cell culture medium and mammalian feed medium, respectively. The basal cell culture medium and feed medium of the present invention are suitable for culturing all types of mammalian cells, such as rodent or human cells, wherein rodent cells are preferred. More preferably, the mammalian cell is a Chinese hamster ovary cell (CHO), such as a CHO-K1 cell, a CHO-DG44 cell, a DuxB11 cell or a CHO GS defective cell, and most preferably, the cell is a CHO-DG44 cell or a CHO GS defective cell.
[0104] The basal cell culture medium comprising the amino acid ratios of the invention may further comprise iron choline citrate at a concentration as described below for the basal cell culture medium. Similarly, the feed medium comprising the amino acid ratios of the invention may further comprise iron choline citrate at a concentration as described below for the feed medium.
[0105] Culture medium and iron carriers
[0106] In mammalian cell culture, iron is needed as a trace element. In vivo, iron is mainly combined by ferritin and transferrin in serum. The typical iron source in cell culture medium is transferrin. In advanced serum-free or even protein-free mammalian cell culture medium, several aspects related to iron need to be addressed, such as identifying suitable iron carriers, the weak bioavailability of iron, identifying sufficient physiological concentration ranges (due to the presence of harmful free radicals in vitro regarding the potential toxicity of iron compounds, and having minimal negative effects / no negative effects on cell viability), complex binding behavior (iron can be combined with a variety of substances in the culture medium formulation, and thereby can easily become biologically unavailable for cell culture), oxidation state and optimal cell culture performance (e.g. titer).
[0107] In the present invention, the compound iron choline citrate is provided as a novel iron carrier in mammalian cell culture compared to established iron carriers used in cell culture.
[0108] Therefore, in another aspect, the present invention provides a basal cell culture medium for culturing mammalian cells, comprising iron choline citrate at a concentration of about 0.1 to 5.0 mM, about 0.2 to 2.0 mM, about 0.2 to 1.0 mM, or about 0.4 to 1.0 mM.
[0109] In yet another aspect, the present invention provides a feed medium comprising iron choline citrate at a concentration of about 0.4 to 5.0 mM, about 0.4 to 1.0 mM, or about 0.5 to 1 mM, preferably about 0.5 to 0.6 mM.
[0110] The concentration of iron choline citrate in the basal medium and the feed medium is based on iron choline citrate (ferric choline citrate, CAS No. 1336-80-7, molecular weight Mw=991,5 g / mol + / - 49.57 g / mol due to 5% crystal water content, an iron complex with an iron content of about 10.2-12.4%, a molecular ratio of iron:choline:citrate of 2:3:3, molecular formula C 33 H 57 Fe2N3O 24 ). However, the present invention includes other iron choline citrate structures and can be used in equimolar amounts based on iron concentration, for example at a 1:1:1 ratio of iron:choline:citrate, with a molecular weight of Mw=348.11 g / mole. This means, for example, that 1 mM iron choline citrate with a molar iron:choline:citrate ratio of 2:3:3 is equivalent to 2 mM iron choline citrate with a molar iron:choline:citrate ratio of 1:1:1.
[0111] The use of ferrous choline citrate as an iron carrier results in an increased product titer. In addition, compared with other iron sources confirmed as iron carriers such as ferric citrate, the novel iron carrier ferrous choline citrate is generally chemically characterized by a higher purity compared with ferric citrate. The higher potential batch-to-batch variability of the iron carrier confirmed such as ferric citrate can cause a negative effect (e.g., the reproducibility in manufacturing is negatively affected) in biopharmaceutical manufacturing. Ferrous choline citrate can be used in both basal and / or feed medium, preferably ferrous choline citrate is added to both basal medium and feed medium. Compared with other iron sources used in cell culture medium such as iron phosphate (III) or iron pyrophosphate (III), the use of ferrous choline citrate results in improved culture performance, such as significantly higher product titer. The basal cell culture medium comprising ferrous choline citrate according to the present invention can further include the novel amino acid ratio of the basal medium according to the present invention as described above. Similarly, the feed medium comprising ferrous choline citrate according to the present invention can further include the novel amino acid ratio of the feed medium according to the present invention as described above.
[0112] The basal cell culture medium and / or feed medium of the present invention are serum-free, preferably chemically defined or chemically defined and protein-free. In addition, the basal cell culture medium and feed medium of the present invention are suitable for culturing mammalian cells, i.e., they are basal mammalian cell culture medium and mammalian feed medium, respectively. The basal cell culture medium and feed medium of the present invention are suitable for culturing all types of mammalian cells, such as rodent or human cells, wherein rodent cells are preferred. More preferably, the mammalian cell is a Chinese hamster ovary cell (CHO), such as a CHO-K1 cell, a CHO-DG44 cell, a DuxB11 cell or a CHO GS defective cell, and most preferably, the cell is a CHO-DG44 cell or a CHO GS defective cell.
[0113] Culture medium and other components
[0114] The cell culture medium for culturing mammalian cells may further comprise essential nutrients and components such as vitamins, trace elements, salts, bulk salts, lipids or lipid precursors and carbohydrates in a preferably buffered medium. Growth factors may also be added to the basal cell culture medium or feed medium, such as recombinant insulin-like growth factor (IGF) or recombinant insulin.
[0115] Non-limiting examples of suitable vitamins are biotin (B7), calcium pantothenate, cyanocobalamin (B12), folic acid, inositol, nicotinamide (B3), pyridoxal hydrochloride, pyridoxine hydrochloride, riboflavin (B2) and / or thiamine (B1). Non-limiting examples of trace elements are ammonium molybdate, ammonium vanadate, copper sulfate, nickel sulfate, sodium selenite, sodium silicate and zinc sulfate and / or zinc chloride. Non-limiting examples of lipid precursors are choline chloride, ethanolamine, glycerol, inositol, linoleic acid, fatty acids, phospholipids or cholesterol-related compounds.
[0116] In addition, the salt can be (but not limited to) calcium chloride, calcium nitrate, magnesium chloride, magnesium sulfate, potassium chloride and / or sodium chloride. One function of the salt is to adjust the osmotic pressure in the culture medium. Preferably, the osmotic pressure of the basal cell culture medium does not exceed the optimal range usually between 280-350mOsmo / kg. Typically, the osmotic pressure of the concentrated feed medium is <2000mOsmo / kg, preferably <1500mOsmo / kg, more preferably <1000mOsmo / kg. The osmotic pressure of the feed medium can be higher, but after addition, the osmotic pressure in the cell culture should not be increased beyond the optimal range of 270-550mOsmo / kg, preferably 280-450mOsmo / kg, more preferably 280-350mOsmo / kg.
[0117] Preferably, the feed medium of the invention in any embodiment thereof has a reduced salt content or a low salt content. Reduced salt content or low salt content means, for example, a total salt concentration of about 100 mM or less, preferably about 50 mM or less (e.g. a feed medium without sodium chloride and a reduced concentration of potassium chloride). A reduced low salt content in the feed medium of the invention is particularly preferred when the feed medium is used as a conventional growth medium in combination with the basal cell culture medium of the invention.
[0118] The most important contributors to osmotic pressure are sodium, chloride and bicarbonate as well as glucose and other carbon sources such as amino acids. For media developers, the challenge is to create highly concentrated nutrient mixtures and powder formulations for their manufacture that meet the following requirements: preferably, an x-fold concentrate of the basal medium combination (positive impact on supply chain management and regulatory aspects), providing essential nutrients and nutrients that cannot be synthesized by the cells themselves in sufficient quantities (preferably as a reasonably balanced composition), overcoming the solubility aspects of feed concentrates, removing bulk salts due to osmotic pressure reasons, avoiding toxicity ranges, designing powder formulations that require carbon carriers for pharmaceutical reasons. In addition, for common fed-batch processes, the feed medium needs to be concentrated to minimize the culture volume during cultivation. The size of the bioreactor can actually lead to feeding constraints, which only allow a total feed dose of approximately 30% (25-35%) of the culture starting volume.
[0119] Carbohydrates can be, but are not limited to, glucose, mannose, galactose, fructose, sucrose or glucosamine, etc. These carbohydrates can be added directly to the basal cell culture medium and / or the feed medium, or can be added separately to the cell culture. Other energy sources include, but are not limited to, sodium pyruvate.
[0120] Mammalian cells should be cultured at a neutral pH, e.g., about pH 6.5 to about pH 7.5, preferably about pH 6.6 to about pH 7.3, and more preferably at a pH of about 7. Therefore, a buffering agent should be added to the basal cell culture medium. For the feed medium, the pH may be slightly outside the range, as long as the addition of the feed medium does not bring the pH of the cell culture outside the range, as the feed medium is added as a concentrate. The preferred range of pH in the feed medium is about 6 to about 8. Suitable buffering agents include, but are not limited to, Hepes, phosphate buffers (e.g., monopotassium phosphate and dipotassium hydrogen phosphate and / or anhydrous disodium hydrogen phosphate and monosodium hydrogen phosphate), phenol red, sodium bicarbonate and / or sodium hydrogen carbonate.
[0121] Typically, the feed medium contains nutrients consumed during cell culture, such as amino acids and carbohydrates, while salts and buffers are less important. Some salts can therefore be omitted from the feed medium completely.
[0122] Cell culture performance
[0123] The basal cell culture medium of the present invention and / or feed medium or the cell culture medium platform comprising the basal culture medium determined by the chemical composition of the present invention and the feed medium determined by the chemical composition leads to improved cell culture performance. As used herein, the term "improved cell culture performance" includes, for example, significantly improved product titer, improved cell growth (e.g., viable cell count, cell viability) and favorable phenotypic behavior of the cell culture process, such as the reduced overflow metabolism (e.g., reduced lactate formation) of unwanted and toxic by-products. It also contributes to the osmotic pressure level reduced in the cell culture process.
[0124] The basal cell culture medium and / or feed medium of the present invention meet the cell-specific needs and metabolic needs of mammalian cell culture during the time course of cell culture. In other words, it meets the cell-specific needs of (i) mammalian cells, (ii) in a cell culture system, and (iii) throughout the life cycle of a culture run (which is about 10-20 days). Mammalian cells in culture have different nutritional requirements at different stages of a cell culture process. However, ideally, only one optimal basal medium and one (or very few) optimal feed medium / culture medium need to be designed to allow for the design of a sturdy, safe and effective bioprocess. The basal medium and / or feed medium provided herein meet this need.
[0125] Basal cell culture medium of the present invention and / or feed medium have improved cell culture performance.The limiting examples of improved cell culture performance are the increase of product titer, improved viable cell concentration and / or cell survival rate.In addition, cell expansion can be improved, which is required for inoculation training in the expansion program.For example, the culture scale is progressively increased from the thawing (mL scale) of the cell bank to the production scale (>10.000L scale).The better the growth in each Nx stage (wherein the N stage means the final production scale, and Nx means the cell expansion stage before the common final production stage in batch mode), the faster and better each transfer to the next stage can occur.Specifically, better cell growth and higher viable cell concentration allow Nx to cultivate and can be performed with the running time (therefore faster) of reduction.Better cell growth and higher viable cell concentration also result in improved transfer, resulting in overall improved performance. For example, when a certain Nx stage should be inoculated with a certain planting cell density, and the viable cell concentration is very high, it is necessary to transfer a relatively low volume of cell culture from one stage to the next stage (the transfer / CSV of the inoculum volume is defined as the spit ratio, and generally, 1:5 to 1:20 is common). This means that the "used" cell culture medium that only reduces the volume is transferred from one stage to the next stage at the same time, and the "new" culture medium of the maximum volume can be added to the next stage (constant overall culture volume). This also leads to improved overall cell culture performance (e.g., increased product titer) in the last N stage. Utilizing the novel basal cell culture medium and feed medium provided in the present invention, all these stages are improved. The positive effects of the novel iron carrier choline iron and / or the novel amino acid ratio are not limited to the basal culture medium and feed medium in the final production stage. It is also shown that the positive effects of the culture medium platform are suitable for the Nx stage, particularly the amino acid ratio. In the case of the culture medium modification in the Nx stage, these positive effects are also maintained. For example, MTX (methotrexate) is usually provided in the early stages of seeding training in order to maintain the selection pressure in mammalian cell culture using a recombinant cell line, such as a CHO cell line, preferably a CHO-DG44 cell line. In such examples, the use of the basal cell culture medium and / or feed medium or culture medium platform of the present invention results in significantly improved viable cell concentrations.
[0126] Cell culture / feed medium addition
[0127] Compared to conventional batch fermentation in which concentrated feed medium is not added to the culture during the entire culture period, the addition of nutrient concentrates named "feed medium" is required for standard fed-batch applications. In contrast to batch applications, it is well known that cell culture performance, such as maximum viable cell count, final product titer, metabolic waste accumulation, is significantly improved in fed-batch processes due to the supplementation of nutrients, vitamins, salts and other components. Typically, the maximum amount of feed solution added to the culture during the culture time depends on technical aspects, as well as metabolic driven aspects: the maximum volume of the bioreactor constrains the total feed volume to be added, while non-technical feed dosages are suitable for meeting the real cell nutrient requirements at any time during the culture period. In addition, depending on the cell line and process mode, feed addition can be added at a constant feed rate of, for example, 5-60 ml feed / L / d or, for example, continuously added at a small scale of 2-80 L (development, less work intensity), or, for example, added at a large scale of 2000-10.000 L with a discontinuous (large-scale manufacturing, more work intensity) method to minimize the risk of contamination. Typical intervals of feed addition during e.g. an 11 day fed-batch culture may vary between several times a day, daily or every 2-4 days and generally depend on the actual nutrient levels, growth phase, culture conditions such as pH or nutrient requirements of the culture.
[0128] Lactate / Carbon Dioxide / Glucose
[0129] In most cell cultures, non-ideal nutrient burning of the main carbon can be determined due to overflow metabolism. This means that the main carbon source, glucose, is ineffectively utilized and this contributes to an increase in organic acids such as lactic acid. The increased level of lactic acid can contribute to a pH drop below 6.65, and this will negatively affect the buffering capacity of the culture medium and thus the survival of the culture. For this reason, the CO2 concentration in the culture atmosphere is reduced at the beginning of the exponential growth phase to minimize the acid level in the culture medium.
[0130] Cell lines and cell culture
[0131] The basal cell culture medium and / or feed medium or culture medium platform of the present invention can be applied to all mammalian cell lines. However, the culture medium of the present invention can be further suitable for other eukaryotic cells, such as yeast, plant or insect cells. Mammalian cells according to the present invention can be oocytes, embryonic stem cells, hematopoietic stem cells or any type of differentiated cells. Preferably, mammalian cells are human, ape, mouse, goat, cattle, sheep, pig cells or rodent cell lines such as rats, rabbits or hamsters. Mammalian cells can be isolated primary cells or cell lines. Preferred cell lines or "host cells" for producing recombinant biopharmaceuticals are human, monkey or rodent cell lines (mouse, rat or hamster). Preferred human cells are PER.C6 or HEK 293 cells.
[0132] More preferred are rodent cells, such as hamster cells, preferably BHK21, BHK TK-, Chinese hamster ovary cells (CHO), CHO-K1, CHO-DXB11 (also known as CHO-DUKX or DuxB11), CHO-DUKX B1, CHO-S, CHO-DG44 and CHO glutamine synthetase (GS) deficient cells or derivatives / progeny of any such cell lines. Particularly preferred are CHO-DG44, CHO-DUKX, CHO-K1, CHO-S, CHO-DG44GS deficient cell lines and BHK21, and even more preferred are CHO-DG44 cells, CHO GS deficient cells (e.g. CHO-K1 GS deficient cells) and CHO-DUKX cells. In addition, murine myeloma cells, preferably NS0 and Sp2 / 0 cells or derivatives / progeny of any such cell lines are also referred to as production cell lines for biopharmaceutical proteins.
[0133] All cells and cell lines can be used in all kinds of cell culture, for example, ranging from plastic microtiter plates (nL to mL scale) to industrial-scale stainless steel bioreactors (L to kL scale), which also include any type of disposable system and all kinds of process control strategies from uncontrolled systems to fully controlled systems, including, for example, advanced online monitoring and advanced control strategies. Suitable culture conditions for mammalian cells are known in the art. Mammalian cells can be, for example, cultured in suspension or attached to a fixed surface.
[0134] Non-limiting examples of mammalian cells that can be used with the culture medium of the present invention are summarized in Table C.
[0135] Table C: Suitable exemplary mammalian production cell lines
[0136]
[0137] The production cells are preferably cultured under conditions that allow cell proliferation. In addition, the production cells are preferably cultured under conditions that are conducive to the expression of the desired gene and / or target protein. The target protein is not isolated from cells and / or cell culture supernatants. Preferably, the target protein is recovered from the culture medium as a secreted polypeptide, or if it is expressed without a secretion signal, it can be recovered from host cell lysates.
[0138] Usually, it is necessary to purify the target protein in such a way that other recombinant proteins, host cell proteins and pollutants are removed in order to obtain a substantially homogeneous preparation of the target protein. As a first step, cells and / or granular cell debris can be removed from the culture medium or lysate. Usually, the target product is then purified of pollutant soluble proteins, polypeptides and nucleic acids, for example by classification on immunoaffinity or ion exchange columns, ethanol precipitation, reversed-phase HPLC, Sephadex chromatography, chromatography on silicon dioxide or cation exchange resins such as DEAE.
[0139] Uses of culture medium
[0140] The basal cell culture medium or feed medium of the present invention can be used as a growth medium, as an inoculum medium, as a medium for cell expansion or cell line development, including transfection, expansion or both. In addition, the basal cell culture medium or feed medium can preferably be used in combination to produce the target protein from mammalian cells expressing the target protein.
[0141] Specifically, the basal medium and feed medium of the present invention can be used in a method for culturing mammalian cells, comprising the steps of: a) providing mammalian cells, b) culturing the cells in the basal cell medium of the present invention, and c) optionally adding the feed medium of the present invention to the basal cell medium; wherein the cells are cultured under conditions that allow cell proliferation. Preferably, the feed medium is also used in the method.
[0142] The basal medium and feed medium of the present invention can further be used in a method for producing a target protein, comprising the steps of: a) providing mammalian cells comprising a target gene encoding a target protein, b) culturing cells in a basal cell culture medium of the present invention, and c) optionally adding a feed medium of the present invention to the basal cell culture medium, and d) optionally separating and / or isolating and / or purifying the target protein from the cell culture; wherein the cells are cultured under conditions that allow the expression of the target protein. Preferably, the feed medium is used in the method. The feed medium can be added to the cells cultured in the basal cell culture medium at about 10-50 ml / L / day, preferably at about 15 to 45 ml / L / day, more preferably at about 20-40 ml / L / day, and more preferably at about 30 ml / L / day, based on the starting volume of the culture (CSV), wherein the culture medium can be added continuously, or as a bolus several times a day, twice a day, once a day, every other day or every two days. Preferably, the feed medium is added starting at day 0, 1, 2 or 3. The rate (volume / day) of adding feed medium to the cell culture in ml / L / day (feed volume added in ml / culture starting volume in vessel liter / day) is understood to be an average rate over the feeding period, and the volume added may vary between individual additions during the feeding period. Feeding may also be stopped about 1 to 3 days before termination of culture and / or harvesting.
[0143] Separation of the target protein from the cell culture can be accomplished by, for example, centrifugation, filtration, or any other method known in the art for separating the supernatant containing the protein from the cells or cell debris. If the protein is produced intracellularly, this may include lysis. Purification of the target protein from the cell culture means separating one or more proteins from a complex mixture, such as a cell culture supernatant or lysate, by methods known in the art, such as precipitation, chromatography, or gel electrophoresis.
[0144] The basal medium and feed medium of the present invention can be used for large-scale cell culture, preferably 100 L or more, more preferably 1000 L or more, or even more preferably 10000 L or more of cell culture.
[0145] The protein of interest may be an antibody, an enzyme, a cytokine, a lymphokine, an adhesion molecule, a receptor or a derivative or fragment thereof, and any other polypeptide that may act as an agonist or antagonist and / or have therapeutic or diagnostic uses or may act as a research reagent. The protein of interest may be, for example, an antibody, such as rituximab or an Fc-fusion protein. Preferably, the antibody is a monoclonal IgG1 antibody having heavy and light chains of the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2, or having heavy and light chains of the amino acid sequences of SEQ ID NO:3 and SEQ ID NO:4. The Fc-fusion protein preferably has the amino acid sequence of SEQ ID NO:5.
[0146] The protein of interest may also be a protein / polypeptide used to alter host cell properties within the scope of so-called "cell engineering", such as anti-apoptotic proteins, chaperones, metabolic enzymes, glycosylation enzymes and derivatives or fragments thereof, but not limited thereto.
[0147] In particular, the desired protein / polypeptide or target protein is (not limited thereto) such as insulin, insulin-like growth factor (IGF1), hGH, tPA, cytokines (e.g., interleukins (IL), such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, interferon (IFN) α, IFNβ, IFNγ, IFNω or IFNτ, tumor necrosis factor (TNF) such as TNFα and TNFβ, TNFγ, TRAIL; G-CSF, GM-CSF, M-CSF, MCP-1, VEGF and nanobodies. Also included is the production of erythropoietin or any other hormone growth factor and any other polypeptide that can act as an agonist or antagonist and / or has therapeutic or diagnostic use. The method according to the invention can also be advantageously used to produce antibodies, such as monoclonal, polyclonal, multispecific and single-chain antibodies, or fragments derived therefrom, such as Fab, Fab', F(ab')2, Fc and Fc' fragments, heavy and light immunoglobulin chains and their constant, variable or hypervariable regions and Fv- and Fd- fragments.
[0148] As used herein, the terms "antibody", "antibodies" or "immunoglobulins" relate to proteins selected from the group consisting of globulins, which are formed as a result of the host biological response of differentiated B lymphocytes (plasma cells) to foreign bodies (= antigens). They act as a specific defense against these foreign bodies. There are various classes of immunoglobulins: IgA, IgD, IgE, IgG, IgM, IgY, IgW. Preferably, the antibody is an IgG antibody, more preferably an IgG1 antibody. The terms immunoglobulin and antibody are used interchangeably. Antibodies include polyclonal, monoclonal, monospecific, bispecific, multispecific, single-chain antibodies, antigen-binding fragments of antibodies (e.g. Fab or F(ab')2 fragments), disulfide-linked Fvs, etc. Antibodies may be of any species and include chimeric and humanized antibodies. "Chimeric" antibodies are molecules in which antibody domains or regions are derived from different species. For example, the variable regions of the heavy and light chains may be derived from rat or mouse antibodies, and the constant regions derived from human antibodies. In "humanized" antibodies, only the minimum sequence is derived from non-human species. Usually only the CDR amino acid residues of human antibodies are replaced with CDR amino acid residues of non-human species, such as mice, rats, rabbits or llamas. Sometimes, several key framework amino acid residues that have an impact on antigen binding specificity and affinity are also replaced by non-human amino acid residues. Antibodies can be produced by chemical synthesis, by recombinant or transgenic means, by cell (e.g., hybridoma) culture, or by other means.
[0149] Immunoglobulin is a tetrameric polypeptide composed of two pairs of heterodimers, each of which is formed by a heavy chain and a light chain. The stabilization of both heterodimer and tetrameric polypeptide structures occurs via interchain disulfide bridges. Each chain consists of a domain called an "immunoglobulin domain" or "immunoglobulin region", whereby the terms "domain" or "region" are used interchangeably. Each domain contains about 70-110 amino acids and forms a compact three-dimensional structure. Both heavy and light chains contain a "variable domain" or "variable region" with less conserved sequences at their N-termini, which is responsible for antigen recognition and binding. The variable region of the light chain is also referred to as "VL", and the variable region of the heavy chain is also referred to as "VH".
[0150] The term "Fab fragment" (Fragment antigen binding = Fab) or "Fab" consists of the variable regions of both the heavy and light chains of an antibody (VH and VL), which are bound together by adjacent constant regions (CH1 and CL). These can be formed from conventional antibodies by protease digestion, for example using papain, but similar Fab fragments can also be produced simultaneously by genetic engineering. Further antibody fragments include "F(ab')2 fragments" or "F(ab')2", which can be prepared by proteolytic cleavage with pepsin or by genetic engineering, in which the two Fab arms of the antibody are still connected via an inter-heavy chain disulfide bridge located in the hinge region.
[0151] Due to their tendency to crystallize (Fc=crystallizable fragment), immunoglobulin fragments consisting of the CH2 and CH3 domains of the antibody heavy chains are called "Fc fragments", "Fc regions" or "Fc". These can be formed from conventional antibodies by protease digestion, for example using papain or pepsin, but can also be produced by genetic engineering. The N-terminal part of the Fc fragment may vary depending on how many amino acids of the hinge region are still present.
[0152] The term "Fc-fusion protein" describes a polypeptide containing a natural or modified (e.g., substituted, deleted, inserted) Fc region of an immunoglobulin as a fusion partner. The Fc fusion protein can be a naturally occurring protein (e.g., an antibody) or an engineered recombinant protein (e.g., a TNF receptor-Fc fusion protein or a VH region fused to an Fc region). The Fc-fusion protein can exist as a monomer or as a multimer, whereby the polypeptides can have identical or different sequences, may contain a linker sequence between two fusion partners and / or a hinge region of a polypeptide or a portion of a modified hinge region, or the polypeptide is directly fused to a CH2 domain.
[0153] Using genetic engineering methods, shortened antibody fragments consisting only of the variable regions of the heavy (VH) and light chains (VL) can be produced. These are called "Fv fragments" (variable fragment = fragment of the variable part) or "Fv". Because these Fv fragments lack the covalent bonding of the two chains through the cysteine of the constant chain, Fv fragments are generally stable. It is advantageous to connect the variable regions of the heavy and light chains by short peptide fragments of, for example, 10 to 30 amino acids, preferably 15 amino acids. In this way, a single peptide chain consisting of VH and VL connected by a peptide linker is obtained. This antibody protein is called "single-chain-Fv" or "scFv". Examples of such scFv antibody proteins are known from the prior art. In addition, more than one VH and / or VL region can be linked together.
[0154] In recent years, various strategies have been developed for preparing scFv as multimer derivatives. This is expected to lead to recombinant antibodies with improved pharmacokinetic and biodistribution properties and increased binding affinity in particular. In order to achieve the multimerization of scFv, scFv is prepared as a fusion protein with a multimerization domain. The multimerization domain can be, for example, the CH3 region of IgG or a coiled coil structure (helical structure), such as a leucine zipper domain. However, there are also strategies in which the interaction between the VH / VL regions of scFv is used for multimerization (such as dimers, trimers and pentamers). By dimers, technicians mean divalent homodimer scFv derivatives. The joint in the scFv molecule is shortened to 5-10 amino acids, resulting in the formation of homodimers in which interchain VH / VL superposition occurs. The dimers can be additionally stabilized by incorporating disulfide bridges. Examples of diabody-antibody proteins are known from the prior art.
[0155] By microbody, the skilled person means a bivalent, homodimeric scFv derivative. It consists of a fusion protein containing the CH3 region of an immunoglobulin, preferably IgG, most preferably IgG1, as a dimerization region, which is connected to the scFv via a hinge region (e.g., also from IgG1) and a connecting region. Examples of microbody-antibody proteins are known from the prior art.
[0156] By trimer the skilled person means: trivalent homotrimeric scFv derivatives. scFv derivatives in which VH-VL are directly fused without a linker sequence leading to the formation of trimers.
[0157] Those skilled in the art are also familiar with so-called minibodies, which have a bivalent, trivalent or tetravalent structure and are derived from scFv. Multimerization is carried out through a dimer, trimer or tetramer coiled-coil structure. In a preferred embodiment of the present invention, the target gene encodes any of those desired polypeptides mentioned above, preferably a monoclonal antibody, a derivative or a fragment thereof.
[0158] The term "antibody-derived molecule" is used interchangeably with "antibody-derived fragment" or "antibody fragment" and refers to polypeptides containing only a portion of one or more antibody domains or regions and / or the entire domain or region. Antibody fragments can a) form molecules by themselves, b) be linked to each other in various combinations, c) be fused to non-antibody sequences, d) be fused or linked to non-polypeptides (e.g., radionuclides), or d) any combination of the above. These polypeptides can exist as monomers or as multimers, whereby the polypeptides can have the same or different sequences.
[0159] Example
[0160] Materials and Methods
[0161] Cell lines
[0162] The CHO cell line (CHO-DG44) was adapted to serum-free medium conditions and further transfected with DNA to produce recombinant products relevant to industrial manufacturing, such as monoclonal antibodies, fusion proteins or bi / multispecific proteins. Specifically, two proprietary BIHEX (HEX I and HEX II) cells expressing different IgG constructs were used. B oehringer- I Ngelheim H igh E The cell line was derived from CHO-DG44 (HEX II) cells. These cells are DHFR-(dihydrofolate reductase) deficient, and methotrexate is used as a selection marker. If not otherwise specified, the cells used in the experiment are CHO-DG44 (HEX II) cells expressing rituximab as a recombinant protein, wherein the rituximab has a heavy chain containing the amino acid sequence of SEQ ID NO: 1 and a light chain containing the sequence of SEQ ID NO: 2, which is secreted into the culture medium. The cell line is hereinafter referred to as CHO2, CHO-DG44 rituximab or CHO2 (CHO-DG44) rituximab.
[0163] Analytical methods
[0164] Cell concentration and cell viability were determined by trypan blue exclusion using CEDEX (type 5.00, version 2.2) automated cell analyzer (Roche Innovatis, Bielefeld, Germany). The concentration of recombinant proteins such as IgG antibodies produced in quantitative culture medium was determined by Konelab60i (Thermo Scientific, Dreieich, Germany) analyzer based on photometry or by using HPLC method. Konelab 60i instrument is also used for quantitative metabolites in cell culture supernatant, such as glucose, lactic acid (lactate), glutamine, glutamate and ammonium. Amino acid concentration was determined by using GC 6890N / FID gas chromatograph (Agilent Technologies GmbH & Co.KG, Waldbronn, Germany). Amino acid analysis was performed by the EZ-faast scheme from Phenomenex (Aschaffenburg, Germany). The osmotic pressure curve was analyzed by osmomat automatic device (Gonotec GmbH, Berlin, Germany). The method is based on the freezing freezing point of a specific solution, which is proportional to the amount of dissolved particles. Dissolved carbon dioxide pCO2, dissolved oxygen pO2 and pH were measured daily using Rapidlab 248 / 348 instruments (Siemens Healthcare Diagnostics GmbH, Eschborn, Germany). These instruments and the required methods are well known in the art and are used for process monitoring and control in biopharmaceutical process development and manufacturing.
[0165] Shake flask culture
[0166] Shake flasks (Corning BV Life Sciences, Amsterdam, The Netherlands) were generally performed at small scale with a working volume of 60-500 ml in batch mode (no feed addition during cultivation) or fed-batch mode (with a standard feed rate of 30 ml / L / d nutrient feed addition during cultivation). In each experiment, the viable cell concentration at inoculation was usually set at 0.3×10 6Cell / ml. Shake flask culture is derived from the same inoculum pre-culture (thaw, cell expansion in seed training, in terms of cell age) to ensure comparability between different experimental settings when needed. For cell culture, a standard shake flask incubator (Infors AG, Bottmingen, Switzerland) is used with an oscillation rate of 120rpm, a temperature set point of 37°C, and humidity is set to 70%. The analytical method as described above is used to measure the standard process parameters of each day, which are total cell count and viable cell count, cell viability, metabolite concentration and other relevant cell culture parameters, such as dissolved oxygen pO2 (DO), dissolved carbon dioxide pCO2 (DCO) content or pH. This is routinely completed throughout the culture process to monitor and control the culture conditions of each experimental device. In the fed-batch experiment, the concentrated feed solution is added in the fed-batch experiment as a bolus addition of 1.8ml feed / day to the starting volume of 60ml culture (corresponding to a 30ml / L / d nutrient feed rate based on the starting volume of the culture), starting from the 2nd day, in an uncontrolled shake flask system.
[0167] Batch and Fed-Batch Mode
[0168] In order to produce recombinant proteins and antibodies, fed-batch methods are usually used in the final production stage, and batch culture is mainly performed in the cell expansion stage before the final production stage. A series of batch cultures are called seed training during cell expansion, meaning that cells are transferred to a culture vessel with a larger culture volume in each expansion step. Batch processes generally do not lead to high productivity in the final production stage, and are therefore rarely used to manufacture recombinant proteins. In the fed-batch process, concentrated feed medium is added during the incubation period to compensate for nutrients with fresh culture medium. These processes achieve higher productivity, and are therefore predominantly used in the production of recombinant proteins. Compared with batch mode, supplementing nutrients by adding concentrated feed medium also reduces cell growth inhibition by unwanted metabolic byproducts such as lactate or ammonium. Typically, the fed-batch process starts with a volume much lower than the maximum capacity of the stirred tank, so that concentrated nutrient solution can be added during the incubation time of the bioreactor.
[0169] Bioreactor culture
[0170] Bioreactor experiments were performed in a controlled 2-L system (Boehringer-Ingelheim patented multi-fermenter system) with a starting volume of 1.8 L, or in a controlled 48-micro bioreactor system with a starting volume of up to 15 ml. The fully controlled bioreactor was performed in batch or fed-batch mode. In fed-batch, concentrated feed solution was added continuously from the culture via a feed pump, usually starting from day 1-3, with a feed rate of 30 ml / L / d (based on the culture starting volume). Similar to the shake flask system, the inoculation density was set at 0.3x10 6 Cells / ml. Cell expansion in a longer time frame follows a standard seed training protocol for cell growth and culture division to ensure phenotypic stability. This procedure ensures comparability between different experimental settings at different time points. For typical bioreactor culture, the standard method format consists of the following: a pH range of 7.10-6.95 (+ / -0.25), including a pH offset from the 3rd day, a DO set point of 30-60% (air saturation), a constant stirring rate of 140rpm (4-blade disc turbine agitator), and a temperature set point of 36.5-37°C. The analytical method as described above is used to determine the main culture parameters, such as cell count, cell viability and concentration of major carbon metabolites, to provide an ideal nutrient supply for cell culture. In contrast to shake flask experiments, in a bioreactor system, pH and pO2 are monitored online. Offline process parameters and set points are completely controlled by control software (Siemens, Munich Germany), using an automatic closed-loop system for monitoring, such as pH control, nutrient feed addition, temperature control, stirring and degassing.
[0171] Example 1
[0172] CHO2 (CHO-DG44) Rituximab cells were cultured in RPMI-based basal medium with RPMI amino acid (AA) ratios versus optimal amino acid (AA) ratios with different total cumulative amino acid amounts. The medium compositions of medium 4 with RPMI AA ratios (medium 4.0, 4.1, 4.2, and 4.3) and medium with optimized AA ratios with total cumulative amino acid amounts ranging from 22 mM–66 mM (only 37 mM in medium 4) (medium 5.0, 5.1, and 5.2) are shown in Table 1, and the corresponding amino acid ratios are shown in Table 2.
[0173] The minor variations in total AA concentrations are due to variations in molecular weight and minimal variations in the amino acid powders used. The purpose of this experiment was to demonstrate the effect of optimized amino acid ratios at different total cumulative amino acid levels. The experiment was performed in duplicate (N=2) in batch mode.
[0174] Table 1: Composition of Medium 4.0, 4.1, 4.2 and 4.3 and Medium 5.0, 5.1 and 5.2
[0175]
[0176] *Gln, Ile and Cys were added using stock solutions
[0177] **Gln and Ile were added using stock solution
[0178] Table 1a: Amino acid ratios of medium 4 (non-optimized) and medium 5 (optimized)
[0179]
[0180] Table 1b: Composition Powder GM RPMI 86638
[0181] Components [g / L] Disodium hydrogen phosphate (anhydrous) 0.8 Choline chloride 0.003 i-Inositol 0.035 L-Reduced Glutathione 0.001 Biotin 0.0002 Cyanocobalamin (vitamin B12) 0.000005 D-Calcium Pantothenate 0.00025 Folic acid 0.001 Niacinamide 0.001 p-Aminobenzoic acid 0.001 Pyridoxine x HCl 0.001 Riboflavin 0.0002 Thiamine x HCl 0.001 D-Glucose 3.5 Ethanolamine x HCl 0.01563 Putrescine x 2HCl 0.0048 Sodium selenite 0.000003458 Total g / L 4.37
[0182] Materials and Methods
[0183] The RPMI basal medium used in this experiment is based on the commercially available RPMI medium R8755 (Mediatech catalog number 90022PB or Sigma Aldrich catalog number R8755), which was originally developed by Moore and colleagues at Roswell Park Memorial Institute (SAFC, Biosciences product information). For serum-free use, it has been supplemented as shown in Table 1, containing sodium chloride (NaCl 6.0 g / L), potassium chloride (KCl 0.4 g / L), and magnesium sulfate (MgSO4 0.0488 g / L) in a cumulative amount of 108.4 mmol / L of bulk salts.
[0184] Batch experiments were performed in 500 ml shake flasks with a starting volume of 125 ml. CHO2 (CHO-DG44) rituximab cells were grown at 0.3 x 10 6 Cells / ml were seeded in medium 4, 4.1, 4.2 or 4.3 (RPMI AA ratio) and medium 5, 5.1 or 5.2 (optimized AA ratio). Shake flask cultures were incubated in an incubator at 36.5°C with 5% CO2 from day 0-3 and 3% CO2 from day 4 until the end of the culture.
[0185] The amino acid cysteine was provided in a powder formulation in Medium 5 but was added separately from a stock solution in Medium 4. To monitor and control the cultures, total cells, viable cells, viability, product concentration, glucose concentration, lactate concentration, ammonium concentration, and osmolarity were measured up to day 7.
[0186] result:
[0187] Figure 1 (AD) shows the results of cells cultured in RPMI medium with RPMI ratios (filled squares) and optimized AA ratios (filled circles), i.e., viable cell concentration, viability, product concentration, and lactate concentration at a total AA concentration of 44 mM. The highest viable growth and product concentration were at 44 mM ( Figure 1 A and C) and 66mM ( Figure 1 E and G) were achieved in cultures with optimized AA ratios. For example, on days 5 and 7, product concentrations were Figure 1 C), where the maximum product concentration was 166 mg / L, compared to a maximum product concentration of 72 mg / L for cells grown in medium containing the RPMI ratio. This was accompanied by a higher number of viable cells ( Figure 1 A, up to 2.82x10 in medium 5 6 c / ml, and up to 1.13x10 6 c / ml). The viability curves of the two cultures agree well with each other and show a clear drop from day 3 onwards, from 98% to 25% viability on day 7 ( Figure 1 B). In both cultures, glucose concentration, ammonium concentration and osmotic pressure show similar trends. For example, during the incubation period of all cultures, glucose concentration was maintained greater than 1.0 g / L to avoid any restrictions and pH was maintained within the typical range of cell culture processes. This confirms that all cultures are provided with a major carbon source such as glucose in sufficient amounts for cell growth, metabolism and product formation. As expected, the curve for the metabolic waste product lactate shows a growth-dependent pattern, i.e., increased cell concentrations contribute to higher amounts of metabolic waste lactate ( Figure 1 D). It should be noted that lactate production is not always growth-related and can be further understood as an indicator of efficient glucose utilization (e.g. Figure 4 J).
[0188] Similar results were observed for cells cultured in medium containing RPMI ratios (filled squares) and optimized AA ratios (filled circles) at a total amino acid concentration of 66 mM ( Figure 1EH). At days 5 and 7, product concentrations were about 3 times higher in cell cultures with optimized AA ratios (Figure G), with a maximum product concentration of 311 mg / L, compared to a maximum product concentration of 96 mg / L for cells grown in medium containing RPMI ratios. This was accompanied by an increased number of viable cells (Figure E, up to 3.44 x 10 in medium 5.1). 6 c / ml, and up to 1.32x10 6 c / ml). The viability curves for both cultures showed a similar pattern, but the culture in medium 5.1 showed an extended viability of approximately 1 day at day 5 (94% versus 70% for medium 4.2). The viability of both cultures showed a clear decrease from day 3 onwards, from 98% to 55% and 25% viability at day 7 ( Figure 1 F). For lactate concentration, glucose concentration, ammonium concentration and osmotic pressure and pH progression, similar trends were observed as described above for the culture with a total amino acid concentration of 44 mM. At higher total amino acid concentrations (compared to 66 mM ( Figure 1 E and G) relative to 44 mM ( Figure 1 A and C)), overall viable cell concentrations and product concentrations were higher, especially for cells cultured with optimized AA ratios (product concentrations for medium containing RPMI ratios: Medium 4.2 (66 mM) versus Medium 4.1 (44 mM), day 5: 96–72 mg / l = +24 mg / l; product concentrations for medium containing optimized AA ratios: Medium 5.1 (66 mM) versus Medium 5.0 (44 mM), day 5: 290–166 mg / l = +123 mg / l).
[0189] Similar trends can be observed for 22 and 36 mM total amino acid concentrations ( Figure 1 I). The maximum product concentration of about 45 mg / l (22 mM, medium 4.3, RPMI AA ratio; rightward solid triangles) increases with increasing total amino acid concentration to a maximum product concentration of 65 mg / l (36 mM, medium 4.0, RPMI AA ratio; solid crosses). Figure 1 This effect is smaller than the effect associated with the optimized amino acid ratios, as shown in Figure 1, comparing the maximum product concentration of 117 mg / l (22 mM, medium 5.2 and optimized AA ratios; solid squares) relative to 45 mg / l (22 mM, medium 4.3, RPMI ratio).
[0190] If Figure 1As can be seen, the optimized AA ratio at the lowest tested total amino acid concentration of 22 mM (filled squares) resulted in a higher productivity (maximum product concentration 117 mg / l, optimized AA ratio, 22 mM) than the RPMI AA ratio at the highest tested total amino acid concentration of 66 mM (filled circles, maximum product concentration 96 mg / ml, RPMI AA ratio). Thus, the highest productivity was achieved using the medium with the optimized AA ratio, with a maximum product concentration of 117 mg / L (22 mM, optimized AA ratio; Figure 1 I, J), 166 mg / l (44 mM, optimized AA ratio, Figure 1 C) and 290 mg / l (66 mM, optimized AA ratio, Figure 1 E) This shows that optimizing the AA ratio strongly increases productivity, and this can only be compensated to a minimal trend by simply increasing the total AA concentration.
[0191] Example 2
[0192] Based on the optimized amino acid ratios of basal medium 5 (RPMI-based), several amino acids were varied in their molar concentrations as single component methods by + / -20% and + / -40% (calculated as molar percentages based on the optimized AA ratios). The performance was then compared to control cultures grown in medium 5.3 (same as medium 5.0, but all amino acids were added individually as stock solutions). All essential amino acids were provided by concentrated stock solutions to design different medium compositions. Thus, the culture media had comparable total cumulative amino acid amounts of approximately 43-44 mM, but different amino acid ratios. In one experiment, single amino acid concentration variations of +20% and -20% relative to control medium 5.3 were tested (single component methods for L-arginine, L-asparagine, L-aspartate, L-histidine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine). For single amino acid concentration changes of +40% and -40% compared to the control (L-arginine, L-asparagine, L-aspartate, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine). Experiments were performed in batch mode using RPMI-based culture media. For the specific culture media used, AA changes of + / -20% or + / -40% are indicated as (20) or (40).
[0193] Materials and Methods
[0194] The experiments were performed in 250 ml shake flasks with starting volumes of 75 ml and 100 ml. In all cultures, CHO2 (CHO-DG44) Rituximab cells were grown at 0.3 x 10 6 Cells / ml were seeded in control medium 5.3 (N=3) and modified medium 5.3.1 (20) (N=2) (single amino acid concentration changed by + / -20%) and medium 5.3.1 (40) (single amino acid concentration changed by + / -40%). Shake flasks were incubated at 36.5°C in an incubator (5% CO2 atmosphere was provided from day 0 to day 3, followed by 3% CO2 until the end of the culture). Glucose was supplied on day 2 and day 4 and as needed to maintain the final glucose concentration between 2.5 g / l and 4.5 g / l. L-glutamine was also added as needed.
[0195] Medium 5.3 (same as Medium 5.0, but all amino acids were added individually as stock solutions) served as the basis for this experiment. A total of 14 amino acids were tested for the + / -20% single component method: L-arginine, L-asparagine, L-aspartate, L-histidine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine. A total of 7 amino acids were not tested: L-alanine, L-cysteine / L-cystine, L-glutamine, L-glutamate, L-glutamine, L-isoleucine, and L-glycine. A total of 15 amino acids were tested for the + / -40% single component method: L-arginine, L-asparagine, L-aspartate, L-histidine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, and L-isoleucine. A total of 6 amino acids were not tested: L-alanine, L-cysteine / L-cystine, L-glutamine, L-glutamate, L-glutamine, and L-glycine.
[0196] Amino acids not tested were identified as metabolic waste products produced in excess in cell culture (L-alanine, L-glycine, L-glutamate); considered chemically unstable due to oxidation of the compound, or not considered essential compounds for enhancing growth, especially after cell peaks, such as L-glutamine.
[0197] Medium 5.3 was dissolved in water to form a 1.2-fold concentrate without amino acids to prepare Medium 5.3.1 (20), to which all amino acids were added from stock solutions and adjusted with water. Medium 5.3.1 (40) was prepared from Medium 5.3 as a 1.25-fold concentrate to which all amino acids were added from stock solutions and adjusted with water.
[0198] result:
[0199] Variation of single amino acid ratios showed that a 40% decrease in L-leucine, L-phenylalanine, L-threonine, L-valine or L-isoleucine in the medium with optimized AA ratios resulted in decreased productivity ( Figure 2 J and N). A small decrease in productivity was also observed when L-phenylalanine, L-valine or L-leucine was reduced by 20% ( Figure 2 C and EG).
[0200] For example, Figure 2 As shown in Figure 5, for the control medium 5.3 (optimized AA ratios) and the modified medium 5.3.1 (40) (single amino acid reduction -40%), the average product concentrations ranged from 129-184 mg / L on day 5 and from 127-186 mg / L on day 7. This wide range in final titers illustrates that the final product concentrations were similar in most of the media, but decreased in the five cultures (Figure 5A) compared to the maximum control titer of 180 mg / L on day 7. Figure 2 J and 2N). The maximum product concentration of 180 mg / L in the control medium 5.3 (optimized AA ratio) was reduced to a maximum product concentration in the range of 129–149 mg / L on day 5 of culture in the modified medium 5.3.1 (40), with a -40% reduction in L-phenylalanine, L-valine, L-leucine, L-threonine, or L-isoleucine. A similar trend was seen on day 7, with product concentrations of 179 mg / L in the control medium 5.3 and 127–143 mg / L in the five modified media.
[0201] Reducing L-leucine, L-phenylalanine, L-threonine, L-valine or L-isoleucine by 40% in the medium with optimized AA ratios further resulted in a decrease in viable cell concentration, accompanied by a decrease in viability and an increase in the production of waste metabolites (lactate) after day 3 ( Figure 2 H, 2L, 2M, 2O). No differences in viable cell concentration, cell survival or lactate production were observed when these amino acids were reduced by only 20% (see Figure 2 A, 2B, 2D). As expected, due to common nutrient depletion and lack of feed addition in batch mode, a decrease in viable cell concentration and viability occurred in almost all cultures ( Figure 2 A, 2B, 2H, 2I, 2L and 2M). Glucose was maintained above critical levels and lactate production followed growth-related kinetics as expected in all cultures ( Figure 2K and O). Furthermore, no effects were observed on any other parameters measured (e.g. osmolarity, pCO2 and pH).
[0202] The results showed that reduction of some amino acids negatively affected viable cell concentration and / or product formation.
[0203] In media with a 20 or 40% increase in amino acids, no effects on productivity, viable cell concentration, cell survival, or lactate concentration were observed (data not shown).
[0204] Example 3
[0205] Based on the optimized amino acid ratios and the amino acids identified in Example 2 in basal medium 5 (RPMI-based), additional amino acids were varied by -40% in their molar concentrations due to the single component approach in different media backgrounds. This medium containing the optimized AA ratios is further optimized for serum-free recombinant protein production and is chemically defined and superior to the modified RPMI medium used in previous experiments. In this experiment, a single amino acid was reduced in batch mode to demonstrate the effect of the optimized amino acid ratios in the basal medium for pH, dissolved oxygen (DO) and temperature under controlled bioreactor conditions.
[0206] Based on the optimized amino acid ratios in basal medium 6.2, a single amino acid L-lysine, L-methionine, L-proline, L-tryptophan or L-tyrosine was reduced in its molar concentration by 40%, or both L-tyrosine and L-lysine were reduced by 20% or 40%. The resulting performance was compared to control medium containing optimized AA ratios. Cells cultured in control medium 6.2 (optimized AA ratios, AA added as premixed powder) and control medium 6.4.1 (optimized AA ratios, AA added individually from stock solutions) were compared to cells cultured in medium 6.4.9-medium 6.4.15 (modified AA ratios, AA added individually from stock solutions). All tested medium compositions had a comparable total cumulative amino acid concentration of approximately 44 mM.
[0207] Materials and Methods
[0208] Comparisons were made between cells cultured in control medium 6.2 (optimized AA ratios, AA added as premixed powders) and control medium 6.4.1 (optimized AA ratios, AA added individually from stock solutions) and cells cultured in medium 6.4.9 (L-lysine and L-tyrosine - 20%), medium 6.4.10 (L-lysine and L-tyrosine - 40%), medium 6.4.11 (L-tyrosine - 40%), medium 6.4.12 (L-lysine - 40%), medium 6.4.13 (L-methionine - 40%), medium 6.4.14 (L-tryptophan - 40%), medium 6.4.15 (L-proline - 40%). All media compositions tested had comparable total cumulative amino acid concentrations of 44-45 mM. All essential amino acids were provided via concentrated stocks and added to Medium 6.4.0 (same as Medium 6.2 and 6.4.1 but without amino acids) to prepare different medium compositions 6.4.1 and 6.4.9-15.
[0209] The experiments were performed in a 48-well miniaturized bioreactor system with a starting volume of 14 ml. In all cell cultures, CHO2 (CHO-DG44) rituximab cells were grown at 0.3 x 10 6 Cells / ml were seeded in the respective culture media. The bioreactor was incubated at 36.5°C for the entire culture period and dissolved CO2 was controlled between 2-15% to prevent toxic concentrations based on a pH set point of (7.20-6.80) + / - 0.2. Control cultures and experimental runs were performed in duplicate (N=2).
[0210] Table 2: Composition of basal medium (6.2, 6.3 and 6.4.0 without AA)
[0211]
[0212]
[0213] *Contains Taurine and L-Hydroxy-Proline
[0214] **Insulin can be replaced by insulin-like growth factor (IGF) at a final concentration of 50 μl / l
[0215] Table 2a: Amino acid ratios of basal media 6.2 (optimal AA, AA premix powder), 6.3 (non-optimal AA), 6.4.0.1 (optimal AA, control, AA added separately)
[0216] Amino Acids (AA) Medium 6.2 Medium 6.3 Medium 6.4.0.1 Total AA 44mM 45mM 44mM L-Alanine - - - L-Arginine 2.13 2.5 2.1 L-Asparagine 1.82 0.9 1.8 L-Aspartic Acid 1.31 0.4 1.3 L-Cysteine 1.57 1.9 1.6 L-Glutamic Acid 0.89 0.4 0.9 L-Glutamine 46.40 46.4 46.40 L-Glycine 24.70 24.7 24.7 L-Histidine 0.91 0.3 0.9 L-Isoleucine 1.00 1.0 1.0 L-Leucine 1.66 1.0 1.7 L-Lysine 2.24 0.6 2.2 L-Methionine 0.51 0.3 0.5 L-Phenylalanine 0.72 0.3 0.7 L-Proline 2.27 0.5 2.3 L-Serine 2.08 0.8 2.1 L-Threonine 1.46 0.4 1.5 L-Tryptophan 0.37 0.1 0.4 L-Tyrosine 2.09 0.3 2.1 L-Valine 1.49 0.5 1.5
[0217] result:
[0218] In the control culture (optimized AA ratios, medium 6.4.0.1), a maximum product concentration of 317 mg / L was measured at day 8. In all tested cultures, the maximum product concentration was reduced compared to the control culture, ranging from 249 to 279 mg / L at day 8. Specifically, reducing L-lysine or L-tyrosine in the culture medium resulted in product concentrations of 268 mg / L and 279 mg / L, respectively, at day 8. Interestingly, reducing both L-lysine and L-tyrosine by 40% resulted in an even lower product concentration of 249 mg / L, indicating an additive or even synergistic effect ( Figure 3 C, solid cross). Reducing L-methionine, L-proline or L-tryptophan in the medium also resulted in reduced product concentrations at day 8 (265 mg / L, 274 mg / L, 277 mg / L, respectively). In summary, the results show that the medium with optimized amino acid ratios resulted in the best productivity among the tested media.
[0219] Growth curves showed comparable results for the test medium and the control medium ( Figure 3 A and 3B). Compared to control cultures (solid squares), the maximum viable cell concentration was several days earlier and even slightly higher in some cultures. For example, the viable cell concentration of all cultures ranged from 3.7 to 10 6 The peak cell density reached 2.8 cells / ml on day 6. 6 The lower cell density of cells / ml (control) was 2.544 cells / ml. The survival curves of all cultures showed similar trends, with a significant reduction when cultivating the 6th day. However, near the end of the incubation period, the survival rate was even slightly higher in some test cultures. In short, the higher productivity in the control culture can be explained by the higher cell specific productivity. Metabolites and pH curves were routinely monitored every day, but no differences were shown between the cultures.
[0220] Example 4
[0221] It was further found that the combination of novel amino acid ratios in both basal medium and feed medium showed the best performance. The optimized amino acid ratios had an effect not only in basal medium (in batch mode) but also in feed medium (fed-batch mode). Cells were cultured in basal medium with optimized AA ratios or RPMI AA ratios and fed with feed medium with optimized AA ratios or RPMI AA ratios.
[0222] Example 4A
[0223] The effects of basal medium and feed medium were analyzed by culturing CHO2 (CHO-DG44) Rituximab cells in medium with optimized amino acid ratios (optimized AA ratios, medium 6.2 and feed 6.2) or non-optimized amino acid ratios (RPMI AA ratios, medium 6.3 and feed 6.3) for all cultures in fed-batch mode with all four combinations at a standard feed rate of 30 ml / L / d based on the culture starting volume. Basal and feed medium 6.2 containing optimized AA ratios were further optimized for serum-free recombinant protein production and were chemically defined and superior to the modified RPMI medium used. In another experiment (in a 2-L bioreactor system, Example 4C), the final glucose concentration in the feed solution (feed medium 6.2.1 and feed medium 6.3.1) was increased to minimize the number of glucose additions and operator workload by adding stock solutions (Table 3).
[0224] Materials and Methods
[0225] Basal medium 6.2 and medium 6.3 were identically designed to contain about 44 mM total amino acids, but different amino acid ratios (Tables 2 and 2a). Similarly, feed medium 6.2 and feed medium 6.3 were identically designed to contain about 508-511 mM total amino acids, but different amino acid ratios (Tables 3 and 6). In order to avoid increased osmotic pressure, the glucose concentration in feed medium 6.2 and 6.3 was reduced to a final concentration of 42 g / l. During the course of the experiment, glucose was further added as needed to maintain glucose>1 g / L.
[0226] The experiments were performed in a 48-well miniaturized bioreactor system with a starting volume of 14 ml. In all cultures, CHO2 (CHO-DG44) Rituximab cells were grown at 0.3 x 10 6 Cells / ml were seeded in test medium or control medium as follows: basal medium 6.2 and feed medium 6.2 (optimized AA ratios, AA added as premixed powder), medium 6.3 and feed medium 6.3 (RPMI AA ratios, AA added as premixed powder). The bioreactor was incubated at 36.5°C for the entire culture period, and dissolved CO2 was controlled between 2-15% to prevent toxic concentrations based on a pH set point of (7.20-6.80) + / - 0.2.
[0227] Table 3: Composition of feed media 6.2 and 6.2.1 (with optimal AA) and media 6.3 and 6.3.1 (without optimal AA)
[0228]
[0229]
[0230] *The difference between feed medium 6.2 and 6.2.1 and feed medium 6.3 and 6.3.1 is the total glucose content.
[0231] **Feed Medium 6 powder without AA contains 6.6 g glucose.
[0232] ***Insulin can be replaced with IGF at a final concentration of 250 μg / l
[0233] result:
[0234] The effect of optimized amino acid ratios in basal medium and feed medium on the production of IgG1 antibody (rituximab) in a controlled microbial reactor system with fed-batch (n=2) is shown in Figure 4 C. A maximum product concentration of 2786 mg / L at day 10 (2677 mg / L at day 12) was achieved with optimized amino acid ratios in both basal and feed medium. Using basal medium with RPMI AA ratios, but feed medium with optimized AA ratios, resulted in a significantly lower maximum product concentration of 2126 mg / L at day 12. Productivity was even further reduced in cultures using basal medium with optimized AA ratios and feed medium with RPMI AA ratios, resulting in a final titer of 1662 mg / L at day 12. The lowest product concentration was achieved with non-optimized amino acid ratios in both basal and feed medium, with a product concentration of 1577 mg / L at day 12.
[0235] The use of basal medium with non-optimized AA ratios followed by feed medium with optimized AA ratios slightly delayed the viable cell concentration, but reached an almost comparable maximum viable cell concentration. The cell specific productivity was also slightly reduced (132.91 mg / 10 6 Cell relative to 161.3mg / 10 6 Cells). Likewise, productivity was slightly delayed, especially in the early stages (days 4-8), and remained low for a period of time. This shows that optimizing the AA ratio is beneficial for cell productivity in both basal medium and feed medium.
[0236] This was accompanied by an increase in the viable cell concentration and survival rate of the cultures in the medium using the optimized AA ratios, preferably in both the basal and feed medium. The maximum viable cell concentration of cells cultured in the medium with the optimized amino acid ratios was found to be 16.6 x 10 on day 8 in both the basal and feed medium.6 Culturing cells in basal medium with RPMI AA ratios and in feed medium with optimized AA ratios resulted in almost the same 16.0x10 6 The maximum viable cell concentration (day 10) of 10 cells / ml was, however, about two days later. Thus, the non-optimized AA ratio in the basal medium appears to delay viable cell proliferation. Culturing cells in feed medium with RPMI AA ratios severely reduced the maximum viable cell concentration to 13.3 x 10 cells / ml at day 8. 6 cells / ml (basal medium with optimized AA ratio) or 11.5x10 6 cells / ml (basal medium with RPMI AA ratios) Thus, the optimized AA ratios in the feed medium appear to support higher viable cell concentrations.
[0237] A similar trend was observed for survival ( Figure 4 B), an earlier and more severe decrease in viability in cultures without optimized AA ratios in the feed medium. No significant effects were observed for any other measured parameters.
[0238] In summary, the effect of the basal medium without optimized AA ratios appears to result in a reduced cell specific productivity, which cannot be fully compensated by the use of an optimized feed medium. On the other hand, the use of feed medium without optimized AA ratios results in a reduced number of viable cells ( Figure 4 A) and survival rate ( Figure 4 B). Thus, the feed medium with optimized AA ratios improved viability and viable cell concentration and thereby increased productivity, but also showed an effect on cell specific productivity (161.2 mg / 10 6 Cell relative to 124.9mg / 10 6 In contrast, the results of growth, viability and final titer also revealed that the maximum growth and maximum product concentration were significantly affected by the optimized AA ratio in both basal medium and feed medium.
[0239] Example 4B
[0240] The influence of basal medium and feed medium was also analyzed using optimized amino acid ratios (optimized AA ratios, basal medium 6.2 and feed 6.2) or non-optimized amino acid ratios (RPMI AA ratios, medium 6.3 and feed 6.3) in an uncontrolled shake flask system (pH and dissolved oxygen were not controlled) in fed-batch mode with all four combinations at reduced feed rates. The standard fed-batch feed rate was adjusted from 30 ml / L / d (control) to 20 ml / L / d and 8 ml / L / d to avoid overfeeding and thus masking effects.
[0241] Materials and Methods
[0242] CHO2 (CHO-DG44) rituximab cells were grown at 0.3x10 6 Cells / ml were seeded in basal and feed medium 6.2 (optimized AA ratios) or basal and feed medium 6.3 (RPMI AA ratios). Feed medium 6.2 and feed medium 6.3 contained a metabolically adjusted glucose concentration of 42 g / l to ensure comparable metabolic profiles (e.g., glucose) for shake flask experiments and 2L bioreactors. Viable cells, viability, product concentration, glucose concentration, lactate concentration, ammonium concentration, and osmotic pressure were measured as described above according to the sampling intervals. Experiments and controls were performed in duplicate (N=2).
[0243] In this experiment, a 500ml shake flask with a 60ml starting volume was used to culture cells in the basal and feed medium with or without optimized AA ratios. Shake flask cultures were incubated at 36.5°C in an incubator (8% CO from day 0 to day 2, and 5% CO from day 2, and 3% CO from day 3, until the end of culture). The feed rate was set to 20ml / L / d for day 1 to day 5, and to 8ml / L / d for day 5 to day 11. Feed solution was added to the culture every 2 days, in order to prevent excessive feeding of glucose and to minimize the osmotic pressure caused by the increased glucose level. The feed rate was calculated as follows, for example 30ml / L / d*0.06L=1.8ml feed / day=3.6ml feed / 2 days, and the feed rate 20ml / L / d=1.2ml / d=2.4ml feed / 2 days for metabolic adjustment. Glutamine was maintained at >0.1 g / L during the culture period, mainly supplemented by increasing the L-glutamine concentration in the basal medium at the start rather than by the feed medium.
[0244] result:
[0245] Effect of optimized amino acid ratios in medium and feed on IgG1 antibody (rituximab) production in an uncontrolled shake flask system in fed-batch mode at reduced feed rate (N=2).
[0246] The effect of the basal medium can be seen if the maximum product concentration of 897 mg / L (filled diamonds) in the culture with non-optimized amino acid ratios in basal medium 6.3 and optimized amino acid ratios in feed medium 6.2 is compared to 1049 mg / L (filled squares) in the culture with optimized amino acid ratios in basal medium 6.2 and optimized amino acid ratios in feed medium 6.2, both at reduced feed rates. Figure 4F). Having non-optimized amino acid ratios in the basal medium thus leads to delayed and reduced product formation. The maximum product concentration of 641 mg / L (filled circles) in the culture with optimized amino acid ratios in basal medium 6.2 and non-optimized amino acid ratios in feed medium 6.3 is higher than the maximum product concentration of 468 mg / L (filled triangles) in the culture with non-optimized amino acid ratios in basal medium and feed medium ( Figure 4 F). The results clearly demonstrate the positive impact of the optimized amino acids in the basal medium on the maximum product titer.
[0247] Furthermore, a maximum product concentration of 1049 mg / L was reached in the culture with optimized amino acid ratios in the basal medium and feed medium, which was reduced to 641 mg / L ( 0.0547 mg / L) when a feed medium with non-optimized AA ratios at a reduced feed rate was used. Figure 4 F). Similar trends in product production were found for cells cultured in basal medium without optimized AA ratios and feed medium with optimized AA ratios (897 mg / L) or feed medium without optimized AA ratios (468 mg / L). This means that there is a strong positive impact of optimized amino acids in the feed medium on maximum product performance, however, the best results were obtained when optimized AA ratios were used in both basal and feed medium.
[0248] The viability curves followed a similar trend, with all cultures dropping sharply from 96% on day 5 ( Figure 4 E) On days 5-6, the maximum viable cell concentration ranged from 3.8–9.6 10 6 Cells / ml( Figure 4 D). In general, feed medium with optimized AA ratios increased viable cell concentration ( Figure 4 D). This result is associated with improved survival ( Figure 4 E) consistent.
[0249] In addition, the optimized amino acid ratio in the basal medium had a positive effect on cell proliferation. This can be seen from the fact that at day 5, the amino acid ratio of (7.27x10 6 cells / ml, solid circles) or without (3.8x10 6 Comparison of the viable cell concentration of cells cultured in a basal medium with optimized amino acid ratios (100 cells / ml, solid triangles) and a feed medium without optimized amino acid ratios was obtained. This result illustrates the positive effect of an optimized basal medium on maximum growth performance.
[0250] When the feed medium with optimized AA ratio was used, the6 cells / m, solid diamonds) and with the optimized AA ratio (7.9x10 6 cells / ml, filled squares), the maximum viable cell concentrations were comparable. If we compare the basal medium with optimized amino acid ratios and the feed medium with optimized amino acid ratios (7.9x10 6 cells / ml, filled squares) or feed medium without optimized amino acid ratios (7.2×10 6 The maximum growth of cells cultured in feed medium with optimized AA ratios was 9.6 x 10 cells / ml, filled circles. Similarly, when using basal medium without optimized AA ratios, the maximum viable cell concentration for cells cultured in feed medium with optimized AA ratios was 9.6 x 10 6 cells / ml, and this decreased to 3.9 x 10 cells / ml for cells cultured in feed medium without optimized AA ratios. 6 Cells / ml( Figure 4 D).
[0251] In general, there are two main aspects that are consistent with good viable cell growth. First, for cultures with optimized amino acid ratios in the feed (with or without optimized amino acid ratios in the basal medium), the highest remaining viability of 37-40% was reached at day 9. Second, for cultures with optimized amino acids in the feed medium, the viability from day 5 was shifted by about one day. These results clearly show that higher viability and extension of the viability curve can be obtained with optimized basal medium and feed medium.
[0252] Example 4C
[0253] The impact of basal medium and feed medium with and without optimized amino acid ratios was further tested in a scaled-up fully controlled 2-L bioreactor system in a standard fed-batch format.
[0254] The 2L bioreactor system is a representative model for large-scale bioreactors (up to 12,000L scale and above) for commercial manufacturing. A standard fed-batch feed rate of 30 ml / L / d was applied, and the feed solution was fed in continuous mode from day 2 to day 14. Based on our experience, other process parameters were set to our platform conditions for successful expansion, i.e., oxygen transfer, shear force, CO2 removal, pH range, agitation, and power input / volume. The culture medium combinations were tested in duplicate (N=2).
[0255] Materials and Methods
[0256] The experiments were performed in a fully controlled 2 L bioreactor system with a starting volume of 1.8 L. CHO2 (CHO-DG44) Rituximab cells were grown at 0.3 x 10 6 Cells / ml were seeded using basal medium 6.2 (optimized AA ratios) or basal medium 6.3 (RPMI AA ratios) and feed medium 6.2.1 (optimized AA ratios and adapted glucose concentration of 65 g / l) or feed medium 6.3.1 (RPMI AA ratios and adapted glucose concentration of 65 g / l). The bioreactor was incubated at 36.5°C for the entire culture and dissolved CO2 was controlled between 2-15% to prevent toxic concentrations based on a pH set point of (6.95 at days 0-3 and 6.80 at days 3-14) + / - 0.20.
[0257] The glucose concentration in the feed solution was optimized to a final concentration of 65 g / l in order to minimize the osmotic pressure caused by glucose overfeed and, if necessary, to reduce the number of glucose additions from the stock solution. The design of feed medium 6.2 and feed medium 6.2.1 were identical except for the final glucose concentration. Similarly, feed medium 6.3 and feed medium 6.3.1 were identical except for the final glucose concentration.
[0258] Viable cells, viability, product concentration, glucose concentration, lactate concentration, ammonium concentration and osmotic pressure were measured as described above according to the sampling interval. The feed medium contained glucose but no L-glutamine, so glutamine was added from the stock solution as needed to keep the glutamine concentration in the range of 0.1-0.4 g / l. For the entire culture, the glucose level was maintained at> 2 g / L. The experiment was performed in duplicate (N=2).
[0259] result:
[0260] In general, the results for the 2L system were in good agreement with findings from previous shake flask experiments in terms of maximum titer and viable growth. For example, a maximum product concentration of 2213 mg / L (solid squares) was achieved using optimized amino acid ratios in basal medium and feed medium ( Figure 4 I). Cultivating cells without optimized amino acid ratios in feed medium reduced the maximum product concentration to 1654 mg / L (solid circles). Figure 41. Cultivating cells in a basal medium without an optimized amino acid ratio strongly delays product formation. Due to the positive effect of the optimized feed medium, a similar maximum product concentration of 2213 mg / L (optimized amino acid ratio in basal and feed medium) relative to 2144 mg / L (optimized amino acid ratio only in feed medium) was obtained. However, due to the influence of the non-optimized basal medium, the product formation kinetics is clearly different. Therefore, for optimal product concentration, the optimized amino acid ratio needs to be present in both basal and feed medium.
[0261] These observations are in good agreement with the viable cell concentrations. 6 cells / ml, with optimized amino acid ratios in basal medium and feed medium reaching 12.7x10 6 The maximum peak viable cells / ml ( Figure 4 G). 12.7x10 6 The maximum viable growth peak in cells / ml is due to the combined effect of the optimized amino acid ratios in the basal medium and the feed medium on the viable cell concentration for the fed-batch cultures. Furthermore, if the exponential growth phase from day 4-9 is compared for cultures without optimized AA in basal medium and with optimized AA in feed medium relative to cultures with optimized AA in basal medium and without optimized AA in feed medium, the effect of the basal medium and the effect of the feed can be seen. Figure 4 G shows that the growth kinetics for the optimized basal medium were steeper than for the non-optimized basal medium, although both cultures reached approximately 8.6 x 10 6 In contrast, slower growth kinetics using non-optimized basal medium but optimized feed medium resulted in prolonged viable cells from day 10 to day 14.
[0262] The survival curves followed a similar trend as described above. The maximum survival over extended run time can be attributed to the feeding effect (compare 79% vs. 49-54% survival on day 14) ( Figure 4 H). The viability curves of cells with optimized AA ratios in basal medium and feed medium, or with optimized AA ratios in basal medium and without optimized AA ratios in feed medium followed similar trends. Other measured parameters such as metabolites and pH did not show any significant differences.
[0263] Example 4D
[0264] The effect of optimized AA ratios in basal medium and feed medium (optimized AA ratios in RPMI basal medium 3.9 and RPMI feed medium 3 or non-optimized amino acid ratios RPMI AA ratios in RPMI basal medium 3.1 and RPMI feed medium 2) was further investigated for all four combinations using CHO2 (CHO-DG44) Rituximab cells in fed-batch mode in an RPMI environment. RPMI is a commercial medium with a known composition.
[0265] The total amino acid concentration in RPMI basal cell culture medium and RPMI feed medium increased with the adjustment of the amino acid ratio to the optimized amino acid ratio of the present invention. In order to exclude that the observed effect was only due to the increased overall amino acid concentration, in separate experiments, RPMI basal cell culture medium and RPMI feed medium were adjusted with different amino acid ratios (spent medium optimized amino acid ratios).
[0266] Materials and Methods
[0267] The RPMI basal medium used in this experiment is based on the commercially available RPMI medium R8755 (Mediatech catalog number 90022PB or Sigma Aldrich catalog number R8755), which was originally developed by Moore and colleagues at Roswell Park Memorial Institute (SAFC, Biosciences product information). For serum-free use, it has been supplemented as shown in Table 4.
[0268] The experiment was performed in 250 ml shake flasks with a starting volume of 100 ml. All cultures were grown at 0.3 x 10 6Cells / ml were seeded in specific medium compositions in shake flasks: control RPMI medium 3.1 (without optimized AA ratios, total AA 10.0 mM), RPMI medium 3.9 (with optimized amino acid ratios, total AA -15.2 mM), RPMI feed medium-2 (without optimized amino acid ratios, total AA 124 mM), RPMI feed medium-3 (with optimized amino acid ratios, total AA 548 mM), RPMI medium 3.5 (RPMI medium 3.1 + AA, spent medium optimization, total AA 12 mM), RPMI feed medium 3.5 (RPMI feed-2 + AA, spent medium optimization, total AA 140 mM). The 7 amino acids added for the optimization of the spent medium of the basal medium are L-methionine, L-phenylalanine, L-proline, L-threonine, L-tryptophan, and L-tyrosine x 2Na x 2H2O and L-valine, each added at 30 mg / l, and the amino acids added for the optimization of the spent medium of the feed medium are L-cysteine, L-methionine, L-proline, L-threonine, L-tyrosine x 2Na x 2H2O and L-valine, each added at 360 mg / l. Basal medium 3.1, 3.5 and 3.9 are reinforced with plant hydrolysate to support the initial growth at the beginning of cultivation. For this reason, hydrolysate is not provided in the feed solution. As can be seen from the above experiment (referring to medium 4 and medium 5), a medium based on RPMI without the basis of Hypep can also be used.
[0269] The shake flasks were incubated at 36.5°C in an incubator (5% CO2 atmosphere was provided from day 0 to day 3, followed by 3% CO2 until the end of the culture). Feed solution was added every other day, at a feed rate of 30 ml / L / d from day 2-4, and at a reduced feed rate of 3 ml / L / d from day 5-8. Glucose was fed as needed to maintain the actual glucose concentration between 2-4 g / l during the culture. Total cells, viable cells, viability, product concentration, glucose concentration, lactate concentration, ammonium concentration, and osmotic pressure were measured every other day until the end of the culture to monitor and control the experimental progress. The experiment was performed in duplicate (N=2).
[0270] Table 4: Composition of RPMI basal medium 3.1 (non-optimized AA), 3.9 (optimized AA), 3.5 (spent medium analysis)
[0271]
[0272] Table 4a: Amino acid ratios of basal medium RPMI 1640 (original), basal medium 3.1, 3.9, 3.5 (spent medium analysis) and medium 6.2
[0273] Amino Acids RPMI 1640 Medium 3.1 Medium 3.9 Medium 3.5 Medium 6.2 Total AA concentration 6.3mM 10.0mM 15.2mM 12mM 44mM L-Alanine - - - - - L-Arginine 2.5 2.5 2.5 2.5 2.1 L-Asparagine 1.0 1.0 1.8 1.0 1.8 L-Aspartic Acid 0.4 0.4 1.3 0.4 1.3 L-Cysteine 1.0 1.0 2.2 1.0 1.6 L-Glutamic Acid 0.4 0.4 0.9 0.4 0.9 L-Glutamine 5.4 15.3 12.6 15.3 46.4 L-Glycine 0.4 0.4 0.4 0.4 24.7 L-Histidine 0.2 0.2 0.9 0.2 0.9 L-Isoleucine 1.0 1.0 1.0 1.0 1.0 L-Leucine 1.0 1.0 1.7 1.0 1.7 L-Lysine 0.6 0.6 2.3 0.6 2.2 L-Methionine 0.3 0.3 0.5 0.8 0.5 L-Phenylalanine 0.2 0.2 0.7 0.7 0.7 L-Proline 0.5 0.5 2.3 1.1 2.3 L-Serine 0.8 0.8 2.1 0.8 2.1 L-Threonine 0.4 0.4 1.5 1.1 1.5 L-Tryptophan 0.1 0.1 0.4 0.5 0.4 L-Tyrosine 0.3 0.3 2.1 0.6 2.1 L-Valine 0.5 0.5 1.5 1.1 1.5
[0274] Table 5: Composition of RPMI feed medium-2 (non-optimal AA), -3 (optimal AA), -3.5 (spent medium analysis)
[0275]
[0276]
[0277] Table 5a: RPMI feed premix without bulk salts (1x) 83480CP*:
[0278] Components [mg / L] Components [mg / L] L-Arginine 200 L-Lysine x HCl 40 L-Asparagine x H2O 56.8 L-Methionine 15 L-Aspartic Acid 20 Niacinamide 1 D-Biotin 0.2 L-Phenylalanine 15 D-Calcium Pantothenate 0.25 L-Proline 20 Choline chloride 3 PABA (para-aminobenzoic acid) 1 Cyanocobalamin 0.005 Pyridoxine x HCl 1 D-Glucose (anhydrous dextrose)** 2000 Riboflavin 0.2 Folic acid 1 L-Serine 30 L-Glutamic Acid 20 Sodium phosphate (dibasic) 800 L-Glutathione, reduced 1 Thiamine x HCl 1 L-Glycine 10 L-Threonine 20 L-Histidine 15 L-Tryptophan 5 Hydroxy L-Proline 20 <![CDATA[L-Tyrosine 2Na x 2H20**]]> 14.4 Inositol 35 L-Valine 20 L-Isoleucine 50 L-Leucine 50 Total mg / L 3464.4
[0279] *Omitted bulk salts: calcium nitrate x 4H2O, magnesium sulfate, potassium chloride, sodium chloride, and sodium bicarbonate
[0280] **Add separately
[0281] Table 6: Amino Acid Ratios of RPMI Feed-2 (non-optimized) and RPMI Feed-3 (optimized AA), RPMI Feed Medium 3.5 (spent medium analysis), Feed Medium 6.2 and 6.2.1 (optimized AA), and Feed Medium 6.3 and 6.3.1 (non-optimized AA)
[0282]
[0283]
[0284] In the spent medium analysis, the commercially available RPMI medium was modified and fortified with various nutrient supplements to avoid nutrient limitation and to ensure improved growth and product formation in fed-batch experiments. To this end, according to the medium recipe of medium 3.1, an AA supplement was added to the medium. At day 4 and day 7, an amino acid analysis was performed on samples taken from the cell culture supernatant, except for L-arginine. It was thus found that the concentrations of the following seven amino acids were lower than 15 mg / L: L-valine, L-threonine, L-proline, L-methionine, L-phenylalanine, L-tyrosine and L-tryptophan. Based on the spent medium analysis of the prior art, these amino acids were additionally supplemented in the basal medium (RPMI medium 3.5). Specifically, the amino acids L-methionine, L-phenylalanine, L-proline, L-threonine, L-tryptophan, L-tyrosine and L-valine were additionally provided in the basal medium at 30 mg / L each (Tables 4 and 5). Figure 4a). In the feed medium, the amino acids L-methionine, L-threonine, L-proline, L-cystine, L-tyrosine and L-valine were additionally provided at 360 mg / L each (Tables 5 and 6). The experiments were performed essentially as described above, using RPMI basal cell culture medium with or without optimized amino acid ratios and RPMI feed medium with and without optimized amino acid ratios. In addition, cells were incubated with RPMI basal culture medium and feed medium containing the spent culture medium amino acid ratios in either the RPMI basal cell culture medium or the RPMI feed medium or both.
[0285] result:
[0286] In summary, the effect of optimized AA ratios in RPMI basal cell culture medium and / or RPMI feed medium on cell culture performance in fed-batch mode was investigated using CHO2 (CHO-DG44) cells producing the antibody rituximab. Specifically, cell viability ( Figure 4 L, O), living cells ( Figure 4 K, N), product titer ( Figure 4 M, P) and lactate concentrations (data not shown).
[0287] The main effect of the optimized feed medium or basal medium can be seen in the final product concentration as well as the product kinetics (curve slope), e.g. Figure 4 As shown in M.
[0288] For example, cells cultured in RPMI basal cell culture medium and RPMI feed medium both containing optimized amino acid ratios had higher product titers (259 mg / L) compared to control cells cultured in RPMI basal cell culture medium and RPMI feed medium without optimized amino acid ratios (162 mg / L), such as Figure 4 M. In cultures with optimized AA ratios in basal medium but not optimized AA ratios in feed medium, the maximum product titer was reduced to 171 mg / ml. Interestingly, the effect of the optimized amino acid ratios in feed medium was similar until the 4th day (167 mg / L relative to 161 mg / L) and only different in subsequent culture days. In addition, in the case of non-optimized basal medium, product formation and curve kinetics (curve slope) were delayed and resulted in a maximum product concentration of about 152-162 mg / L at the 8th day (without optimized AA ratios in basal medium and with or without optimized AA in feed medium).
[0289] Using the RPMI medium system (RPMI basal cell culture medium and RPMI feed medium), similar positive effects on viable cell concentration and viability can be observed. When the optimized amino acid ratios were used in both RPMI basal cell culture medium and RPMI feed medium, a concentration of approximately 3.5×10 6 cells / mlThe maximum viable cell concentration is the highest viable cell concentration ( Figure 4 K) and the highest cell survival rate ( Figure 4 L). If the optimized amino acid ratios were applied only in the basal cell culture medium, a decrease in viable cell concentration ( Figure 4 K) and survival rate ( Figure 4 The maximum viable cell concentration was 2.2 × 10 6 cells / ml) is lower ( Figure 4 K and N), and was even lower (maximum viable growth up to 1.70 10 6 cells / ml, day 4). In summary, this example demonstrates the superiority of optimized amino acid ratios on cell culture performance in RPMI-based media, i.e., product titer, viable cell concentration, and cell viability.
[0290] Similar results were obtained in another experiment including the same medium and medium supplemented with AA based on spent medium analysis.
[0291] As mentioned above, compared with unmodified RPMI culture medium system, the optimized amino acid ratio in adjustment RPMI basal cell culture medium has significantly improved product titer.Compared with the control without any realization of optimized amino acid ratio in RPMI, the product titer in the cell culture comprising optimized amino acid ratio in both basal and feed medium is higher (0.406g / L is relative to the titer of 0.173g / L).Therefore, by adjusting the amino acid ratio according to the optimized amino acid ratio in both basal medium and feed medium, in commercial culture medium system such as RPMI, product titer increases by about 2.3 times.Compared with the control without any realization of optimized amino acid ratio in basal and feed medium, the product titer in the RPMI basal cell culture medium comprising optimized amino acid ratio and the RPMI feed medium without amino acid adjustment is higher (0.267g / L is relative to the titer of 0.173g / L). The product titer in the culture with optimized amino acid ratios only in RPMI feed medium was almost comparable to the control achieved without any novel amino acid ratios in basal medium or feed medium (titer of 0.159 g / L versus 0.173 g / L). Again, this result confirms that the optimized amino acid ratios should be applied from the beginning of the culture experiment, i.e. in both basal and feed medium. Under this setting, applying the optimized amino acid ratios only in feed medium was not sufficient to reach the maximum product titer.
[0292] The product titer in RPMI with spent culture medium amino acid ratio in both basal medium and feed medium is higher (0.302g / L, hollow square) compared with the control (0.173g / L, solid diamond) without any amino acid ratio adjustment, but lower than the optimized amino acid ratio (0.406g / L, solid square) in RPMI culture medium and RPMI feed medium. In addition, the product titer (0.193g / L, hollow circle) with spent culture medium amino acid adjustment in RPMI basal medium rather than in RPC feed medium is higher than the control (0.173g / L, solid diamond) without optimized amino acid ratio in basal or feed medium, but significantly lower than the optimized amino acid ratio (titer 0.267g / L, solid circle) only in RPMI basal medium ( Figure 4 P).
[0293] Thus, the effect of spent medium amino acid ratio adjustment in basal cell culture medium and feed medium was reduced (maximum titer of 302 mg / L) compared to the effect of optimized amino acid ratios in basal cell culture medium and feed medium (maximum titer of 406 mg / L) on overall cell culture performance. For spent medium amino acid ratio adjustment only in basal medium and not in feed medium, a maximum titer of only 193 mg / L was obtained.
[0294] Depending on the titer, the viable cell concentration achieved for all cultures followed a similar trend with a maximum cell peak at day 4. Most cultures had approximately 3.5 x 10 6 The maximum viable cell concentration of cells / ml, except for cultures in basal medium without any supplementation (1.7-2x10 6 Cells with optimized amino acid ratios in both basal medium and feed medium achieved viable growth with the highest number of viable cells over a period of time. This result confirms the combined effect of optimized basal medium and optimized feed, as shown in Figure 2. Figure 4 N and P shown.
[0295] Survival rate curve ( Figure 4 (B) followed a similar trend with a break at day 4 for most cultures except for the culture with optimized AA ratios in basal and feed media. This finding is consistent with Figure 4 The viable growth pattern shown by N was in good agreement. No significant influence of the culture medium on other parameters such as metabolites and pH was observed.
[0296] Example 5
[0297] It was found that certain amino acids have an impact on the cell metabolism in terms of maximum product concentration, viable cell concentration and survival rate. In fed-batch mode, serum-free, chemically defined culture medium was used to further combine and analyze the impact of changing these amino acids. The changes in amino acids were studied in two AA groups: the two AA groups were a) L-phenylalanine, L-valine, L-leucine, L-threonine, L-isoleucine (5 kinds of AA) and b) L-phenylalanine, L-valine, L-leucine, L-threonine, L-isoleucine, L-tyrosine, L-lysine (7 kinds of AA). Then based on the optimized amino acid ratio from the control (basal medium 6.4.0.1 and feed medium 6.4), amino acids were changed + / -20% and + / -40% in the basal medium and feed medium in a positive or negative alternating mode. Alternating mode means that in the basal medium and feed medium, in the same direction, the first AA increases, the second AA decreases, the third AA increases by 20% or 40%, etc. (calculated on a molar basis). The alternating pattern is described by using lower case letters (decrease by -20% or -40%, e.g. his, tyr) and upper case letters (increase by +20% or +40%, e.g. HIS, TYR). In order to induce a strong cellular response in terms of maximal growth and product formation, the nutrient feed rate was reduced in some experiments.
[0298] Materials and Methods
[0299] CHO2 (CHO-DG44) Rituximab cells were cultured in fed-batch in Medium 6.4.0.1 and Feed Medium 6.4 (with optimized amino acid ratios) at standard feed rate and reduced feed rate. The experiment was divided into 3 approaches, testing AA changes in combination: a) 5 AAs in basal medium and feed medium + / - 40% change, b) 7 AAs in basal medium and feed medium + / - 40% change, and c) 7 AAs in basal medium and feed medium + / - 20% or + / - 40% change at reduced feed rate.
[0300] For the 5AA setup, the amino acids L-phenylalanine, L-valine, L-leucine, L-threonine, L-isoleucine were varied by + / -40% in a positive or negative alternating pattern (uppercase or non-uppercase AA letters) compared to a control with optimized amino acid ratios in basal and feed media. The media used were: basal medium 6.4.3 (5 amino acids PHE, val, LEU, thr, ILE varied by + / -40%, positive), basal medium 6.4.4 (5 amino acids phe, VAL, leu, THR, ile varied by + / -40%, negative), feed medium 6.4.3 (5 amino acids PHE, val, LEU, thr, ILE varied by + / -40%, positive), feed medium 6.4.4 (5 amino acids phe, VAL, leu, THR, ile varied by + / -40%, negative).
[0301] For the 7AA setup, the following culture media were used: basal medium 6.4.5 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS changed by + / -20%, positive), basal medium 6.4.7 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS changed by + / -40%, positive), basal medium 6.4.8 (7 amino acids phe, VAL, leu, THR, ile, TYR, lys changed by + / -40%, negative), feed medium 6.4.5 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS changed by + / -20%, positive), feed medium 6.4.7 (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS changed by + / -40%, positive), feed medium 6.4.8 (7 amino acids phe, VAL, leu, THR, ile, tyr, lys changed by + / -40%, negative). It should be added that due to solubility reasons, L-tyrosine was not increased in the alternating mode of feed medium 6.4.8, which was only associated with a 7AA change of +40% instead of a 20% AA change. The amino acid changes used in the feed medium were the same as in the basal medium in all cultures, except for feed medium 6.4.8 which lacked an increased tyr concentration.
[0302] The experiments were performed in a miniaturized bioreactor system with a starting volume of 14 ml. In all cell cultures, CHO2 (CHO-DG44) rituximab cells were grown at 0.3 x 10 6 Cells / ml were seeded in basal medium for fed-batch culture. The bioreactor was incubated at 36.5°C for the entire culture and the dissolved pCO2 was controlled between 2-15% to prevent toxic concentrations based on a pH set point of (7.20-6.80) + / - 0.2. A standard feed rate of 30 ml / L / d was applied with a 5AA variation of + / - 40% ( Figure 5 AC) and 7AA vary by + / -40% ( Figure 5DF).The reduction feed rate of 20ml / L / d and 8ml / L / d at the 1st-5th day and the 6th-11th day is applied to the culture with 7AA variation + / -20% and + / -40% (Figure GI).Feed solution is added to the culture continuously, and attention is paid to prevent excessive feeding of glucose, and the osmotic pressure caused by the glucose addition of increase is minimized.For example, feed medium 6.4.3, feed medium 6.4.4, feed medium 6.4.7 or feed medium 6.4.8 contain the reduced glucose concentration of 42g / l.All feed media contain glucose, but do not contain L-glutamine, therefore glutamine is added from stock solution as required, so that glutamine concentration remains in the range of 0.1-0.4g / l.Glucose is also added as required, so that glucose level remains>2g / L for the whole cultivation.According to the sampling interval, living cells, survival rate, product concentration, glucose concentration, lactic acid concentration, ammonium concentration and osmotic pressure are measured as described above. Experiments and controls were performed in duplicate (N=2).
[0303] result:
[0304] In media with otherwise optimized AA ratios, combined changes of 5 AAs or 7 AAs (+ / -40% at standard feed rate), and especially combined changes of 7 AAs at reduced feed rate (7 AAs + / -20% and + / -40% at reduced feed rate), reduced productivity and viable growth in cell culture.
[0305] Changes in 5 AA: In the control culture (optimized AA ratios in basal and feed medium), the highest maximum product concentration of 1909 mg / L was reached on day 10 ( Figure 5C). For the variation of the 5 AAs, the maximum product concentration was reduced to 1523 mg / L (phe, VAL, leu, THR, ile + / - 40%, alternating mode) and 1799 mg / L (PHE, val, LEU, thr, ILE + / - 40%, alternating mode), respectively, by alternating the 5 AAs in both directions. Interestingly, the product formation showed different kinetics (curve slopes), as can be seen from the product titers at day 10, 1909 mg / L (control) vs. 1523 mg / L vs. 1498 mg / L (PHE, val, LEU, thr, ILE and phe, VAL, leu, THR, ile, + / - 40%, alternating mode, respectively). Combinatorial changes of 5 AA + / - 20% showed maximum product concentrations that were only slightly reduced (phe, VAL, leu, THR, Ile changed by + / - 20%, 1806 mg / L at day 10) or equivalent to (PHE, val, LEU, thr, ILE changed by + / - 20%, 2058 mg / L at day 12) control cultures (data not shown). The results indicate that a combined change of only + / - 20% of the five amino acids had no significant effect on product formation or maximum product titer.
[0306] For all cultures (control versus test cultures varied by + / - 40%), the viable cell concentration curves followed a similar trend with maximum viable peak densities ranging between 13.8-19.4 x 10 6 cells / ml range ( Figure 5 A). In control cultures with optimized AA ratios in basal medium (basal medium 6.4.0.1) and feed medium (feed medium 6.4), 19.4 x 10 6 The maximum viable cell density of cells / ml. The maximum viable cell concentration in cultures with altered amino acid ratios was considerably lower (PHE, val, LEU, thr, ILE + / - 40%, 13.8 x 10 6 / ml live cell concentration; phe, VAL, leu, THR, ile + / - 40%, 15.3x10 6 Live cell concentration (cells / ml) Figure 5 A). Viable growth of test cultures with + / - 20% (5 AA) of different amino acids was comparable to control cultures with optimized amino acid ratios (data not shown).
[0307] Furthermore, the survival curves of all cultures were quite comparable, showing a drop in the survival of all cultures starting at day 8. Interestingly, in one of the cultures with amino acid ratios of 5 AA altered by + / - 40% (PHE, val, LEU, thr, ILE), the survival rate remained quite high at the end of the culture period (days 11-14) at 56% (P < 0.05), compared to 13% survival of the control culture at day 14. Figure 5 B) For test cultures with amino acid ratios of the 5 AAs varied by + / - 20%, all curves were comparable to the control (data not shown).
[0308] Variation of 7 AAs: Similar results were obtained for variations of 7 amino acids (L-phenylalanine, L-valine, L-leucine, L-threonine, L-isoleucine, L-tyrosine, L-lysine) by + / -40%. For example, product concentrations of 1618 mg / L (phe, VAL, leu, THR, ile, tyr, lys + / -40%, alternating pattern) or 1456 mg / L (PHE, val, LEU, thr, ILE, tyr, LYS + / -40%, alternating pattern) on day 10 were decreased compared to the maximum product concentration of 1909 mg / L measured in control cultures on day 10 ( Figure 5 F). This result is in good agreement with the results obtained with the 5AA variation. Varying the 7 AAs by + / -20% resulted in comparable maximum product concentrations of 1861 mg / l (7AA PHE, val, LEU, thr, ILE, tyr, LYS varied by + / -20%) or with a slightly reduced maximum product concentration of 1622 mg / l (7AA phe, VAL, leu, THR, ile, tyr, lys varied by + / -20%, negative alternating pattern), compared to the control culture with a maximum product concentration of 1909 mg / l at day 10 (data not shown). This means that a variation of the 7 amino acids by + / -20% has only a minor effect on product formation and maximum product concentration in cell culture.
[0309] On day 8, the maximum viable cell concentration ranged from 14.4 to 19.4 x 10 6 Cells / ml( Figure 5 D) The viable growth of the test cultures with 7 different amino acids was comparable to that of the cultures using the medium containing 5 different amino acids varied by + / - 40% (compare Figure 5 A and D). Likewise, the survival rate of the 7AA shift + / - 40% was comparable to the culture with the 5AA shift of 40% (compare Figure 5B and 5E). Again, one culture (7 amino acids PHE, val, LEU, thr, ILE, tyr, LYS, changed by + / - 40%) showed a 45% higher survival rate compared to the control at the end of the culture.
[0310] Varying the 7 AAs by + / - 20% resulted in comparable growth curves for all cultures including control cultures, with 18.9–20.1 x 10 6 cells / ml (data not shown). In addition, the viability curves were comparable for all cultures, remaining fairly high at 95% until day 8 of culture, but then falling below 30% at the end of the culture period (data not shown).
[0311] Variation of 7AA with reduced feed rate: To enhance the effect, cells were additionally cultured in fed-batch mode using a reduced feed rate. Comparisons were made of control cultures with standard feed rate (medium 6.4.0.1 and feed medium 6.4, standard feed), control cultures with reduced feed rate (medium 6.4.0.1 and feed medium 6.4, with reduced feed rate), and test cultures with 7 amino acids varied by + / -20% or + / -40% at reduced feed rate. The maximum product concentration in the control cultures at standard feed rate was 1909 mg / L at day 10 (1782 mg / L at day 12, squares achieved) and for the control cultures with reduced feed rate was 1611 mg / L (day 12, solid circles) ( Figure 5 I). Changing the concentration of the 7 amino acids by 20% (PHE, val, LEU, thr, ILE, tyr, LYS; reduced feed rate) resulted in a maximum product concentration of 1448 mg / l (day 12, solid crosses). In cultures with 7 AAs varied by + / -40%, the titer was further reduced on day 12 to a maximum product concentration of 1269 mg / L (phe, VAL, leu, THR, ile, Tyr, lys; reduced feed rate, solid triangles), or 999 mg / L (PHE, val, LEU, thr, ILE, tyr, LYS; reduced feed rate, solid X). Thus, changes in the AA ratios of the 7 key amino acids reduced productivity compared to control cultures, and this was more pronounced when feed medium was added at a reduced feed rate.
[0312] Regardless of the feed rate, the viable cell concentration showed comparable trends (compare Figure 5 D and 5G). The viable cell concentration showed a maximum cell peak between days 6 and 8 ( Figure 5G). For example, the control culture showed 19.4 x 10 6 cells / ml, and this decreased slightly to 16.5 x 10 6 The maximum cell concentration for cultures with 7 AAs varied by + / -20% (PHE, val, LEU, thr, ILE, tyr, LYS) was approximately 13.5 x 10 6 cells / ml, and even lower for cultures with 7 AAs varied by + / -40%, at about 11x10 6 cells / ml.
[0313] The viability curves for all cultures followed a similar trend, with a clear decrease starting between days 8 and 10 ( Figure 5 H). Other parameters such as glucose, osmotic pressure or pH progression did not show any significant differences compared to control cultures.
[0314] Example 6
[0315] In this fed-batch experiment, the effect of optimized culture medium and feed medium on cell culture performance was demonstrated for multiple CHO-DG44 cell lines producing different monoclonal antibodies or fusion proteins as examples of pharmaceutically relevant proteins. The goal was to demonstrate that an optimized cell culture medium (with optimized amino acid ratios in the basal medium and with optimized amino acid ratios in the feed medium) clearly contributes to improved productivity for use at multiple manufacturing sites.
[0316] Materials and Methods
[0317] The experiment was performed in a miniaturized bioreactor system with a starting volume of 15 ml. All CHO-DG44 cell lines expressing different therapeutic molecules were cultured at 0.3x10 6Cells / ml were seeded in basal medium 6.2 and feed medium 6.2, both with optimized AA ratios. The therapeutic molecules expressed in CHO-DG44 cells were rituximab with a heavy chain containing the amino acid sequence of SEQ ID NO: 1 and a light chain containing the amino acid sequence of SEQ ID NO: 2, mAb6 with a heavy chain containing the amino acid sequence of SEQ ID NO: 3 and a light chain containing the amino acid sequence of SEQ ID NO: 4, mAb5 with the amino acid sequence of SEQ ID NO: 5, and Fc fusion proteins. The bioreactor was incubated at 36.5°C for the entire culture, and dissolved CO2 was controlled between 2-15% to prevent toxic concentrations based on pH set points of 6.95 (+ / - 0.15) and 6.80 + / - 0.15 from day 3. For this fed-batch application, a platform approach for successful scale-up was applied, which included a standard feed rate of 30 ml / L / d. This means that for the entire culture from day 1 until the end of the culture, a nutrient feed solution was added every day. Glutamine was added from the stock solution as needed to keep the glutamine concentration in the range of 0.1-0.4 g / l. Glucose was also added as needed to keep the glucose level >0.6 g / L for the entire culture. Viable cells, viability, product concentration, glucose concentration, lactate concentration, ammonium concentration, and osmotic pressure were measured as described above. Experiments and controls were performed in duplicate (N=2).
[0318] result:
[0319] Product concentrations for several CHO-DG44 cell lines expressing different therapeutic proteins were high for all proteins but varied slightly. The maximum product concentration varied, being 8213 mg / L ( Figure 6 C), for mAb5 production cells at day 11, 4655 mg / L ( Figure 6 C), for Fc fusion protein and rituximab production cells, the concentration was 1778-2061 mg / L on day 11 ( Figure 6 D). This titer variation, ranging from 1.7 g / l up to >8.2 g / l, was accompanied by variable viable cell concentrations and viability. These results demonstrate that different CHO-DG44 cells expressing various recombinant proteins can be grown and proliferated in a fed-batch mode in an optimized culture medium ( Figure 6 AD).
[0320] Example 7
[0321] In shake flask experiments using medium 6.2a, the effect of different concentrations of iron choline citrate on cell culture performance, in particular cell growth and product formation, was investigated. It was found that (i) iron choline citrate increased product titer and (ii) the novel compound iron choline citrate was superior to commonly used iron carriers such as ferric pyrophosphate, ferric phosphate and ferric citrate.
[0322] Materials and Methods
[0323] The experiments were performed in 250 ml shake flasks with a starting volume of 100 ml. All cultures were grown at 0.3 x 10 6 Cells / ml (rituximab producing CHO2 (CHO-DG44) cells) were seeded in a basal medium containing iron choline citrate at three different concentrations (0.2 g / l, 1 g / L or 2 g / l), or iron pyrophosphate (0.5 g / l, 0.8 g / l or 1.3 g / l), or iron phosphate in approximately equimolar amounts (0.3 g / l, 0.5 g / l, 0.7 g / l) and feed medium 6.2a without iron choline citrate. The concentration ranges of iron pyrophosphate and iron phosphate were selected to be within the same range as iron choline citrate (on a molar basis). For example, iron choline citrate at 1.0 g / L (titer of 2.81 g / L) is approximately equimolar to iron phosphate at 0.3 g / L (titer of 2.29 g / L), and is approximately equimolar to iron pyrophosphate at about 1.3 g / L (titer of 2.26 g / L).
[0324] Basal medium 6.2a is a precursor medium that is almost identical to basal medium 6.2, except that it additionally contains some non-essential cofactors and nucleotides and does not contain succinate, contains putrescine at only 4.8 mg / l and a total amino acid concentration of 40 mM instead of 44 mM. In addition, glutamine is added in a lower amount, resulting in a ratio of 37.42 relative to isoleucine.
[0325] In parallel experiments, CHO2 (CHO-DG44) Rituximab cells were cultured in basal medium 6.2a with iron choline citrate at different concentrations (0 g / l, 0.2 g / l, 0.4 g / l or 2 g / l) and feed medium 6.2 containing iron choline citrate at 0.56 g / l, or basal medium with iron citrate at 0.1 g / l and feed medium 6.2a containing iron citrate at 0.25 g / l. The concentration of iron citrate (0.1 g / l and 0.25 g / l) was selected to be approximately equimolar to iron choline citrate at 0.2 g / l in the basal medium and at 0.56 g / l in the feed medium.
[0326] Feed medium 6.2a is a precursor medium that is almost identical to feed medium 6.2, except that it additionally contains some non-essential cofactors and nucleotides and slightly higher sodium bicarbonate, and contains only 33.02 mg / l putrescine and a total amino acid concentration of 511 mM instead of 508 mM. In addition, alanine is additionally present in the medium with a ratio of 0.15 relative to isoleucine.
[0327] Shake flasks with a starting volume of 60 ml in a 250 ml flask were incubated at 37 ° C in an incubator (10% CO2 atmosphere was provided from day 0 to day 3, followed by 3% CO2 for one day and 0% CO2 until the end of cultivation). Starting on the second day, feed solution was added every day at a feed rate of 30 ml / L / d. Glucose was supplemented as needed to maintain the actual glucose concentration between 2-4 g / l during the culture period. Total cells, viable cells, survival rate, product concentration, glucose concentration, lactic acid concentration, ammonium concentration and osmotic pressure were measured every other day until the end of the culture to monitor and control the experimental progress. The experiment was performed in duplicate (N=2).
[0328] result:
[0329] The product titer using 1.0 g / L iron choline citrate was significantly higher than the control using 0.2 g / L iron choline citrate (2.81 g / L vs. 2.07 g / L in the control), and was even slightly higher than the product titer using 2.0 g / L iron choline citrate (2.67 g / L titer) ( Figure 7 B). In addition, product titers were significantly higher using iron choline citrate at 2.0 g / L or 1.0 g / L (titers of 2.67 g / L or 2.81 g / L) compared to approximately equimolar amounts of iron pyrophosphate (titers of 2.24 g / L-2.37 g / L) or iron phosphate (titers of 2.29 g / L-2.38 g / L) ( Figure 7 B).
[0330] The use of 2.0 g / L iron choline citrate in basal medium achieved the greatest viable cell concentration, resulting in improved cell culture performance ( Figure 7 A). The viable cell concentration of cells cultured in basal medium containing ferric phosphate and ferric pyrophosphate as iron carriers dropped sharply from day 10 to day 11, which had a negative impact on cell culture performance.
[0331] Similar results were found in parallel experiments. Product titers with iron choline citrate at 2.0 g / L were higher than negative control cultures without iron choline citrate (3.06 g / L vs. 2.19 g / L in negative control) or with iron choline citrate at 0.4 g / L (titer of 2.87 g / L) or 0.2 g / L (titer of 2.66 g / L) in basal medium ( Figure 7 C). At lower iron choline citrate concentrations (<1 g / l), the effect appeared to be concentration dependent, and a substantial increase in product concentration was obtained when iron choline citrate was added at 0.2 g / L compared to the negative control without iron choline citrate.
[0332] Furthermore, the product titer using ferric citrate at 0.1 g / L was lower than that of the equimolar ferrous choline citrate at 0.2 g / L (2.38 g / L vs. 2.66 g / L titer) ( Figure 7 D).
[0333] Example 8
[0334] The effects of different concentrations of iron choline citrate on cell culture performance, particularly cell growth and product formation, were investigated in shake flask experiments using RPMI-based medium. It was found that (i) iron choline citrate increased product titer and (ii) the novel compound iron choline citrate was superior to commonly used iron carriers such as ferric citrate.
[0335] Materials and Methods
[0336] The experiments were performed in 250 ml shake flasks with a starting volume of 60 ml. All cultures were grown at 0.3 x 10 6 Cells / ml (rituximab-producing CHO2 (CHO-DG44) cells) were seeded in basal medium 3.1 containing iron choline citrate at different concentrations (0 g / l, 0.2 g / l, 0.4 g / l or 2 g / l) or in approximately equimolar amounts of iron citrate (0.1 g / l, 0.2 g / l or 1 g / l) and feed medium 2 containing iron citrate at 0.25 g / l. The iron citrate concentrations of 0.1 g / l, 0.2 g / l and 1 g / l were selected to be approximately equimolar to the iron choline citrate at 0.2 g / l, 0.4 g / l and 2 g / l in the basal medium, respectively.
[0337] The shake flask was incubated at 37°C in an incubator (10% CO2 atmosphere was provided from day 0 to day 3, followed by 5% CO2 for one day and 0% CO2 until the end of the culture). Starting on the second day, feed solution was added every day at a feed rate of 30 ml / L / d. Glucose was supplemented as needed to maintain the actual glucose concentration between 2-4 g / l during the culture period. Total cells, viable cells, survival rate, product concentration, glucose concentration, lactic acid concentration, ammonium concentration and osmotic pressure were measured every other day until the end of the culture to monitor and control the experimental progress. The experiment was performed in duplicate (N=2).
[0338] result:
[0339] The product titer was higher with 2.0 g / L of iron choline citrate than with the negative control without iron choline citrate (0.244 g / L vs. 0.156 g / L in the negative control), or with iron choline citrate at 0.4 g / L (titer of 0.217 g / L) or 0.2 g / L (titer of 0.194 g / L) in the basal medium (see Figure 8 D and compare Figure 8 A, B and C). Thus, the effect of iron choline citrate appears to be concentration dependent and a substantial increase in product concentration was obtained when iron choline citrate was added at 0.2 g / L compared to the negative control without iron choline citrate.
[0340] Furthermore, the product titer using ferric citrate at 0.1 g / L was lower than that of equimolar ferrous choline citrate at 0.2 g / L (0.184 g / L vs. 0.194 g / L; Figure 8 A). Similarly, the product titer using 0.2 g / L ferric citrate was lower than the titer of 0.4 g / L equimolar ferrous choline citrate (0.200 g / L vs. 0.217 g / L; Figure 8 B), and the product titer using 1.0 g / L ferric citrate was significantly lower than that of 2.0 g / L equimolar ferrous choline citrate (0.201 g / L vs. 0.244 g / L titer; Figure 8 C).
[0341] The overall viable cell concentration showed similar curves for iron choline citrate and iron citrate, but equimolar concentrations of iron choline citrate relative to iron citrate resulted in higher viable cell concentrations (e.g., titers obtained with 1.0 g / L equimolar iron citrate (titer 201 mg / L) were significantly lower than those obtained with 2.0 g / l iron choline citrate (titer 244 mg / L). Furthermore, the (equimolar) use of iron choline citrate resulted in lower osmotic pressure values compared to commercial iron carriers such as iron citrate, which is considered beneficial for mammalian cell culture in terms of viable cell concentration and cell viability. Iron choline citrate only slightly increased osmotic pressure compared to the negative control (no addition of iron choline citrate) (data not shown). Viable cell concentration and cell viability were only slightly improved when iron choline citrate was added in increasing concentrations.
[0342] Example 9
[0343] The effect of iron choline citrate and equimolar ferric citrate on cell culture performance, in particular cell growth and product formation, in a 2-L bioreactor in fed-batch mode (rituximab-producing CHO2 (CHO-DG44)) in medium platform 6.2 or in a RPMI-based medium platform (basal medium 3.1 and feed medium 2) was investigated. It was found that (i) iron choline citrate increased product titer and (ii) was superior compared to commonly used iron carriers such as ferric citrate. Thus, the positive effect of iron choline was independent of the culture system applied (e.g. shake flask experiments or controlled 2-L bioreactors or the culture medium used).
[0344] Materials and Methods
[0345] The experiments were performed in a fully controlled 2 L bioreactor system with a starting volume of 1.8 L. CHO2 (CHO-DG44) Rituximab cells were grown at 0.3 x 10 6 Cells / ml were seeded in all cultures using basal medium 6.2a containing iron choline citrate (0.2 g / l or 2.0 g / l) or iron citrate (1 g / l) and feed medium 6.2a containing iron choline citrate at 0.56 g / l ( Fig. 9AC), or RPMI-based basal medium 3.1 containing iron choline citrate (0.2 g / l or 2.0 g / l) or iron citrate (1 g / l) and RPMI-based feed medium 2 containing iron citrate at 0.25 g / l. The concentration range of iron citrate was selected in the same range as iron choline citrate (on a molar basis). The bioreactor was incubated at 37°C for the entire culture, and dissolved CO2 was controlled between 2-15% to prevent toxic concentrations based on a pH set point of (7.07 at days 0-3 and 6.92 at days 3-14) + / - 0.17. The DO set point was 60%, and feed was added continuously at 30 ml / L / d. Viable cells, viability, product concentration, glucose concentration, lactate concentration, ammonium concentration, and osmotic pressure were measured as described above according to the sampling intervals. The feed medium contained glucose, and the glucose level was maintained at> 2 g / L for the entire culture. Glutamine was added from the stock solution as needed to keep the glutamine concentration in the range of 0.1-0.4 g / l. The experiments were performed in duplicate (N=2).
[0346] result:
[0347] Product titers were higher with 2.0 g / L iron choline citrate in basal medium 6.2a compared to control cultures with 0.2 g / L iron choline citrate (2.04 g / L vs. 1.62 g / L titer in control) or 1.0 g / L iron citrate (1.73 g / L titer). Fig. 9 C). This demonstrates that the effect of iron choline citrate on product titer is superior to that of ferric citrate at equimolar concentrations. Despite the increase in product concentration, the viable cell concentration and cell viability using different concentrations of iron choline citrate or equimolar concentrations of iron citrate were comparable. A slightly faster decrease in viable cell concentration and viability starting at day 8 was observed for cultures treated with iron choline citrate ( Fig. 9 A and B). The total osmotic pressure in cultures using medium platform 6.2a was within the acceptable range for all samples (280 - approximately 400 mOsmo / kg, days 0-12, data not shown).
[0348] Likewise, product titers were higher with 2.0 g / L iron choline citrate in RPMI-based media compared to controls with 0.2 g / L iron choline citrate (0.257 g / L vs. a titer of 0.237 g / L in the control) or 0.1 g / L iron citrate (titer of 0.200 g / L). Fig. 9D). Despite the increase in product concentration, the viable cell concentration and cell viability in RPMI-based medium systems with different concentrations of iron choline citrate or equimolar iron citrate were comparable. The overall osmotic pressure in cultures using the RPMI-based medium platform increased slightly (350-440 mOsmo / kg, days 0-12, data not shown).
[0349] Example 10
[0350] A glutamine synthetase (GS)-deficient cell line derived from CHO-K1 (CHO-K1 GS) was transfected to express and produce rituximab as an example protein using a glutamine synthetase-based protein expression system. The growth of this rituximab-producing CHO-K1 GS cell line and the production of rituximab as an example protein were analyzed. It was found that the culture medium with improved amino acid ratios can also be used for GS-deficient cell lines, and the amount of the target protein produced is comparable to that of other cell lines (see Figure 6 C).
[0351] Materials and Methods
[0352] The experiment was performed in a miniaturized bioreactor system with a starting volume of 15 ml. CHO-K1 GS cell line expressing rituximab was cultured at 0.7 x 10 6 Cells / ml were seeded in basal medium 6.2GS and cultured using feed medium 6.2GS, both with optimized AA ratios. Some minor changes were made compared to basal medium 6.2 and feed medium 6.2:
[0353] - Basal Medium 6.2GS: Due to the GS system elimination of glutamine from the AA premix powder (optimized AA ratios), changed from succinate 1.5 g / L to disodium succinate 6H2O 3.43 g / L formulation, and iron choline citrate increased from 0.2 g / L to 1.8 g / L.
[0354] - Feed medium 6.2GS: Glucose increased from 35.4 g / L to 83.4 g / L, and changed from succinic acid 5.2 6 g / L to disodium succinate 6H2O 12.0 g / L formulation
[0355] The therapeutic molecule expressed in CHO-K1GS cells is rituximab with a heavy chain containing the amino acid sequence of SEQ ID NO:1 and a light chain containing the amino acid sequence of SEQ ID NO:2. The bioreactor was incubated at 34.5°C for the entire culture, and the dissolved CO2 was controlled between 2-15% to prevent toxic concentrations based on a pH set point of 6.95 (+ / -0.25). For this fed-batch application, a platform method for successful expansion was applied, which included a standard feed rate of 30ml / L / d. This means that for the entire culture from the first day until the end of the culture, a nutrient feed solution is added every day. Glucose is also added as needed to keep the glucose level>0.6g / L for the entire culture. Viable cells, viability, product concentration, glucose concentration, lactate concentration, ammonium concentration and osmotic pressure are measured as described above. The experiment was performed in duplicate (N=2).
[0356] result:
[0357] The parameters viable cell density, viability and product concentration from duplicates of the CHO-K1 GS cell line expressing rituximab were comparable or even better than those of other cell lines. Two small-scale bioreactors showed high pre-harvest product concentrations of 8665 mg / L and 8102 mg / L after a 14-day fed-batch culture process. These results demonstrate that the glutamine synthetase (GS)-deficient cell line derived from CHO-K1 is able to proliferate and produce the target protein ( ) at very high titers using a culture medium with an optimized AA ratio. Fig.10 AC).
[0358] In view of the above, it should be understood that the present invention also relates to the following items:
[0359] project
[0360] 1. A basal cell culture medium for culturing mammalian cells, comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0361] About 1.2-2.2 L-leucine / L-isoleucine,
[0362] About 0.5-0.9 L-phenylalanine / L-isoleucine,
[0363] About 1.5-2.7 L-tyrosine / L-isoleucine,
[0364] about 1.0-1.9 L-threonine / 1-isoleucine, and
[0365] About 1.0-1.9 L-valine / L-isoleucine,
[0366] The basal cell culture medium has a total amino acid content of about 25 to 150 mM.
[0367] 2. The basal cell culture medium of item 1, further comprising L-lysine at a molar ratio (mM / mM) of about 1.6-2.9 relative to isoleucine.
[0368] 3. The basal cell culture medium of item 1 or 2, further comprising at least one of the following amino acids at the following molar ratios (mM / mM) relative to isoleucine:
[0369] About 0.3-0.5 L-tryptophan / L-isoleucine,
[0370] About 1.6-3.0 L-proline / L-isoleucine; or
[0371] About 0.4-0.7 L-methionine / L-isoleucine.
[0372] 4. The basal cell culture medium of item 3, comprising L-tryptophan, L-proline and L-methionine in a molar ratio respectively according to item 3.
[0373] 5. A basal cell culture medium for culturing mammalian cells, comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0374] About 1.3-1.8 L-leucine / L-isoleucine,
[0375] About 0.6-0.9 L-phenylalanine / L-isoleucine,
[0376] About 1.7-2.5 L-tyrosine / L-isoleucine,
[0377] about 1.2-1.8 L-threonine / 1-isoleucine, and
[0378] About 1.3-1.6 L-valine / L-isoleucine,
[0379] The basal cell culture medium has a total amino acid content of about 25 to 100 mM.
[0380] 6. The basal cell culture medium of item 1 or 5, further comprising L-lysine at a molar ratio (mM / mM) of about 1.8-2.7 relative to isoleucine.
[0381] 7. The basal cell culture medium of item 1, 2, 5 or 6, further comprising at least one of the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0382] About 0.3-0.5 L-tryptophan / L-isoleucine,
[0383] About 1.6-3.0 L-proline / L-isoleucine; or
[0384] About 0.4-0.7 L-methionine / L-isoleucine.
[0385] 8. The basal cell culture medium of item 7, comprising L-tryptophan, L-proline and L-methionine in a molar ratio respectively according to item 7.
[0386] 9. The basal cell culture medium of item 5, further comprising the following amino acids at the following molar ratios (mM / mM) relative to isoleucine:
[0387] (a) about 1.8-2.7 L-lysine / L-isoleucine; and / or
[0388] (b) about 0.3-0.5 L-tryptophan / L-isoleucine,
[0389] About 1.6-3.0 L-proline / L-isoleucine; and
[0390] About 0.4-0.7 L-methionine / L-isoleucine.
[0391] 10. A basal cell culture medium for culturing mammalian cells, comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0392] About 1.5-1.8 L-leucine / L-isoleucine,
[0393] About 0.6-0.8 L-phenylalanine / L-isoleucine,
[0394] About 1.9-2.3 L-tyrosine / L-isoleucine,
[0395] about 1.3-1.6 L-threonine / 1-isoleucine, and
[0396] About 1.3-1.6 L-valine / L-isoleucine,
[0397] The basal cell culture medium has a total amino acid content of about 25 to 100 mM.
[0398] 11. The basal cell culture medium of item 1, 5 or 10, further comprising L-lysine at a molar ratio (mM / mM) of about 2.0-2.5 relative to isoleucine.
[0399] 12. The basal cell culture medium of item 1, 2, 5, 6, 10 or 11, further comprising at least one of the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0400] About 0.3-0.5 L-tryptophan / L-isoleucine,
[0401] About 1.6-3.0 L-proline / L-isoleucine; or
[0402] About 0.4-0.7 L-methionine / L-isoleucine.
[0403] 13. The basal cell culture medium of item 12, comprising L-tryptophan, L-proline and L-methionine in a molar ratio respectively according to item 12.
[0404] 14. The basal cell culture medium of item 10, further comprising the following amino acids at the following molar ratios (mM / mM) relative to isoleucine:
[0405] (a) about 2.0-2.5 L-leucine / L-isoleucine, and / or
[0406] (b) about 0.3-0.5 L-tryptophan / L-isoleucine,
[0407] About 1.6-3.0 L-proline / L-isoleucine; and
[0408] About 0.4-0.7 L-methionine / L-isoleucine.
[0409] 15. The basal cell culture medium according to any one of items 1 to 14, wherein the culture medium is a serum-free culture medium, preferably a chemically defined culture medium or a chemically defined and protein-free culture medium.
[0410] 16. The basal cell culture medium of any one of items 1 to 15, further comprising iron choline citrate at a concentration of about 0.1 to 5.0 mM, about 0.2 to 2.0 mM, about 0.2 to 1.0 mM or about 0.4 to 1.0 mM.
[0411] 17. The basal cell culture medium according to any one of items 1 to 16, wherein the basal cell culture medium has a total amino acid content of about 30 to about 80, preferably about 35 to about 65, more preferably about 40 to about 50 mM.
[0412] 18. A basal cell culture medium for culturing mammalian cells, comprising iron choline citrate at a concentration of 0.1 to 5.0 mM, about 0.2 to 2.0 mM, about 0.2 to 1.0 mM, or about 0.4 to 1.0 mM.
[0413] 19. A feed medium for culturing mammalian cells, comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0414] About 2.3-4.2 L-leucine / L-isoleucine,
[0415] About 0.6-1.1 L-phenylalanine / L-isoleucine,
[0416] about 1.3-2.4 L-threonine / 1-isoleucine, and
[0417] About 1.1-2.0 L-valine / L-isoleucine,
[0418] wherein the feed medium has a total amino acid content of about 100 to 1000 mM.
[0419] 20. The feed medium of item 19, further comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0420] About 0.6-1.1 L-tyrosine / L-isoleucine and / or about 1.1-2.1 L-lysine / L-isoleucine, preferably
[0421] About 0.6-1.1 L-tyrosine / L-isoleucine and about 1.1-2.1 L-lysine / L-isoleucine.
[0422] 21. The feed medium of item 19 or 20, further comprising at least one of the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0423] About 0.3-0.6 L-tryptophan / L-isoleucine,
[0424] About 0.9-1.8 L-proline / L-isoleucine; or
[0425] About 0.4-0.8 L-methionine / L-isoleucine.
[0426] 22. The feed medium of item 21, comprising L-tryptophan, L-proline and L-methionine in a molar ratio respectively according to item 21.
[0427] 23. A feed medium for culturing mammalian cells, comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0428] About 2.6–3.9 L-leucine / L-isoleucine,
[0429] About 0.7-1.0 L-phenylalanine / L-isoleucine,
[0430] about 1.5-2.2 L-threonine / 1-isoleucine, and
[0431] About 1.3-1.9 L-valine / L-isoleucine,
[0432] wherein the feed medium has a total amino acid content of about 100 to 1000 mM.
[0433] 24. The feed medium of item 19 or 23, further comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0434] About 0.7-1.0 L-tyrosine / L-isoleucine and / or about 1.3-1.9 L-lysine / L-isoleucine, preferably
[0435] About 0.7-1.0 L-tyrosine / L-isoleucine and about 1.3-1.9 L-lysine / L-isoleucine.
[0436] 25. The feed medium of item 19, 20, 23 or 24, further comprising at least one of the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0437] About 0.4-0.5 L-tryptophan / L-isoleucine,
[0438] About 1.1-1.6 L-proline / L-isoleucine; or
[0439] About 0.5-0.7 L-methionine / L-isoleucine.
[0440] 26. The feed medium of item 25, comprising L-tryptophan, L-proline and L-methionine in a molar ratio respectively according to item 25.
[0441] 27. The feed medium of claim 23, further comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0442] (a) about 0.7-1.0 L-tyrosine / L-isoleucine, and
[0443] about 1.3-1.9 L-lysine / L-isoleucine, and / or
[0444] (b) about 0.4-0.5 L-tryptophan / L-isoleucine,
[0445] About 1.1-1.6 L-proline / L-isoleucine; and
[0446] About 0.5-0.7 L-methionine / L-isoleucine.
[0447] 28. A feed medium for culturing mammalian cells, comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0448] About 2.9-3.5 L-leucine / L-isoleucine,
[0449] About 0.8-0.9 L-phenylalanine / L-isoleucine,
[0450] about 1.7-2.0 L-threonine / 1-isoleucine, and
[0451] About 1.4-1.7 of L-valine / L-isoleucine,
[0452] wherein the feed medium has a total amino acid content of about 100 to 1000 mM.
[0453] 29. The feed medium of item 19, 23 or 28, further comprising the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0454] About 0.7-0.9 of L-tyrosine / L-isoleucine and / or about 1.4-1.8 of L-lysine / L-isoleucine, preferably
[0455] About 0.7-0.9 L-tyrosine / L-isoleucine and about 1.4-1.8 L-lysine / L-isoleucine.
[0456] 30. The feed medium of item 19, 20, 23, 24, 28 or 29, further comprising at least one of the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0457] About 0.4-0.5 L-tryptophan / L-isoleucine,
[0458] About 1.2-1.5 L-proline / L-isoleucine; or
[0459] About 0.5-0.6 L-methionine / L-isoleucine.
[0460] 31. The feed medium of item 30, comprising L-tryptophan, L-proline and L-methionine in a molar ratio respectively according to item 30.
[0461] 32. The feed medium of claim 28, further comprising at least one of the following amino acids in the following molar ratios (mM / mM) relative to isoleucine:
[0462] (a) about 0.7-0.9 L-tyrosine / L-isoleucine, and
[0463] about 1.4-1.8 L-lysine / L-isoleucine, and / or,
[0464] (b) about 0.4-0.5 L-tryptophan / L-isoleucine,
[0465] About 1.2-1.5 L-proline / L-isoleucine; and
[0466] About 0.5-0.6 L-methionine / L-isoleucine.
[0467] 33. The feed medium of any one of items 19 to 32, wherein the feed medium is a concentrated feed medium for adding to the cell culture at about 10-50 ml / L / day, preferably at about 15-45 ml / L / day, more preferably at about 20-40 ml / L / day, and more preferably at about 30 ml / L / day, based on the starting volume of the culture.
[0468] 34. The feed medium according to any one of items 19 to 32, wherein the culture medium is a serum-free medium, preferably a chemically defined medium or a chemically defined and protein-free medium.
[0469] 35. The feed medium according to any one of items 19 to 34, further comprising iron choline citrate at a concentration of about 0.4 to 5 mM, about 0.4 to 1.0 mM or about 0.5 to 1.0 mM, preferably about 0.5 to 0.6 mM.
[0470] 36. The feed medium according to any one of items 19 to 35, further characterized in that it has a low salt content, preferably about 100 mM or lower, more preferably 50 mM or lower.
[0471] 37. The feed medium according to any one of items 19 to 36, wherein the feed medium has a total amino acid content of about 200 to about 900, preferably about 300 to about 800, more preferably about 400 to about 700 mM.
[0472] 38. A feed medium for culturing cells, comprising iron choline citrate at a concentration of about 0.4 to 5 mM, about 0.4 to 1.0 mM or about 0.5 to 1.0 mM, preferably about 0.5 to 0.6 mM.
[0473] 39. A culture medium platform for culturing mammalian cells, comprising:
[0474] a) the basal cell culture medium of items 1 to 18, and
[0475] b) The feed medium of items 19 to 38.
[0476] 40. The cell culture medium of any one of items 1 to 18 or the feed medium of any one of items 19 to 38, wherein the mammalian cells are rodent or human cells, wherein the rodent cells are preferably Chinese Hamster Ovary (CHO) cells, such as CHO-K1 cells, CHO-DG44 cells, DuxB11 cells or CHO GS-deficient cells, most preferably, the cells are CHO-DG44 cells or CHO GS-deficient cells.
[0477] 41. A method for producing a basal cell culture medium, comprising:
[0478] a) providing a basal cell culture medium, and
[0479] b) adding amino acids to a final molar ratio according to items 1 to 17 or adjusting the amino acid ratios to a final molar ratio according to items 1 to 17.
[0480] 42. The method of item 41, further comprising the step of adding or adjusting iron choline citrate as an iron source, wherein the concentration of iron choline citrate is about 0.1 to 5.0 mM, about 0.2 to 2.0 mM, about 0.2 to 1.0 mM, or about 0.4 to 1.0 mM.
[0481] 43. A method for generating a feed medium, comprising:
[0482] a) providing feed medium, and
[0483] b) adding amino acids in a final molar ratio according to items 19 to 37 or adjusting the amino acid ratios to a final molar ratio according to items 19 to 37.
[0484] 44. The method of claim 43, further comprising the step of adding or adjusting iron choline citrate as an iron source, wherein the concentration of iron choline citrate is about 0.4 to 5 mM, about 0.4 to 1.0 mM or about 0.5 to 1.0 mM, preferably about 0.5 to 0.6 mM.
[0485] 45. The method according to any one of items 41 to 44, wherein the culture medium is a serum-free culture medium, preferably a chemically defined culture medium or a chemically defined and protein-free culture medium.
[0486] 46. A method for culturing mammalian cells, comprising the steps of:
[0487] a) providing mammalian cells,
[0488] b) culturing the cells in the basal cell culture medium of any one of items 1 to 18, and
[0489] c) optionally adding the feed medium of any one of items 19 to 38 to the basal cell culture medium;
[0490] wherein the cells are cultured under conditions that allow the cells to proliferate.
[0491] 47. A method for producing a target protein, comprising the steps of:
[0492] a) providing a mammalian cell comprising a gene of interest encoding a protein of interest,
[0493] b) culturing the cells in the basal cell culture medium of any one of items 1 to 18, and
[0494] c) optionally adding the feed medium of any one of items 19 to 38 to the basal cell culture medium, and
[0495] d) optionally separating and / or isolating and / or purifying the protein of interest from the cell culture;
[0496] The cells are cultured under conditions that allow expression of the target protein.
[0497] 48. The method of item 47, wherein the target protein is a secreted protein, preferably, the target protein is an antibody or an Fc-fusion protein.
[0498] 49. The method of any one of items 46 to 48, wherein the mammalian cell is a rodent or human cell, preferably, the rodent cell is a Chinese hamster ovary (CHO) cell, such as a CHO-K1 cell, a CHO-DG44 cell, a DuxB11 cell or a CHO GS-deficient cell, most preferably, the cell is a CHO-DG44 cell or a CHO GS-deficient cell.
[0499] 50. The method of any one of items 46 to 49, wherein the feed medium of any one of items 19 to 38 is added to cells cultured in the basal cell culture medium, and wherein
[0500] (a) the feed medium is added to the basal cell culture medium at about 10-50 ml / L / day, preferably about 15-45 ml / L / day, more preferably about 20-40 ml / L / day, and more preferably about 30 ml / L / day, based on the starting volume of the culture,
[0501] (b) the feed medium is added starting at day 0, 1, 2 or 3, and / or
[0502] (c) The feed medium is added continuously or as a bolus several times a day, twice a day, once a day, every other day or every three days.
[0503] 51. The method of any one of items 46 to 50, wherein the cell culture is a large-scale cell culture, preferably a cell culture having a working volume of 100 L or more, more preferably 1000 L or more, or even more preferably 10000 L or more.
[0504] 52. A kit of parts comprising the basal cell culture medium of any one of items 1 to 18 and / or the feed medium of any one of items 19 to 39, and optionally mammalian cells.
[0505] 53. Use of the basal cell culture medium of any one of items 1 to 18 for producing a protein, comprising culturing mammalian cells producing a target protein in the culture medium for a period of time under conditions suitable for cell growth and protein production, harvesting the target protein, and recovering the protein from the culture medium or cell lysate.
[0506] 54. The use of item 53, further comprising supplying the cells with the feed medium of any one of items 19 to 38 during the culturing.
[0507] 55. Use of the feed medium of any one of items 19 to 39 for producing a protein, which comprises culturing mammalian cells producing a target protein in the basal cell culture medium of any one of items 1 to 18 for a period of time under conditions suitable for cell growth and protein production, supplying the cells with the feed medium, harvesting the target protein and recovering the protein from the culture medium.
[0508] 56. Use of iron choline citrate as an iron carrier in a mammalian cell culture medium, wherein the iron choline citrate is present in the mammalian cell culture medium at a concentration of about 0.2 to 2.0 mM.
Claims
1. A basal cell culture medium for culturing mammalian cells, comprising iron choline citrate at a concentration of 0.1 to 5.0 mM.
2. A basal cell culture medium for culturing mammalian cells, comprising iron choline citrate at a concentration of 0.2 to 2.0 mM.
3. A basal cell culture medium for culturing mammalian cells, comprising iron choline citrate at a concentration of 0.2 to 1.0 mM.
4. A basal cell culture medium for culturing mammalian cells, comprising iron choline citrate at a concentration of 0.4 to 1.0 mM.
5. A feed medium for culturing cells, comprising iron choline citrate at a concentration of 0.4 to 5 mM.
6. A feed medium for culturing cells, comprising iron choline citrate at a concentration of 0.4 to 1.0 mM.
7. A feed medium for culturing cells, comprising iron choline citrate at a concentration of 0.5 to 1.0 mM.
8. A feed medium for culturing cells, comprising iron choline citrate at a concentration of 0.5 to 0.6 mM.
9. A culture medium platform for culturing mammalian cells, comprising: a) the basal cell culture medium according to any one of claims 1 to 4, and b) the feed medium according to any one of claims 5 to 8.
10. A method for culturing mammalian cells, comprising the steps of: a) providing mammalian cells, b) culturing the mammalian cells in the basal cell culture medium according to any one of claims 1 to 4, and c) adding a feed medium according to any one of claims 5 to 8 to the basal cell culture medium; wherein the mammalian cells are cultured under conditions that allow the mammalian cells to proliferate.
11. A method for producing a target protein, comprising the following steps: a) providing a mammalian cell comprising a target gene encoding the target protein, b) culturing the mammalian cell in the basal cell culture medium according to any one of claims 1 to 4, and c) adding a feed medium according to any one of claims 5 to 8 to the basal cell culture medium, d) purifying the target protein from the cell culture; wherein the mammalian cell is cultured under conditions that allow expression of the target protein.
12. The method of claim 11, wherein the protein of interest is a secreted protein.
13. The method of claim 11, wherein the protein of interest is an antibody. The method of claim 11 , wherein the protein of interest is an Fc-fusion protein.
15. The cell culture medium of any one of claims 1-4, wherein the mammalian cells are rodent cells or human cells.
16. The cell culture medium of claim 15, wherein the rodent cells are Chinese hamster ovary cells.
17. The cell culture medium of claim 15, wherein the rodent cells are CHO-K1 cells, CHO-DG44 cells, DuxB11 cells, or CHO GS-deficient cells.
18. The cell culture medium of claim 15, wherein the rodent cells are CHO-DG44 cells or CHO GS-deficient cells.
19. The feed medium of any one of claims 5-8, wherein the cells are mammalian cells.
20. The feed medium of claim 19, wherein the mammalian cells are rodent cells or human cells.
21. The feed medium of claim 20, wherein the rodent cells are Chinese hamster ovary cells.
22. The feed medium of claim 20, wherein the rodent cells are CHO-K1 cells, CHO-DG44 cells, DuxB11 cells or CHO GS-deficient cells.
23. The feed medium of claim 20, wherein the rodent cells are CHO-DG44 cells or CHO GS-deficient cells.
24. The method of any one of claims 10-14, wherein the mammalian cell is a rodent cell or a human cell.
25. The method of claim 24, wherein the rodent cell is a Chinese hamster ovary cell.
26. The method of claim 24, wherein the rodent cell is a CHO-K1 cell, a CHO-DG44 cell, a DuxB11 cell, or a CHO GS-deficient cell.
27. The method of claim 24, wherein the rodent cell is a CHO-DG44 cell or a CHO GS-deficient cell.
Citation Information
Patent Citations
Cell culture medium
CN107429227A
Perfusion medium
CN110462054A
Cell culture medium
US20180346881A1
